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CHAPTER 1 
THE ENDOCANNABINOID SYSTEM AND STRESS-INDUCED ANXIETY: A CASE 
OF MODERATION IN THE AMYGDALA 
 
Introduction 
 At least once in an individual’s lifetime, anxiety, a natural response to a stressful event, 
will be encountered.  However, for some individuals, anxiety can become so maladaptive and a 
daily burden that it can eventually develop into a psychiatric disorder.  Millions of people 
worldwide are affected by psychiatric disorders that are classified as an anxiety, trauma-related, 
or stressor-related disorder.  Some examples of these psychiatric disorders are GENERALIZED 
ANXIETY DISORDER (GAD)1, PANIC DISORDER2, POSTTRAUMATIC STRESS 
DISORDER (PTSD)3, SOCIAL PHOBIA4, OBSESSIVE COMPULSIVE DISORDER (OCD)5, 
AGORAPHOBIA6, and other SPECIFIC PHOBIAS1-4.  In the United States, anxiety, trauma-
related, and stressor-related disorders are the most common mental health problems, imposing a 
social and economic challenge on the U.S. health care system and society.  Affecting about 20% 
of the U.S. population aged 18 or older1 and about 10% of teenagers between the ages of 13 and 
182, these psychiatric disorders cost the U.S. over $40 billion annually due to prescribed 
medications, repeated hospitalizations5, reduced productivity, absenteeism from the workplace, 
and suicide6.  More effective and inexpensive treatment options to manage the negative effects of 
                                                        
1 GENERALIZED ANXIETY DISORDER: An anxiety disorder that consists of constant, excessive, and impractical worry and tension 
about everyday concerns that lasts up to six months. 
2 PANIC DISORDER: An anxiety disorder that is characterized by spur-of-the-moment panic attacks and persistent worry about the 
fear of experiencing another panic attack. 
3 POSTTRAUMATIC STRESS DISORDER: An anxiety disorder that involves enduring recurrent nightmares following reminders of a 
single or repeated traumatic occurrence experienced directly or witnessed in others. 
4 SOCIAL PHOBIA: An anxiety disorder, also known as social anxiety disorder that is characterized by an intense fear of being judged 
by others in social settings. 
5 OBSESSIVE COMPULSIVE DISORDER: An anxiety disorder that is characterized by continuous, unwelcomed thoughts (e.g., 
obsessions) that compels an individual to enact routines repeatedly (e.g., compulsions) in order to lessen anxiety resulting from the 
obsessions. 
6 AGORAPHOBIA: An anxiety disorder that involves avoidance of situations or places where an individual experienced a panic attack 
as a result of fear of experiencing another panic attack. 
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anxiety are needed.  Molecular targets involved in the endocannabinoid (eCB) system (ECS) have 
provided a promising alternative to treat individuals burdened by anxiety.  Cannabinoid receptor 
agonists have proven to be effective in lessening anxiety-like behaviors caused by stress in 
experimental animals and humans7-12.  However, preclinical animal studies provide evidence that 
these ligands produce adverse motor responses and cognitive impairments and bimodal control of 
anxiety, which is dependent upon many variables, including, but not limited to, dosage, time of 
drug administration, and the context in which a stressor is applied13-21.  Thus, other molecular 
targets, such as eCB degradative enzymes, that can enhance signaling through cannabinoid 
Figure 1.  Intraamygdalar stress circuits and molecular mechanisms in stress-induced anxiety.  a. In response 
to stress, the neuronal circuit that includes the amygdala and involves the hippocampus or prefrontal cortex sending 
glutamatergic projections (GREEN) to the LA or directly to the BLA is activated.  The LA then sends 
glutamatergic inputs that project onto glutamatergic pyramidal neurons in the BLA, which then sends 
glutamatergic afferents to the CeA.  Next, the CeA sends inhibitory inputs (RED) to the PVN of the hypothalamus 
indirectly via the BNST, where the HPA axis is activated.  b. Upon increases in excitation or depolarization, 
glutamate is released from the presynaptic axon terminal.  Glutamate then activates glutamate receptors on the 
postsynaptic neurons, initiating the synthesis of the endocannabinoids (eCBs), anandamide (AEA) and 2-
arachidonylglycerol (2-AG), which are released and travel to a presynaptic axon terminal, where the eCBs activate 
cannabinoid receptors.  Activation of the cannabinoid receptor, CB1R, triggers downstream signaling which 
induces a reduction in synaptic transmission of either glutamate or GABA. [Figure adapted from Hill, M. and 
Patel, S. (2013). Translational evidence for the involvement of the eCB system in stress-related psychiatric 
illnesses. Biology of Mood & Anxiety Disorders. 3 (19): 1-14.]  c. In the amygdala, stress causes increased synaptic 
glutamate release and decreased synaptic GABA release, inducing amygdalar excitability.  This causes a reduction 
in AEA synthesis via NAPE-PLD and an increase in its degradation via FAAH and COX-2, reducing signaling 
through the CB1R.  Consequently, the HPA axis is stimulated and dendritic hypertrophy occurs.  These biochemical 
and morphological changes induce the development of anxiety-like behaviors. HPA, hypothalamic-pituitary-
adrenal. 
 3 
receptors by augmenting eCB levels in the brain upon pharmacological inhibition, are being 
investigated for their potential for combating anxiety and stress responses22-28. 
 
Retrograde Endocannabinoid Signaling 
Endocannabinoids (eCBs) are lipid derived molecules that activate endogenous G PROTEIN-
COUPLED RECEPTORS (GPCR)7, called cannabinoid receptors, in the central nervous system.  
The eCBs, anandamide (AEA) and 2-arachidonylglycerol (2-AG), are synthesized “on demand” 
at postsynaptic sites in brain structures, such as the amygdala, as a result of elevations in neuronal 
excitation or calcium levels caused by depolarization29.  Upon synthesis, eCBs are released and 
transported in a retrograde fashion from postsynaptic sites to presynaptic axon terminals, where 
they activate cannabinoid receptors (Fig. 1b)30-34.  One of the endogenous cannabinoid receptors 
is the cannabinoid type 1 receptor (CB1R)
35.  CB1R mRNA and protein have been identified in 
many brain structures, including, but not limited to, the cerebral cortex, hippocampus, 
AMYGDALOID COMPLEX8, hypothalamus, thalamus, olfactory-associated structures, 
brainstem, and the cerebellum36-43.  The amygdala is comprised of several nuclei with three 
prominent nuclei: the lateral (LA), basolateral (BLA), and central (CeA) nuclei36.  More CB1R 
mRNA and protein are expressed in the BLA and LA than in the CeA42,44-46.  CB1Rs are located 
on axon terminals that contain gamma-aminobutyric acid (GABA) or glutamate47,48.  In the 
amygdala, where the majority of neurons are excitatory pyramidal neurons followed by 
GABAergic interneurons36,49-57, CB1Rs are highly expressed in interneurons as opposed to 
                                                        
7 G-PROTEIN-COUPLED RECEPTOR: A receptor that interacts with a group of integral membrane proteins that bind to guanosine triphosphate 
(GTP) in its active form (G proteins), catalyze the hydrolysis of GTP to GDP when activated, and relay signals from the receptor to other molecules 
and downstream effectors. 
8 AMYGDALOID COMPLEX: A brain structure comprised of the following nuclei: the basolateral nuclei (e.g., lateral nucleus (LA), basolateral 
nucleus (BLA), and the accessory basal nucleus (AB)), corticomedial nuclei (e.g., nucleus of the lateral olfactory tract (NLOT), bed nucleus of the 
accessory olfactory tract (BAOT), anterior and posterior cortical nucleus (CoA and CoP, respectively)), centromedial nuclei (e.g., central (CeA), 
medial (M), and amygdaloid part of the bed nucleus of stria terminalis (BNST)), and other amygdaloid nuclei (e.g., anterior amygdale area, 
amygdalo-hippocampal area, intercalated nuclei, and the ventral pallidum. 
 4 
projecting pyramidal neurons58.  When activated, the CB1R inhibits cyclic adenosine 
monophosphate (cAMP) formation via inhibition of adenylyl cyclase, which downregulates 
protein kinase A signaling, and activates extracellular signal-regulated kinase by signaling through 
Gi/o proteins
35,59-68.  Such effects on downstream effectors result in activation of potassium ion 
channels, inhibition of calcium channels, and subsequently, reduced synaptic transmission of 
glutamate or GABA from amygdalar axon terminals (Fig. 1b)69.  Reduced GABA release from 
axon terminals of interneurons has been suggested to increase the excitability of pyramidal neurons 
in intraamygdalar pathways, targeting brain regions which mediate stress responses and 
anxiogenic behaviors, such as the bed nucleus of stria terminalis (BNST) and the paraventricular 
nucleus (PVN) of the hypothalamus (Fig. 1a)70,71. 
 
Endocannabinoid System Modulation of Anxiety-Like Behaviors in the Amygdala 
Stress, whether induced by physical or psychological means, can alter the form and structure of 
neurons as well as their biochemical makeup.  These morphological and biochemical alterations 
caused by stress can be manifested in the form of anxiety-like behaviors72-76.  One brain structure 
that plays a role in emotional processing and mediates stress responses is the amygdala.  The 
amygdala, which is located within the medial temporal lobe of the brain, processes visual, auditory, 
olfactory, and somatosensory information originating from the external environment that is 
transmitted from cortical brain areas.  It then assigns emotional significance to such external 
stimuli by activating efferent neuronal projections from the amygdala to other brain structures and, 
subsequently, produces corresponding behavioral responses to the stimuli.36,77-81.   
Effects of Stress on Amygdalar Morphology and Biochemistry.  In studies involving experimental 
animals, physical stress in the form of acute and chronic immobilization stress has been reported 
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to cause anxiety-like behaviors.  Under chronic stress conditions (5, 10, or 21 days), these 
behavioral manifestations of anxiety accompany enhanced dendritic hypertrophy and spine density 
in excitatory pyramidal neurons of the BLA and decreased dendritic arborization in GABAergic 
interneurons of the LA and BLA28,74,82-85.  This morphological phenotype is analogous to that 
observed in the BLA of mice with CB1R gene disruption
86.  With reference to altering neuronal 
biochemistry, chronic immobilization stress also induces neuronal activation and excitotoxicity by 
increasing glutamate release at excitatory synapses and decreasing inhibitory tone in the amygdala, 
causing activation of glutamate receptors and loss of local calcium-activated potassium 
channels43,76,87-96.  These findings correspond to studies which found increased amygdalar activity 
in patients with PTSD, social anxiety disorder, or specific phobia97.  Changes in amygdalar 
morphology and biochemistry as a consequence of stress have been suggested to be the result of 
stress-induced increases in corticosterone, a glucocorticoid hormone that modulates stress 
responses98-100.  In addition, immobilization stress applied acutely or chronically can alter eCB 
levels in the brain.  Acute and chronic immobilization stress causes decreases in AEA content in 
the amygdala, whereas only chronic immobilization stress causes increases in 2-AG content in the 
amygdala28,101.  These changes in eCB content correspond to changes in the levels of eCB 
biosynthetic and degradative enzymes in the amygdala as a consequence of stress.  Rats exposed 
to the odor of a cat, its natural predator, induce decreases in genes that code for the AEA 
biosynthetic enzyme, N-arachidonoyl phosphatidyl-ethanolamine phospholipase D (NAPE-PLD), 
and the 2-AG biosynthetic enzyme, diacylglycerol lipase (DAGLα), and increases in the AEA 
degradative enzyme, fatty acid amide hydrolase (FAAH), in the amygdala102,103.  Also, chronic 
immobilization stress causes increases in amygdalar FAAH activity28.  Collectively, these findings 
support the hypothesis that stress increases mobilization of eCB degradative enzymes, decreases 
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eCB signaling through the CB1R, and enhances excitability in the amygdala to drive anxiogenic 
behaviors (Fig. 1c).   
Endocannabinoid System Regulation of Stress Effects on Anxiety-Like Behaviors.  Data from 
preclinical animal studies provide evidence for the biphasic effects of cannabinoid receptor ligands 
on anxiety-like behaviors, where high doses of cannabinoids can illicit anxiogenic behaviors and 
low doses of cannabinoids can cause anxiolytic behaviors104. Thus, substantial increases or 
decreases in eCB signaling through cannabinoid receptors appear to induce anxiety, whereas 
minute enhancements or reductions in eCB signaling appear to lessen anxiety.  Onaivi and others 
demonstrated that under basal conditions a high dose of the psychoactive component found in 
marijuana, 9-tetrahydrocannabinol (9-THC), a partial CB1R agonist61,105, administered 
systemically (10 mg/kg) or microinjected (100 μg) into the CeA elicit anxiogenic-like behaviors 
in rodents15,106.  Comparable results were obtained in rats administered systemically with a high 
dose of HU-210 (100 μg/kg), a full CB1R agonist61,105, for 12 consecutive days before exposure to 
acute immobilization stress as well as in humans that orally ingested marijuana (5-10 g)104,107.  In 
contrast, a low dose of 9-THC (≤ 0.75 mg/kg) or WIN 55,212-2 (1 and 3 mg/kg), a full CB1R 
agonist61,105, administered systemically or microinjected into the BLA (9-THC, 1 μg) under basal 
conditions induced anxiolytic-like responses in rodents14,64,108,109.  Similar results occurred when 
WIN 55,212-2 was microinjected into the BLA (5 μg) before acute stress in the form of a footshock 
and before and after a single episode of prolonged stress, a rodent model of PTSD that is comprised 
of restraint stress, forced swim stress, and isoflurane-induced loss of consciousness110,111.  These 
findings parallel a study on recreational cannabis users that did not use marijuana on a daily basis 
but had used marijuana at least 10 times in their lives.  Phan and others demonstrated that these 
subjects after orally ingesting 9-THC (7.5 mg) had decreased threat-related amygdala reactivity 
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when exposed to social signals of threat112.  Moreover, previous studies have shown that blockade 
of the CB1R with rimonabant (SR141716)
61,105 can generate anxiogenic behaviors at high doses 
administered systemically (3 or 10 mg/kg) and microinfused in the CeA (0.5 μg)113-116 similar to 
CB1R gene disruption
108,116 and anxiolytic behaviors at low doses (1 mg/kg) in animals and 
humans115,116.  These pharmacological effects can be context dependent at times, where brightly 
illuminated, novel or stressful environments induce anxiety as opposed to unstressful, familiar 
environments lessening anxiety in both animals and humans115,117-120.  Nevertheless, bimodal 
control of anxiety by cannabinoid receptor ligands can be alleviated when the stressor applied is 
increased in intensity, suggesting intense stress can enhance CB1R responsiveness to these ligands.  
Hill and Gorzalka demonstrated that rats subjected to chronic unpredictable stress and, 
subsequently, administered HU-210 (10 and 50 μg/kg) systemically appeared less anxious in the 
elevated plus maze21.  Apparently, depending on the time or dosage at which a drug is 
administered, the potency of a drug, and the environment in which stress is induced, activation or 
blockade of CB1Rs by psychoactive or synthetic cannabinoids in the brain can produce very 
different and complex effects on anxiety-like behaviors in both animals and humans119,121.  These 
bimodal effects of cannabinoids on anxiety have been suggested to be mediated through CB1Rs 
located on cortical glutamatergic neurons when animals exhibit anxiolytic behaviors and on 
GABAergic axon terminals when animals exhibit anxiogenic behaviors122.  Moreover, the 
effectiveness of cannabinoid receptor ligands in alleviating anxiety may depend on the magnitude 
at which stress increases CB1R levels
123 or activity, making more CB1Rs available to be acted upon 
by the cannabinoid ligands or eCBs synthesized as a consequence of stress.  Another alternative 
to the bidirectional effects of cannabinoids on anxiety is that depending on the magnitude of a 
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ligand’s potency or stress, sensitization of one of the CB1R downstream effectors may increase or 
decrease upon activation or inhibition of the CB1R. 
 
Endocannabinoid Augmentation Strategies Can Regulate Anxiety 
Using psychoactive cannabinoids or synthetic cannabinoid analogs to activate or inhibit 
cannabinoid receptor activity in the brain is not the only approach that can control anxiety-like 
behaviors in animals and humans.  Another method for modulating anxiety is pharmacologically 
and genetically targeting enzymes involved in the eCB system in order to augment eCB levels in 
the brain.  Previous studies have demonstrated that genetic removal of genes for enzymes that 
degrade eCBs or pharmacologically inhibiting these enzymes can cause increases in eCBs in the 
brain27,124,125.  It is assumed that elevating eCB levels in the brain will result in enhanced eCB 
signaling through cannabinoid receptors.  This endocannabinoid augmentation strategy may 
possibly counteract the morphological and biochemical effects of stress on the brain, particularly 
the amygdala, and, subsequently, on anxiety.  This hypothesis has been implied by several research 
studies that target eCB degradative enzymes, such as FATTY ACID AMIDE HYDROLASE 
(FAAH), MONOACYLGLYCEROL LIPASE (MAGL), and CYCLOOXYGENASE-2 (COX-2), 
in order to regulate anxiety-like behaviors in animals and humans. 
Fatty acid amide hydrolase.  FAAH is a postsynaptic, membrane-bound enzyme that catalyzes 
the hydrolysis of AEA to ethanolamine and a free fatty acid and the hydrolysis of 2-AG, to a lesser 
extent, to arachidonic acid and glycerol126-128.  FAAH mRNA is located predominantly in the 
lateral, basal, and basomedial nuclei of the amygdala129,130.  FAAH is localized to somata and 
proximal dendrites of glutamatergic neurons in the amygdala with greater distribution in the LA 
and BLA as opposed to the CeA129,131.  This pattern of FAAH protein expression is similar to the 
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distribution of CB1Rs in the amygdala
42,70,131,132.  Morphological and biochemical changes as a 
consequence of stress can be reduced or reversed by genetically removing or inhibiting FAAH.  
Patel and others illustrated that neuronal activation in amygdalar structures, such as the BLA and 
CeA, can be prevented when FAAH is genetically removed in mice (FAAH-/-) that are subjected 
to acute immobilization stress43.  Hill and others showed that chronic immobilization stress 
inflicted upon FAAH-/- mice prevented dendritic remodeling in the amygdala28.  With respect to 
altering eCB levels in the brain, under basal conditions, inhibition of FAAH by URB597 at low 
doses (1 mg/kg) can induce increases in AEA levels in whole brain23.  Interestingly, animals 
subjected to stress and administered a FAAH inhibitor can produce similar results22,133,134.  
Moreover, microinjections of a low dose (0.1 μg) of the FAAH inhibitor, URB597, in the BLA 
reduced stressed-induced increases in serum corticosterone.  In addition, this effect was not 
observed when the CB1R was pharmacologically blocked with a CB1R antagonist, AM251, 
suggesting that the reduction in stress-induced corticosterone levels as a consequence of FAAH 
inhibition was CB1R mediated
100.  Similar to that observed in FAAH-/- rodents subjected to acute 
immobilization stress, the genetic removal of FAAH abolishes stress-induced increases in FAAH 
activity and decreases in AEA content in the amygdala of FAAH-/- mice subjected to chronic 
immobilization stress28,135.  FAAH inhibition by drugs or removal of the FAAH gene in mouse 
strains can lessen the effects of stress on anxiety-like behaviors.  Systemically, pharmacological 
FAAH inhibition at low doses (URB597, 0.05-1 mg/kg) has been shown to evoke anxiolytic-like 
behaviors in rodents, which has been reversed by blockade of the CB1R with rimonabant, a CB1R 
antagonist and inverse agonist when it reverses adenylyl cyclase inhibition27,136-139.  Similar 
behavioral effects can be observed when the aversiveness of an animal’s environment (e.g., 
increase in illumination and removing habituation of an animal to an experimental room) is 
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increased and FAAH is pharmacologically inhibited140.  In addition, genetically eliminating FAAH 
in mice subjected to chronic immobilization stress has been shown to prevent anxiogenic-like 
behaviors as compared to wildtype littermates subjected to the same stress paradigm28.  These 
findings parallel studies examining threat processing in human carriers of polymorphisms in the 
FAAH gene that renders FAAH vulnerable to proteolytic degradation, causing reduced protein 
expression of FAAH and FAAH activity141,142.  Human subjects that are carriers of the FAAH gene 
variant C385A have decreased threat-related amygdala reactivity and associated trait anxiety, 
possibly contributing to enhanced habituation and reduced sensitivity to perceived threats or harm 
from the external environment141-144.     
Monoacylglycerol lipase.  MAGL is a presynaptic enzyme that catalyzes the hydrolysis of 2-AG 
to arachidonic acid and glycerol24,31,127,128,145.  As observed with FAAH, the regional distribution 
of MAGL is analogous to CB1Rs in the BLA and CeA, localized to axon terminals in the amygdala 
with greater distribution in the BLA as opposed to the CeA12, 25, 42,132.  Under basal conditions, 
MAGL inhibition by JZL 184 at acute and low or high doses (8, 16, or 40 mg/kg) can induce 
increases in 2-AG levels in whole brain and anxiolytic-like behaviors in rodents in a time-
dependent manner26, 32-34, 23,24,26,146.  In addition, chronic JZL 184 treatment at a high dose (40 
mg/kg/day for 6 days) induces greater increases in 2-AG levels and increases in AEA levels in 
whole brain from rodents but causes desensitization of CB1Rs in the amygdala
147.  Similarly, whole 
brains from mice injected with a high dose of JZL 184 (16 mg/kg/day for 10 days) 1h before being 
exposed to restraint stress showed increases in 2-AG levels and anxiolytic-like behaviors in the 
novelty-induced hypophagia assay24.  However, such increases in 2-AG content in whole brain 
may exhibit brain region specificity since another study by Rademacher and others showed that 
chronic instead of acute restraint stress (30 minutes/day for 10 days) subjected to mice resulted in 
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elevated 2-AG levels in the amygdala28, 135.  In addition, chronic stress in contrast to basal 
conditions has been shown to reduce membrane-bound levels of MAGL in the BLA of mice 
chronically stressed via restraint in a conical tube for 10 days, demonstrating changes in eCB 
content parallel changes in eCB degradative enzyme levels in the amygdala as a consequence of 
stress24, 32.  These results were illustrated again in the BLA, but only during the first 20 min of a 
1h restraint stress episode on the 10th day, suggesting the short-lived or phasic nature of changes 
in 2-AG levels36, 87.  Similar to previous studies involving pharmacological FAAH inhibition, acute 
and chronic pharmacological MAGL inhibition at low doses (8 mg/kg) in rats only produce 
anxiolytic effects when the rats were subjected to a more aversive environment (e.g., high 
illumination).  This observation was blocked by co-administration of JZL 184 with rimonabant, 
suggesting the anxiolytic effects detected were mediated through the CB1R
37, 148.  Also, another 
study showed similar results under basal conditions when JZL 184 (8 mg/kg) was administered 
acutely or chronically (6 days).  However, the anxiolytic effects of acute JZL 184 treatment at a 
low dose was blocked in mice injected with a cannabinoid type 2 receptor (CB2R) antagonist, 
SR144528, or mice genetically altered such that the gene for the CB2R, was removed
23, 26.  
Differences in observations between these two studies may be the result of variations in the context 
in which the rodents were subjected to before and during experimental testing.  
Cyclooxygenase-2.  COX-2 is a postsynaptic enzyme that catalyzes the hydrolysis of AEA to 
prostamide E2 and 2-AG to prostaglandin E2 glyceryl ester
128,149-154.  COX-2 is localized to 
dendritic arbors of excitatory neurons in the amygdala154.  Stress-induced excitotoxicity has been 
shown to induce activation of downstream effectors that can upregulate COX-2 protein expression.  
Acute cold swim stress or immobilization stress can cause a prolonged elevation in COX-2 mRNA 
or protein levels and PGE2 levels, a biomarker for COX-2 activity, as well as stimulation of the 
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HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS9 as observed through elevated serum 
corticosterone levels (Fig. 1c)94,155-158.  These biochemical alterations can be reduced upon 
administration of low and high doses of the COX-2 inhibitor, NS-398 (0.5-10 mg/kg)94,155.  Also, 
subchronic immobilization or acoustic stress has been shown to induce increases in COX-2 protein 
levels and activity in the brain.  These changes in COX-2 activity after stress were mediated via 
CB1Rs since activation of CB1Rs by the CB1R agonist, arachidonyl-2’-chloroethylamide, reduced 
PGE2 levels in the brain
123.  Although there is limited information as to whether or not selective 
COX-2 inhibitors can reduce or reverse the biochemical, morphological, and behavioral changes 
caused in the brain, particularly the amygdala, after stress, some studies have demonstrated the 
anxiolytic potential of selective COX-2 inhibitors under normal, unstressful conditions and before 
the onset of stress.  In one study, under basal conditions, the inhibition of COX-2 
pharmacologically has been shown to result in reduced anxiety-like behaviors in mice and 
increased AEA and 2-AG levels in the brain.  These effects are removed when mice are co-injected 
with the COX-2 inhibitor (LM-4131, 10 mg/kg) and rimonabant or have been genetically altered 
such that the gene for COX-2 has been eliminated, suggesting the increased levels of eCBs and 
anxiolytic behaviors as a result of COX-2 inhibition is CB1R mediated
125.  Other studies have 
demonstrated that COX-2 inhibitors can prevent stress-induced anxiogenic behaviors.  These 
studies illustrate that acute or chronic pretreatment with selective COX-2 inhibitors (rofecoxib, 2-
10 mg/kg or valdecoxib, 5-10 mg/kg) before the onset of immobilization stress (1 day or 7 days) 
can decrease anxiety-like behaviors in mice159,160.  Nevertheless, further evidence for which 
cellular and molecular mechanisms are involved in anxiolytic behaviors after stress as a 
                                                        
9 HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS: A feedback system involving the paraventricular nucleus (PVN) of the 
hypothalamus, the anterior lobe of the pituitary gland, and the adrenal glands that mediates stress responses.  In response to stress, the PVN of the 
hypothalamus synthesizes corticotrophin-releasing factor (CRF), which bind to the CRF receptor on the pituitary gland.  This triggers release of 
adrenocorticotropic hormone (ACTH), which binds to the melanocortin receptor in the adrenal gland, and, subsequently, induces the synthesis of 
glucocorticoids, which decrease further activation of the HPA axis. 
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consequence of COX-2 inhibition and the limitations of COX-2 inhibitors in modulating 
anxiogenic behaviors in animals and humans is needed. 
 
Conclusion 
Direct activation or inhibition of cannabinoid receptors has been shown to modulate anxiety-like 
behaviors under basal and stressful conditions in preclinical animal studies and humans.  
Nevertheless, previous studies have demonstrated that direct stimulation of cannabinoid receptors 
pharmacologically provides bidirectional results on controlling stress-induced anxiety.  In 
addition, levels of eCBs and cellular expression and activity of degradative enzymatic have been 
shown to vary with age in preclinical studies with mice129,156,161.  Increasing eCB levels by 
pharmacologically inhibiting FAAH, MAGL, or COX-2 may provide a better alternative to 
inducing eCB signaling through cannabinoid receptors than by direct activation of cannabinoid 
receptors with psychoactive cannabinoids or synthetic cannabinoid analogs.  Given the potential 
clinical and societal importance of reducing stress-induced anxiety in humans by 
pharmacologically elevating eCB levels in the brain, it is essential to comprehend the biological, 
morphological, and physiological effects of such pharmacological manipulations under basal and 
stressful conditions, particularly in a brain structure, such as the amygdala, that is known to store 
fearful memories and regulate stress responses. 
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CHAPTER II 
ANXIOLYTIC POTENTIAL OF SUBSTRATE-SELECTIVE COX-2 INHIBITION IN 
ANIMAL MODELS OF ACUTE AND CHRONIC TRAUMATIC STRESS 
 
Introduction 
Few studies have addressed the association between the eCB system, anxiety disorders 
induced by trauma or stress, and the underlying mechanisms that contribute to their persistence 
and severity for many reasons.  For one, the eCB system has only been investigated for its role in 
modulating stress and emotional behavior for little over a decade.  As a result, the pathways for 
eCB synthesis and how they are altered by stress or trauma exposure is still being elucidated.  
Moreover, much remains unknown about the neurobiological consequences of anxiety, trauma-
related, and stressor-related disorders.  There are huge gaps in knowledge because an individual’s 
reaction to stress or trauma depends on a multitude of factors, such as the stressor or trauma 
characteristics and inter-individual variability.  Also, neurobiological systems that regulate stress 
responses, including endocrine and neurotransmitter (NT) pathways, as well as a network of brain 
regions known to regulate fear behavior are complex and interconnected.  In the following 
chapters, a unique research approach will be discussed.  This research approach will provide 
insight into how the eCB system is affected after acute and chronic stress exposure and can be 
tailored using a novel molecular drug discovery approach, termed substrate-selective COX-2 
inhibition (SSCI)162, to alleviate anxiety-like behaviors in an animal model of stress-induced 
anxiety.  SSCI, which increases brain AEA levels by pharmacologically inhibiting COX-2, will be 
described in the context of testing the hypothesis that endocannabinoid augmentation via SSCI can 
counteract stress-induced anxiety-like behaviors by elevating AEA levels in the brain, resulting in 
enhanced eCB signaling through cannabinoid receptors located on glutamatergic neurons.  This 
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hypothesis was examined by determining the anxiolytic potential of SSCIs in animals subjected to 
acute and chronic traumatic stress (CHAPTER II) and its relation to eCB synaptic signaling in the 
amygdala (CHAPTER III).  
 
Experimental 
Animals.  Male or female ICR (CD-1) mice between 4-7 weeks of age (juvenile) or between 12-
15 weeks of age (adult) were used for all experiments (Harlan, Indianapolis, IN) unless otherwise 
noted.  For some contextual fear conditioning, extinction, and recall experiments, male C57BL/6J 
mice between 4-7 weeks of age were used (The Jackson Laboratory, Bar Harbor, ME).  All mice 
were housed on a 12:12 light-dark cycle (lights on at 6:00 a.m.) with food and water available ad 
libitum.  All studies were carried out in accordance with the National Institute of Health Guide for 
the Care and Use of Laboratory Animals and approved by the Vanderbilt University Institutional 
Animal Care and Use Committee. All behavioral testing was performed during the inactive light 
phase of the mouse circadian cycle (between 6:00 a.m. and 6:00 p.m.). 
Drugs and treatment. The following drugs were used for the experiments: the COX-2 inhibitors, 
LM-4131 (10 mg/kg; gift from Dr. Lawrence Marnett laboratory), lumiracoxib (1 mg/kg; Selleck 
Chemicals, Houston, TX), and celecoxib (10 mg/kg; Cayman Chemical, Ann Arbor, MI), the SK 
channel antagonist, apamin (0.4 mg/kg; Tocris Bioscience (Bio-Techne), Minneapolis, MN), the 
SK channel agonist, 1-EBIO (5 mg/kg; Tocris Bioscience (Bio-Techne), Minneapolis, MN), the 
TRPV1 antagonist, capsazepine (10 mg/kg; Cayman Chemical, Ann Arbor, MI), the CB1 receptor 
antagonist, rimonbant (2 mg/kg or 5 mg/kg), and the CB2 receptor antagonist, SR144528 (3 
mg/kg). The CB1 receptor antagonist, rimonabant, and the CB2 receptor antagonist, SR144528, 
were gifts from the National Institute of Mental Health Drug Supply Program. Drugs or vehicle 
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(dimethyl sulfoxide or DMSO) were administered by i.p. injection.  Drugs were dissolved in 
DMSO at a volume of 1 mL/kg.  Drug pretreatment times were two hours prior to behavioral 
testing. 
Endocannabinoid quantification.  Endocannabinoids were quantified and detected using LC-
MS/MS on a Quantum triple-quadrupole mass spectrometer in positive-ion mode using selected 
reaction monitoring as previously described125. 
Behavioral testing. 
A. Novelty-induced feeding suppression (NIFS) or novelty-induced hypophagia (NIH) test.  
Individually-house mice were habituated to a novel, palatable food (Ensure® Homemade 
Vanilla Shake) in their home cages for 30 min/day for 3 days under red light conditions (40 
lux) before testing. The day after habituation, mice were presented with the shake in their home 
cages under red light conditions. For each mouse, we measured the latency to begin feeding 
(an indicator of anxiety-like behavior) and the amount consumed (an indicator of anhedonic 
behavior).  On the following day, mice were moved to a holding room adjacent to the test room 
for fear conditioning and acclimated for 1 h before testing under bright light conditions (175-
177 lux).  For fear conditioning procedures, mice were moved to the test room under bright 
light conditions (175-177 lux) and placed in the conditioning chamber for 30 seconds.  After 
the initial one-half minute of habituation, mice were presented with six conditioned stimulus-
unconditioned stimulus (CS-US) pairings (e.g., tone-footshock pairings) separated by a 30 
second interval.  Each tone (80 dB, 3000 Hz) lasted 30 seconds.  Mice were presented with the 
electric footshock at 0.7 mA the last two seconds of the 30 s tone.  At the end of the fear 
conditioning protocol, mice were returned to the holding room and their home cages.  Two 
hours or six hours later on the same day, 22 hours later on the following day, or 70 hours later, 
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mice were administered a drug by i.p. injection two hours before being presented with the 
shake in a novel cage without bedding and with a white bottom under bright light conditions 
(295 lux).  Latency to feed in the novel cage and the amount of Ensure® consumed were 
reported. 
B. Elevated plus maze.  The  elevated plus maze apparatus was elevated 47 cm from the ground, 
and consisted of two open arms (30 × 5 cm; 90 lux) and two closed arms (30 × 5 × 15 cm; 20 
lux) extending from a 5 × 5 cm central area (San Diego Instruments). The walls and floor were 
made from black ABS (acrylonitrile butadiene styrene) plastic. To begin the 5-min test each 
mouse was placed in the center, facing an open arm. Total distance traveled and time spent, 
latency to enter, and total entries into the open and closed arms were recorded and analyzed 
using Any Maze tracking software. The mouse was considered to be in an arm when all four 
paws were in the arm.  
C. Tail suspension test.  The tail suspension test was performed as previously described115 using 
six chambers that interfaced with the Tail Suspension software (Version 3.30, MED 
Associates) for five minutes. 
D. Sucrose preference test.  Before testing, each mouse was given 24 hours to choose freely 
between a 2% sucrose solution and tap water contained in a 50-mL clear plastic conical tube 
that was closed by a rubber stopper encasing a metal sipper.  To prevent side preference bias, 
the position of the two tubes was switched at every measurement of the amount of fluid 
consumed (e.g., 2-4 hours).  No previous water or food deprivation was applied before testing.  
The consumption of the 2% sucrose solution or water was measured by weighing the conical 
tubes containing the fluids.  Percentage sucrose preference was calculated as the ratio of 2% 
sucrose consumed over total fluid consumption multiplied by 100.     
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E. Open field assay.  Open field locomotor activity was analyzed and performed as previously 
described115 for one hour.  
F. Acoustic startle and prepulse inhibition.  Percentage acoustic startle response and prepulse 
inhibition of the startle response was measured. During all experimental testing, the 
background was set at 70 dB white noise. The acoustic startle response test consisted of several 
trial types, each of which was presented in a pseudorandom order. The trial types consisted of 
a single startle stimulus of 70, 76, 82, or 88 dB. 
G. Y maze.  Each mouse was placed at the end of an arm and allowed to explore the maze freely 
for 10 min. The number of entries into each arm, the total arm entries, mean speed, the total 
distance traveled in the Y maze, and spontaneous alternation percentage were measured. The 
percentage of spontaneous alternation was defined as a ratio of the number of arm entries that 
differed from the previous two arm entries to total number of arm entries during each testing 
session. 
H. Cued and contextual fear conditioning, extinction, and recall.  All fear conditioning and 
extinction procedures were adapted from Hefner and co-workers163.  A video fear conditioning 
system and software from Med Associates, Inc. was used to measure freezing in the mice while 
in a conditioning chamber (dimensions: 30.5 cm x 24.1 cm x 21.0 cm), which was cleaned in 
between testing with Vimoba, a chlorine dioxide solution.  Freezing was defined as no 
movement other than breathing and measured when mouse movement fell below a preset 
motion threshold of 18.  Mice were moved to a holding room adjacent to the test room and 
acclimated for 1 h before testing under bright light conditions (175-177 lux). For fear 
conditioning procedures, mice were moved to the test room under bright light conditions (175-
177 lux) and placed in the conditioning chamber for 30 seconds.  After the initial one-half 
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minute of habituation, mice were presented with six conditioned stimulus-unconditioned-
stimulus (CS-US) pairings (e.g., tone-footshock pairings) separated by a 30 second interval.  
Each tone (80 dB, 3000 Hz) lasted 30 seconds.  Mice were presented with the electric footshock 
at 0.7 mA the last two seconds of the 30 s tone.  At the end of the fear conditioning protocol, 
mice were returned to the holding room and their home cages.  Twenty-two or six hours later, 
mice were administered either vehicle or a COX-2 inhibitor with or without rimonabant (5 
mg/kg) by i.p. injection two hours before being placed in the conditioning chamber for 
extinction training.   Mice were placed in the conditioning chamber with or without a white 
smooth floor contextual insert that was positioned over the grid floor and a white curved wall 
contextual insert for cued fear extinction and contextual fear extinction training, respectively.  
Vanilla extract was used as a distinctive olfactory cue in the conditioning chamber for the cued 
extinction training.  After 30 seconds of habituation in the chamber, mice were presented with 
20 tones (80 dB, 3000 Hz) with a duration of 30 seconds each and each separated by a 30 
second interval.  After 20 minutes and 30 seconds, mice were returned to a holding room and 
their home cages.  The extinction protocol was repeated the 16 hours later or the following day 
to measure extinction recall. 
High performance liquid chromatography (HPLC).    Tissue sections were homogenized using a 
tissue dismembrator in 100-750 l of 0.1M TCA, which contained 10-2 M sodium acetate, 10-4 M 
EDTA, and 10.5 % methanol (pH 3.8).  Twenty microliters of homogenate was used for the protein 
assay. Then samples were spun in a microcentrifuge at 10,000 g for 20 minutes.  The supernatant 
was removed for analysis on HPLC. Remaining samples were stored at –80oC.   Biogenic amines 
were determined using an Antec Decade II (oxidation: 0.65) electrochemical detector operated at 
33°C.  Twenty microliter samples of the supernatant were injected using a Water 2707 autosampler 
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onto a Phenomenex Kinetix C18 HPLC column (2.6 µm, 4.6 x 100 mm).  Biogenic amines were 
eluted with a mobile phase consisting of 89.5% 0.1 M TCA, 10-2 M sodium acetate, 10-4 M EDTA 
and 10.5 % methanol (pH 3.8).  Solvent was delivered at 0.6 ml/min using a Waters 515 HPLC 
pump.  Using this methodology, the biogenic amines eluted in the following order over 30 minutes: 
norepinephrine, epinephrine, DOPAC, Dopamine, 5-HIAA, HVA, 5-HT, and 3-MT.  HPLC 
control and data acquisition were managed by Empower software.  Amino Acids were determined 
by the Waters AccQ-Tag system utilizing a Waters 2475 Fluorescence Detector. To prepare for 
HPLC analysis, 10 l samples of the supernatant were diluted with 70 l of borate buffer to which 
20 l aliquots of 6-aminoquinol-N-hydroxysuccinimidyl carbamate were added to form the 
fluorescent derivatives. After heating the mixture for 10 minutes at 55C, 10 l of derivatized 
samples were injected into the HPLC system, consisting of a Waters 2707 Autosampler, two 515 
HPLC pumps, column heater (35C), and the fluorescence detector.  Separation of the amino acids 
was accomplished by means of a Waters amino acid column and supplied buffers (A – 19% sodium 
acetate, 7% phosphoric acid, 2% triethylamine, 72% water; B – 60% acetonitrile) using a specific 
gradient profile. HPLC control and data acquisition was managed by Empower 2 software. Amino 
acid concentrations were normalized by the amount of protein in tissue.  Protein concentration was 
determined by a BCA Protein Assay Kit (Thermo Scientific). Ten microliters of the tissue 
homogenate was distributed into a 96-well plate (in duplicate) and 200 l of mixed BCA reagent 
(25 ml of Protein Reagent A is mixed with 500 μl of Protein Reagent B) was added. The plate was 
incubated at room temperature for two hours for color development. A bovine serum albumin 
(BSA) standard curve was ran at the same time. Absorbance was measured by the plate reader 
(POLARstar Omega, BMG LABTECH Company).  
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Corticosterone levels assay.  Trunk blood samples were obtained from mice at the end of the NIFS 
assay under basal and acute and chronic stress conditions.  Blood samples were centrifuged at 1500 
× g for 10 min at 4°C. The plasma was separated and stored at −80°C until assayed for 
corticosterone (CORT). CORT levels in the plasma were determined using a commercially 
available corticosterone enzyme-linked immunosorbent assay (ELISA) kit (Assay Designs, Inc., 
Ann Arbor, MI) according to the manufacturer's instructions. 
Statistical analyses.  For all experiments, statistical significance was calculated by two-tailed 
unpaired Student's t-test or Kolmogorov-Smirnov test (only for frequency plots) or one-way or 
two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test.   
 
Results and Discussion 
Effects of substrate-selective COX-2 inhibition on stress-induced anxiety  
We have previously shown that pharmacologically increasing AEA levels in the brain with 
a fatty acid amide hydrolase inhibitor can enhance CB1R signaling and reverse anxiety-like 
behaviors in animals subjected to acute electric footshock stress133.   Also, we have discovered that 
substrate-selective COX-2 inhibitors (SSCIs) can increase whole brain AEA levels and reduce 
anxiety in animals under basal conditions125.  Thus, SSCIs may have the capacity to reduce 
anxiety-like behaviors in animals subjected to acute and chronic stress.  To test this hypothesis, 
we first performed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure 
AEA levels in amygdala tissue sections from juvenile male ICR (CD-1) mice subjected to no stress 
(controls) or acute (1 day) electric footshock stress and, subsequently, injected intraperitoneally 
(i.p.) with vehicle (dimethyl sulfoxide or DMSO) or the SSCI, LM-4131 (10 mg/kg).  We observed 
a significant increase in AEA levels in the lipid extracts from the brain tissue of LM-4131treated 
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mice under stressed conditions (unpaired, two-tailed t test: ****p < 0.0001, t = 6.854, df = 14, 
LM-4131 (mean ± s.e.m.: 152.5 ± 6.828, N = 8) vs. vehicle (mean ± s.e.m.: 84.47 ± 7.197, N = 8); 
Fig. 2a).  Surprisingly, we did not observe similar changes in AEA levels in the lipid extracts from 
the brain tissue when the mice were not exposed to acute electric footshock stress (unpaired, two-
tailed t test: p = 0.3316, ns (not significant), t = 1.006, df = 14, LM-4131 (mean ± s.e.m.: 179.4 ± 
25.43, N = 8) vs. vehicle (mean ± s.e.m.: 139.0 ± 31.12, N = 8); Fig. 2a).  This discrepancy may 
be due to variability in the amygdala tissue samples.  Increasing the number of samples used in 
quantifying AEA in the amygdala lipid extracts could have increased the chance of detecting a 
difference between the vehicle- and LM-4131-treated sample populations.  Thus, an increase in 
the sample size of the amygdala tissue sections could have increased the statistical power of the 
comparison being made, reduce random sample variation, and thus improve the reliability of the 
p value for the comparison164.  Since we were not able to reproduce similar increases in AEA levels 
in the amygdala lipid extracts under basal conditions as we have shown previously with the SSCI, 
LM-4131, in whole brain lipid extracts125, another alternative to this inconsistency in amygdala 
AEA levels is possible.  The subregions of the amygdala may have different roles when responding 
to the degree of aversiveness from external stimuli and whether or not such aversiveness can evoke 
a negative emotion.  This may explain the differences in the amygdala AEA levels when an animal 
is subjected to a non-aversive stimulus in comparison to one that is aversive and capable of 
inducing fear or anxiety-like behavior, such as an electric footshock133,165.  Several studies in 
humans and rodents have suggested that amygdala subregions respond differently to emotional 
and non-emotional stimuli.  Using diffusion tensor imaging (DTI) and high-resolution blood 
oxygenation level-dependent (BOLD) imaging, Balderson and others identified the basolateral 
subregion of the amygdala as responsive to all external stimuli and the centromedial subregion of 
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Figure 2.  Stress-induced anxiety and anhedonic behavioral effects of substrate-selective COX-2 inhibition.  
(a) Quantification of the endocannabinoid, anandamide (AEA), in amygdala lipid extracts using LC-MS/MS and 
after mice were exposed to non-stressful and acute stress conditions.  (b) Diagram of experimental design for 
NIFS. (c) Latency to feed in home cage environment under red light illumination and non-stressful or acute stress 
conditions.  (d, e) Cumulative frequency of mice feeding and latency to feed in NIFS test under non-stressful and 
acute stress conditions, respectively.  (f) Feeding latency before acute stress exposure (trait anxiety) and after acute 
stress exposure (state anxiety) for respective COX-2 inhibitor treatment groups but prior to treatment (left in novel 
cage environment).  Change in feeding latency between state anxiety prior to treatment and after acute stress 
exposure and treatment of COX-2 inhibitor (right) in novel cage environment.  (g) Latency to feed at different 
time points after acute stress exposure in novel cage environment.  (h) Cumulative frequency of mice feeding and 
latency to feed in NIFS test under acute stress conditions after administering drugs two hours prior to stressor in 
novel cage environment.  (i) Total amount of shake consumed compared between home cage and novel cage 
environment under non-stressful conditions.  (j) Total amount of shake consumed in home cage environment under 
red light illumination and non-stressful or acute stress conditions.  (k, l) Cumulative frequency of mice consuming 
shake and amount of shake consumed in NIFS test under non-stressful and acute stress conditions, respectively, in 
novel cage environment.  Data are shown as the mean ± s.e.m.  NS = no stress, S = stress (e.g., stress exposure in 
the form of an electric footshock administered 8h prior to testing), *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. 
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the amygdala as responsive to external stimuli that predicts an aversive outcome166.  Animal 
studies have shown that the basolateral nucleus of the amygdala (BLA) plays a role in determining 
the aversive value of an external stimulus, such as an electric footshock, whereas the basomedial 
amygdala (BMA) functions in distinguishing between environments that are assigned a safe or 
aversive value167. 
To determine if the increases observed in amygdala AEA levels showed a relationship with 
the anxiolytic nature of SSCIs, we assessed anxiety-like behavior in the mice using the novelty-
induced feeding suppression (NIFS) assay (Fig. 2b).  To do this, we measured feeding latency 
(e.g., time lapsed from the start of the NIFS assay to the first consumption of a palatable vanilla 
ENSURE® shake) in a home cage environment under red light illumination and in a novel cage 
environment under bright illumination after the mice were exposed to either basal (no stress) or 
acute footshock conditions.  Since LM-4131-induced increases in amygdala AEA levels were more 
robust under stressed conditions, this enabled us to ascertain if the SSCIs ability to  reduce anxiety-
like behavior in the mice depended on the degree of aversiveness or novelty of the cage 
environment used in the NIFS assay, the degree of aversiveness of stress exposure, or a 
combination of the two.  When the mice were tested in a safe, familiar cage environment (e.g., 
home cage) under basal conditions, we observed no changes in feeding latency between all COX-
2 inhibitor treatment groups and the vehicle treatment group (one-way ANOVA: F(3, 36) = 0.5460, 
p = 0.6540, ns; Holm-Sidak’s multiple comparisons test: ns, t = 0.09107, df = 36, LM-4131 (mean 
± s.e.m.: 4.900 ± 4.392, N = 10) vs. vehicle (mean ± s.e.m.: 5.300 ± 4.392, N = 10); ns, t = 0.6375, df = 
36, LMX (mean ± s.e.m.: 2.500 ± 4.392, N = 10) or celecoxib (mean ± s.e.m.: 8.100 ± 4.392, N = 10) vs. 
vehicle (mean ± s.e.m.: 5.300 ± 4.392, N = 10); Fig. 2c (left panel)).  However, when we tested the 
mice in the same cage environment 8 hours after being subjected to acute electric footshock stress, 
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we observed a decrease in feeding latency in mice treated with the substrate-selective COX-2 
inhibitor, LM-4131, compared to those treated with vehicle (one-way ANOVA: F(3, 36) = 3.542, p 
= 0.0240, *p<0.05; Holm-Sidak’s multiple comparisons test: **p<0.01, t = 3.161, df = 36, LM-
4131 (mean ± s.e.m.: 3.500 ± 2.404, N = 10) vs. vehicle (mean ± s.e.m.: 11.10 ± 2.404, N = 10); 
ns, t = 2.163, df = 36, LMX (mean ± s.e.m.: 5.900 ± 2.404, N = 10) vs. vehicle (mean ± s.e.m.: 
11.10 ± 2.404, N = 10); ns, t = 2.121, df = 36, celecoxib (mean ± s.e.m.: 6.000 ± 2.404, N = 10) 
vs. vehicle (mean ± s.e.m.: 11.10 ± 2.404, N = 10); Fig. 2c (right panel)).  Further analysis with an 
unpaired t test revealed a significant difference in the means of the LM-4131 or LMX treatment 
group compared to the vehicle treatment group (p=0.0046, **p<0.01, t = 3.239, df = 18, LM-4131 
(mean ± s.e.m.: 3.500 ± 1.522, N = 10) vs. vehicle (mean ± s.e.m.: 11.10 ± 1.785, N = 10); p=0.0438, 
*p<0.05, t = 2.168, df = 18, LMX (mean ± s.e.m.: 5.900 ± 1.602, N = 10) vs. vehicle). 
Since we observed decreased anxiety-like behavior in the juvenile male mice under 
stressed conditions in the home cage environment, we wanted to determine next if increasing the 
aversiveness or novelty of the cage environment would change the anxiolytic action of the SSCIs 
previously demonstrated in the non-stressful home cage environment.  To increase the 
aversiveness or novelty of the cage, we removed all bedding and placed a white paper towel under 
the cage to amplify the intensity of the bright light illumination of the cage.  This change in the 
environmental context of the cage can induce anxious behavior in mice since mice have a tendency 
to avoid well-lit areas in favor of ones that are dark and can exhibit neophobia (e.g., an animal’s 
hesitation to explore a new or novel environment) in stressful or fear-inducing environments.  Of 
all of the COX-2 inhibitors administered i.p. to the mice, only LM-4131 slightly decreased anxiety-
like behavior in the mice under no stress in the mildly stressful, novel cage environment.  
According to the cumulative frequency distribution percentile plot of juvenile (5-7 weeks of age) 
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ICR male mice feeding in the NIFS assay (Fig. 2d (left panel)), 100% of vehicle-treated mice had 
a feeding latency ≤ 1755 s (e.g., 100th percentile), 100% of LM-4131-treated mice had a feeding 
latency ≤ 870 s, 100% of LMX-treated mice had a feeding latency ≤ 345 s, and 100% of celecoxib-
treated mice had a feeding latency ≤ 255 s in the novel cage environment.  A Kolmogorov-Smirnov 
(K-S) test of the feeding latency data presented in the cumulative frequency distribution percentile 
plot revealed significant differences between the cumulative frequency distribution for all COX-2 
inhibitor treatment groups and the cumulative frequency distribution for the vehicle treatment 
group (D = 0.5950, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle; D = 0.7769, ****p < 
0.0001, LMX at 1 mg/kg vs. vehicle; D = 0.8264, ****p < 0.0001, celecoxib at 10 mg/kg vs. 
vehicle; Fig. 2d (left panel)).  Thus, there is a high likelihood that the two treatment groups (e.g., 
COX-2 inhibitor vs vehicle) are derived from different populations.  This is based on the fact that 
the K-S test statistic, D (e.g., the maximum vertical deviation or distance between two distribution 
curves), is greater than the critical value of the comparisons being made between the COX-2 
inhibitor and vehicle treatment groups.  More specifically, the feeding latency data indicate that 
the feeding latency of mice treated with a COX-2 inhibitor is significantly less than the feeding 
latency of mice treated with vehicle.  When the same set of feeding latency data was evaluated 
with one-way analysis of variance (ANOVA), we found that the results acquired with the one-way 
ANOVA was consistent only with the results for the LM-4131 treatment group obtained with the 
Kolmogorov-Smirnov test.  There was a significant difference among the means for feeding 
latency between the LM-4131 treatment group and the vehicle treatment group (one-way ANOVA: 
F(3, 108) = 3.440, p = 0.0194, *p < 0.05; Holm-Sidak’s multiple comparisons test: *p < 0.05, t = 
2.528, df = 108, LM-4131 (mean ± s.e.m.: 192.7 ± 54.27, N = 46) vs. vehicle (mean ± s.e.m.: 329.9 
± 54.27, N = 45); ns, t = 2.222, df = 108, LMX (mean ± s.e.m.: 153.9 ± 79.21, N = 14) vs. vehicle 
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(mean ± s.e.m.: 329.9 ± 79.21, N = 45); ns, t = 2.109, df = 108, celecoxib (mean ± s.e.m.: 108.1 ± 
105.2, N = 7) vs. vehicle (mean ± s.e.m.: 329.9 ± 105.2, N = 45); Fig. 2d (right panel)).  A 
discrepancy between the results obtained from the K-S test and the one-way ANOVA may be due 
to the oversensitivity of the K-S test near the center as opposed to the tails of the distribution of 
the feeding latency data from the LMX and celecoxib treatment groups.  It could also be due to 
the small sample size in the LMX and celecoxib treatment groups as compared to vehicle and LM-
4131 treatment groups.  One-way ANOVA with small sample sizes may not have enough power 
to detect significant differences among the samples even if the means are different.  Power 
decreases as the sample variance increases and sample size decreases168. 
All COX-2 inhibitors decreased feeding latency when the mice were tested in the aversive, 
novel cage environment 8 hours after exposure to acute footshock stress.  According to the 
cumulative frequency distribution percentile plot of juvenile ICR male mice feeding in the NIFS 
assay (Fig. 2e (left panel)), 100% of vehicle-treated mice had a feeding latency ≤ 1800 s, 100% of 
LM-4131-treated mice had a feeding latency ≤ 420 s, 100% of LMX-treated mice had a feeding 
latency ≤ 600 s, and 100% of celecoxib-treated mice had a feeding latency ≤ 465 s in the novel 
cage environment.  A Kolmogorov-Smirnov test of the feeding latency data presented in the 
percentile plot revealed a significant difference between the cumulative frequency distributions 
for all COX-2 inhibitor treatment groups and the cumulative frequency distribution for the vehicle 
treatment group (D = 0.8430, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle; D = 0.6942, 
****p < 0.0001, LMX at 1 mg/kg vs. vehicle; D = 0.7603, ****p < 0.0001, celecoxib at 10 mg/kg 
vs. vehicle; Fig. 2e (left panel)).  There was a significant difference among the means for feeding 
latency between all COX-2 inhibitor treatment groups and the vehicle treatment group (one-way 
ANOVA: F(3, 120) = 8.165, ****p < 0.0001; Holm-Sidak’s multiple comparisons test: ****p < 
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0.0001, t = 4.671, df = 120, LM-4131 (mean ± s.e.m.: 141.3 ± 74.02, N = 36) vs. vehicle (mean ± 
s.e.m.: 487.0 ± 74.02, N = 54); **p < 0.01, t = 2.980, df = 120, LMX (mean ± s.e.m.: 231.7 ± 
85.66, N = 23) vs. vehicle (mean ± s.e.m.: 487.0 ± 85.66, N = 54); *p < 0.05, t = 2.142, df = 120, 
celecoxib (mean ± s.e.m.: 243.2 ± 113.8, N = 11) vs. vehicle (mean ± s.e.m.: 487.0 ± 113.8, N = 
54); Fig. 2e (right panel)).  Our findings thus far suggest that substrate-selective COX-2 inhibition 
can reduce anxiogenic behaviors in juvenile male mice under both basal and stressed conditions.  
However, the anxiolytic effects of SSCI in the mice were more robust when the mice were either 
exposed to environmental stress (e.g., environments with bright light illumination) or exposed to 
a form of physical stress that can induce anxiety or fear (e.g., electric footshock stress) in the mice.  
Thus, one plausible explanation for these results could be that COX-2 expression in the brain can 
be differentially modulated by stress exposure severity and duration.  Various stressors, such as 
acute cold swim stress and immobilization stress, have been shown to cause a prolonged elevation 
and attenuated degradation in COX-2 protein levels and an increase in PGE2 levels, a biomarker 
for COX-2 activity94,157,158,169,170.  Moreover, we have previously shown that components of the 
endocannabinoid system are sensitive to environmental stress, specifically bright light 
illumination, and, subsequently, can modulate anxiogenic behaviors in mice differentially115.  
Accordingly, our acute traumatic stress paradigm may have the potential to increase COX-2 
expression in limbic brain regions, such as the amygdala, involved in modulating stress responses.  
If this is so, stress-induced increases in COX-2 expression levels in the brain could increase the 
availability of COX-2 protein to be acted upon by a substrate-selective COX-2 inhibitor, such as 
LM-4131 or LMX, thereby increasing the efficacy of the SSCIs in reducing anxiogenic behaviors 
in mice.   
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Pre-stress or trauma psychopathologies, such as anxiety or depression disorders, are 
believed to represent risk factors for the development and persistence of anxiety and stressor-
related or trauma-related disorders.  However, inter-individual variability in stress responses, such 
as anxiety-like behavioral phenotypes, may account for different vulnerability in humans and 
rodents to develop anxiety-like symptoms during or after stress exposure.  In addition, anxiety-
like behaviors under basal conditions are not always predictive of anxiety-like behavioral 
responses due to stress exposure.  The behavioral response of an individual mouse to acute stress 
is multifaceted and involves genetic and environmental factors that play a major role in 
characterizing an individual behavioral response to stress exposure.  Thus, a potential problem in 
interpreting the anxiolytic potential of a COX-2 inhibitor is individual variability within the ICR 
mouse strain regarding their anxiety-like behavioral responses in the NIFS assay or other 
behavioral assays that assess anxiety (i.e., elevated plus maze) after being subjected to the acute 
footshock stress paradigm.  Accordingly, the efficacy of a COX-2 inhibitor in reducing stress-
induced anxiety in the mice we used for our studies may be affected by the degree of individual 
variability in anxiety-like behavioral responses within each cohort of mice.  To examine the degree 
to which the SSCI, LM-4131, in comparison to the other COX-2 inhibitors, LMX and celecoxib, 
can reduce feeding latency regardless of an animal’s anxiety-like behavioral characteristics under 
control (no stress) conditions and after exposure to an external stressor (e.g., electric footshock) in 
the NIFS assay, we first measured feeding latency in a cohort of mice in the NIFS assay under 
basal conditions (trait anxiety or intrinsic basal anxiety characteristic) and then a week later after 
stress conditions (state anxiety or anxiety characteristic induced by an external stimulus, such as 
footshock stress) (Fig. 2f (left panel)).  Next, we measured feeding latency again within the same 
cohort of mice after systemic administration of the different COX-2 inhibitors in the NIFS assay 
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and acute stress exposure (e.g., one week after assessing feeding latency in the NIFS assay after 
acute footshock stress exposure without systemic drug administration).  We summarized these 
findings in a histogram (Fig. 2f (right panel)) that depicts the change in () feeding latency between 
the different treatment groups from the time the mice were exposed to acute footshock stress before 
drug administration to the time the same set of mice were exposed to acute footshock stress again 
and administered a COX-2 inhibitor by i.p.  The change in feeding latency was calculated as 
follows:  in feeding latency = [feeding latency of a mouse after stress exposure and i.p. drug 
administration (S + 8h + Drug) – feeding latency of a mouse after stress exposure without i.p. drug 
administration (S + 8h)] divided by feeding latency of a mouse after stress exposure without i.p. 
drug administration (S + 8h).  We found that regardless of an animal’s anxiety-like behavioral 
responses at baseline and after exposure to an external stressor (Fig. 2f (left panel)), the SSCI, LM-
4131, was more effective at reducing anxiety-like behavior in the mice subjected to acute stress in 
comparison to another SSCI, LMX (one-way ANOVA: F(2, 65) = 28.14, ****p < 0.0001; Holm-
Sidak’s multiple comparisons test: ****p < 0.0001, t = 7.496, df = 65, LM-4131 (mean ± s.e.m.: 
-0.7672 ± 0.3096, N = 45) vs. LMX (mean ± s.e.m.: 1.553 ± 0.3096, N = 12); Fig. 2f (right panel)).  
There was no difference among the means for feeding latency between the LM-4131 treatment 
group and the celecoxib treatment group (Holm-Sidak’s multiple comparisons test: ns, t = 1.832, 
df = 65, LM-4131 (mean ± s.e.m.: -0.7672 ± 0.3205, N = 45) vs. celecoxib (mean ± s.e.m.: -0.1802 
± 0.3205, N = 11); Fig. 2f (right panel)).  Thus, celecoxib was just as effective as LM-4131 at 
reducing stress-induced anxiety-like behavior in the mice.  Differences in the effectiveness of the 
COX-2 inhibitors to reduce stress-induced anxiety-like behaviors in mice with variable levels of 
trait and state anxiety may depend on where and how the COX-2 inhibitors bind to the COX-2 
protein.  Substrate-selective COX-2 inhibitors bind to one of two active sites of the COX-2 
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homodimer and induce a conformational change in the catalytic active site, inhibiting the 
oxygenation of the endocannabinoids, 2-AG and AEA, but not arachidonic acid.  In particular, 
LMX binds in an inverted orientation in the active site of COX-2, forming hydrogen bonds 
between its carboxylic acid group and serine at position 530 and tyrosine at position 385 in the 
active site of COX-2162,171.  LM-4131, on the other hand, has reduced hydrogen-bonding capacity 
since its carboxylic acid group has been converted to a tertiary amide that forms bonds with 
tyrosine at position 355 and arginine at position 120 in the active site of COX-2162.  Moreover, 
COX-2’s efficiency toward oxygenation of arachidonic acid or an endocannabinoid has been 
suggested to depend on if substrates for COX-2 bind to either the catalytic or allosteric sites of 
COX-2 or both sites and to what extent these substrates allosterically modulate COX-2172. 
We chose the 8h post-stress time point for testing the mice for anxiety-like behaviors due 
to the robustness of our preliminary findings that LM-4131 can reduce stress-induced anxiety-like 
behaviors in the NIFS assay more effectively at the 8h post-stress time point than at other time 
points (e.g., 4h, 24h, and 72h) and in comparison to the effects of the other COX-2 inhibitors on 
anxiety-like behavior in the NIFS assay under stressed conditions (Fig. 2g and see APPENDIX 
Fig. A).  According to the cumulative frequency distribution percentile plot of mice feeding in the 
NIFS assay 4h post-footshock stress (Fig. Aa (left panel)), 100% of vehicle-treated mice had a 
feeding latency ≤ 750 s and 100% of LM-4131-treated mice had a feeding latency ≤ 390 s in the 
novel cage environment.  A Kolmogorov-Smirnov test of the feeding latency data presented in the 
percentile plot revealed a significant difference between the cumulative frequency distribution for 
the LM-4131 treatment group and the cumulative frequency distribution for the vehicle treatment 
group (D = 0.1983, p = 0.0171, *p < 0.05, LM-4131 at 10 mg/kg vs. vehicle).  Thus, four hours 
post-footshock stress LM-4131 caused a decrease in feeding latency in mice.  A Mann Whitney 
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test indicated that the feeding latency was greater for vehicle-treated mice (median = 238 s) than 
for the LM-4131-treated mice (median = 126 s), U = 15.00, p = 0.0124, *p < 0.05 (Fig. Aa (right 
panel)).  According to the cumulative frequency distribution percentile plot of mice feeding in the 
NIFS assay 24h post-footshock stress (Fig. Ab (left panel)), 100% of vehicle-treated mice had a 
feeding latency ≤ 1095 s, 100% of LM-4131-treated mice had a feeding latency ≤ 390 s, and 100% 
of LMX-treated mice had a feeding latency ≤ 450 s in the novel cage environment.  A Kolmogorov-
Smirnov test of the feeding latency data presented in the percentile plot revealed a significant 
difference between the cumulative frequency distribution for the LM-4131 and LMX treatment 
groups and the cumulative frequency distribution for the vehicle treatment group (D = 0.3884, 
****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle; D = 0.3554, ****p < 0.0001, LMX at 1 mg/kg 
vs. vehicle).  Thus, 24 hours post-footshock stress LM-4131 and LMX caused a decrease in feeding 
latency in mice.  A Mann Whitney test indicated that the feeding latency was greater for vehicle-
treated mice than for the LM-4131-treated mice (U = 117.0, p = 0.0007, ***p < 0.001; LM-4131 
(median = 146.5 s) vs. vehicle (median = 319.0 s)) and the LMX-treated mice (U = 59.00, p = 
0.0081, **p < 0.01; LMX (median = 140.5 s) vs. vehicle (median = 319.0 s); Fig. Ab (right panel)).  
According to the cumulative frequency distribution percentile plot of mice feeding in the NIFS 
assay 72h post-footshock stress (Fig. Ac (left panel)), 100% of vehicle-treated mice had a feeding 
latency ≤ 660 s and 100% of LM-4131-treated mice had a feeding latency ≤ 375 s in the novel 
cage environment.  A Kolmogorov-Smirnov test of the feeding latency data presented in the 
percentile plot revealed no difference between the cumulative frequency distribution for the LM-
4131 treatment group and the cumulative frequency distribution for the vehicle treatment group 
(D = 0.1570, p = 0.1012, ns, LM-4131 at 10 mg/kg vs. vehicle).  Thus, 72 hours post-footshock 
stress LM-4131 caused no changes in feeding latency in mice.  A Mann Whitney test indicated 
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that the feeding latency was similar for vehicle-treated mice (median = 268 s) and for the LM-
4131-treated mice (median = 206 s), U = 37.00, p = 0.3473, ns (Fig. Ac (right panel)).   
Since the COX-2 inhibitors were effective at reducing stress-induced anxiety-like behavior 
in the NIFS assay 8h after acute stress exposure, we determined if the anxiolytic potential of the 
COX-2 inhibitors remained before an animal was exposed to acute footshock stress and tested in 
the NIFS assay 8 hours later.  Interestingly, none of the COX-2 inhibitors, LM-4131, LMX, or 
celecoxib, were able to prevent stress-induced anxiety-like behaviors in the NIFS assay (Fig. 2h) 
even though other studies have illustrated that COX-2 inhibitors are neuroprotective against stress-
induced behavioral changes in animals159,160.  According to the cumulative frequency distribution 
percentile plot of juvenile ICR male mice feeding in the NIFS assay (Fig. 2h (left panel)), 100% 
of vehicle-treated mice had a feeding latency ≤ 645 s, 100% of LM-4131-treated mice had a 
feeding latency ≤ 660 s, 100% of LMX-treated mice had a feeding latency ≤ 345 s, and 100% of 
celecoxib-treated mice had a feeding latency ≤ 285 s in the novel cage environment.  A 
Kolmogorov-Smirnov test of the feeding latency data presented in the percentile plot revealed a 
significant difference only between the cumulative frequency distributions for the celecoxib 
treatment group and the cumulative frequency distribution for the vehicle treatment group (D = 
0.07438, p = 0.8914, ns, LM-4131 at 10 mg/kg vs. vehicle; D = 0.1653, p = 0.0733, ns, LMX at 1 
mg/kg vs. vehicle; D = 0.1983, p = 0.0171, *p < 0.05, celecoxib at 10 mg/kg vs. vehicle; Fig. 2h 
(left panel)).  There was no difference among the means for feeding latency between all COX-2 
inhibitor treatment groups and the vehicle treatment group (one-way ANOVA: F(3, 32) = 0.4616, p 
= 0.7111, ns; Holm-Sidak’s multiple comparisons test: ns, t = 0.04327, df = 32, LM-4131 (mean 
± s.e.m.: 241.2 ± 67.55, N = 13) vs. vehicle (mean ± s.e.m.: 238.3 ± 67.55, N = 13); ns, t = 0.2152, 
df = 32, LMX (mean ± s.e.m.: 218.8 ± 90.63, N = 5) vs. vehicle (mean ± s.e.m.: 238.3 ± 90.63, N 
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= 13); ns, t = 1.074, df = 32, celecoxib (mean ± s.e.m.: 238.3 ± 90.63, N = 5) vs. vehicle (mean ± 
s.e.m.: 238.3 ± 90.63, N = 13); Fig. 2h (right panel)).  A discrepancy between the results obtained 
from the K-S test and the one-way ANOVA may be due to the oversensitivity of the K-S test near 
the center as opposed to the tails of the distribution of the feeding latency data from the celecoxib 
treatment group.  It could also be due to the small sample size in the celecoxib treatment group as 
compared to vehicle and LM-4131 treatment groups.  One-way ANOVA with small sample sizes 
may not have enough power to detect significant differences among the samples even if the means 
are different.  Power decreases as the sample variance increases and sample size decreases168. 
 
Effects of SSCI on stress-induced anhedonia and despair-like behavior 
Since anxiety-like behaviors have been suggested to be co-morbid with depressive-like 
behaviors173-177, we wanted to determine the antidepressant potential of the SSCI, LM-4131.  First, 
we measured anhedonia or loss of interest or pleasure in consuming a sweet, palatable ENSURE® 
vanilla shake in the NIH test.  Anhedonia is a core feature of major depression in humans178-180.  
In addition, previous studies have suggested that hedonic deficits in rodents can occur after 
exposure to stress or placed in a stressful environmental context181,182.  The NIH test can measure 
both anhedonia and hyponeophagia, a predictor of the anxiolytic effects of antidepressants, by 
determining how much of a sweet, palatable fluid an animal can consume in response to an 
anxiogenic, novel environment as opposed to a nonanxiogenic, familiar environment.  In the NIH 
test, animals experience conflict between the desire to approach and consume a palatable liquid 
and the anxiety-induced avoidance of the novel environment (e.g., a new cage without bedding 
and illuminated by bright light)183,184.   We have found that the NIH test in a mildly stressful, novel 
cage environment can induce both anhedonia and hyponeophagia.  An unpaired t test revealed a 
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significant difference in the means of the amount of consumption of a sweet, palatable shake in 
mice tested in the nonanxiogenic and familiar, home cage environment compared to the same mice 
that were tested one day later in the anxiogenic, novel cage environment (****p<0.0001, t = 7.107, 
df = 54, novel (mean ± s.e.m.: 0.5321 ± 0.05682, N = 28) vs. home (mean ± s.e.m.: 1.521 ± 0.1271, N = 
28); Fig. 2i).  We also found that LM-4131 was able to decrease anhedonia in the NIH test only 
when the mice were previously exposed 8h earlier to an acute stressor regardless of the 
aversiveness of the cage environment in the NIH test.  When the mice were tested in a safe, familiar 
cage environment (e.g., home cage) under basal conditions, we observed no changes in shake 
consumption between all COX-2 inhibitor treatment groups and the vehicle treatment group (one-
way ANOVA: F(3, 36) = 1.003, p = 0.4028, ns; Holm-Sidak’s multiple comparisons test: ns, t = 
0.08231, df = 36, LM-4131 (mean ± s.e.m.: 1.330 ± 0.2430, N = 10) vs. vehicle (mean ± s.e.m.: 1.310 
± 0.2430, N = 10); ns, t = 0.8231, df = 36, LMX (mean ± s.e.m.: 1.510 ± 0.2430, N = 10) or celecoxib 
(mean ± s.e.m.: 1.090 ± 0.2430, N = 10) vs. vehicle (mean ± s.e.m.: 1.310 ± 0.2430, N = 10); Fig. 2j (left 
panel)).  However, when we tested the mice in the same cage environment 8 hours after being 
subjected to acute electric footshock stress, we observed an increase in shake consumption in mice 
treated with the substrate-selective COX-2 inhibitor, LM-4131, compared to those treated with 
vehicle.  An unpaired t test revealed a significant difference in the means of the LM-4131 treatment 
group compared to the vehicle treatment group (p=0.0319, *p<0.05, t = 2.326, df = 18, LM-4131 
(mean ± s.e.m.: 1.440 ± 0.1536, N = 10) vs. vehicle (mean ± s.e.m.: 0.8500 ± 0.2018, N = 10); p=0.1340, 
ns, t = 1.569, df = 18, LMX (mean ± s.e.m.: 1.290 ± 0.1946, N = 10) vs. vehicle; p=0.0632, ns, t = 
1.980, df = 18, celecoxib (mean ± s.e.m.: 1.370 ± 0.1680, N = 10) vs. vehicle; Fig. 2j (right panel)). 
Since we observed decreased anhedonia in the juvenile male mice under stressed 
conditions in the home cage environment, we wanted to determine next the effect of the SSCI, 
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LM-4131, on hyponeophagia and if increasing the aversiveness or novelty of the cage environment 
would change the hedonic action of the SSCIs previously demonstrated in the non-stressful home 
cage environment.  None of the COX-2 inhibitors administered by i.p. to the mice decreased 
anhedonia and hyponeophagia in the mice under no stress in the mildly stressful, novel cage 
environment.  According to the cumulative frequency distribution percentile plot of juvenile (5-7 
weeks of age) ICR male mice feeding in the NIFS assay (Fig. 2k (left panel)), 25% of vehicle-
treated mice consumed ≤ 0.4 g of the shake (e.g., 25th percentile), 25% of LM-4131-treated mice 
consumed ≤ 0.55 g of the shake, 25% of LMX-treated mice consumed ≤ 0.575 g of the shake, and 
25% of celecoxib-treated mice consumed ≤ 0.7 g of the shake in the novel cage environment.  A 
Kolmogorov-Smirnov (K-S) test of the shake consumption data presented in the cumulative 
frequency distribution percentile plot revealed significant differences between the cumulative 
frequency distribution for the LMX and celecoxib treatment groups and the cumulative frequency 
distribution for the vehicle treatment group (D = 0.1563, p = 0.1918, ns, LM-4131 at 10 mg/kg vs. 
vehicle; D = 0.2604, p = 0.0030, **p < 0.01, LMX at 1 mg/kg vs. vehicle; D = 0.2083, p = 0.0310, 
*p < 0.05, celecoxib at 10 mg/kg vs. vehicle; Fig. 2k (left panel)).  Thus, there is a likelihood that 
the two treatment groups (e.g., the COX-2 inhibitor, LMX or celecoxib, vs. vehicle) are derived 
from different populations.  The shake consumption data indicate that the shake consumption in 
mice treated with the COX-2 inhibitor, LMX or celecoxib, is significantly greater than the shake 
consumption in mice treated with vehicle.  When the same set of shake consumption data was 
evaluated with one-way analysis of variance (ANOVA), we found that the results acquired with 
the one-way ANOVA were not consistent with the results for the LMX or celecoxib treatment 
group obtained with the Kolmogorov-Smirnov test.  There was no significant difference among 
the means for shake consumption between the LMX or celecoxib treatment group and the vehicle 
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treatment group (one-way ANOVA: F(3, 91) = 1.173, p = 0.3243, ns; Holm-Sidak’s multiple 
comparisons test: ns, t = 1.649, df = 91, LM-4131 (mean ± s.e.m.: 0.9000 ± 0.09668, N = 37) vs. 
vehicle (mean ± s.e.m.: 0.7405 ± 0.09668, N = 37); ns, t = 1.003, df = 91, LMX (mean ± s.e.m.: 
0.8714 ± 0.1305, N = 14) vs. vehicle (mean ± s.e.m.: 0.7405 ± 0.1305, N = 37); ns, t = 1.264, df = 
91, celecoxib (mean ± s.e.m.: 0.9571 ± 0.1714, N = 7) vs. vehicle (mean ± s.e.m.: 0.7405 ± 0.1714, 
N = 37); Fig. 2k (right panel)).  A discrepancy between the results obtained from the K-S test and 
the one-way ANOVA may be due to the oversensitivity of the K-S test and the small sample size 
in the LMX and celecoxib treatment groups as compared to the vehicle and LM-4131 treatment 
groups. 
Of all the COX-2 inhibitors, only LM-4131 decreased anhedonia and hyponeophagia when 
the mice were tested in the aversive, novel cage environment 8 hours after exposure to acute 
footshock stress.  According to the cumulative frequency distribution percentile plot of juvenile 
ICR male mice feeding in the NIFS assay (Fig. 2l (left panel)), 100% of vehicle-treated mice 
consumed ≤ 1.12 g of the shake, 100% of LM-4131-treated mice consumed ≤ 1.62 g of the shake, 
100% of LMX-treated mice consumed ≤ 0.92 g of the shake, and 100% of celecoxib-treated mice 
consumed ≤ 1.20 g of the shake in the novel cage environment.  A Kolmogorov-Smirnov test of 
the shake consumption data presented in the percentile plot revealed a significant difference 
between the cumulative frequency distributions for the LM-4131 and LMX treatment groups and 
the cumulative frequency distribution for the vehicle treatment group (D = 0.2970, p = 0.0003, 
***p < 0.001, LM-4131 at 10 mg/kg vs. vehicle; D = 0.1980, p = 0.0381, *p < 0.05, LMX at 1 
mg/kg vs. vehicle; D = 0.2153, p = 0.2153, ns, celecoxib at 10 mg/kg vs. vehicle; Fig. 2l (left 
panel)).  There was a significant difference among the means for feeding latency between the LM-
4131 treatment group and the vehicle treatment group (one-way ANOVA: F(3, 105) = 5.731, p = 
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0.0011, **p < 0.01; Holm-Sidak’s multiple comparisons test: **p < 0.01, t = 3.355, df = 105, LM-
4131 (mean ± s.e.m.: 0.8306 ± 0.09625, N = 36) vs. vehicle (mean ± s.e.m.: 0.5077 ± 0.09625, N 
= 39); ns, t = 0.4674, df = 105, LMX (mean ± s.e.m.: 0.4565 ± 0.1095, N = 23) vs. vehicle (mean 
± s.e.m.: 0.5077 ± 0.1095, N = 39); ns, t = 0.4378, df = 105, celecoxib (mean ± s.e.m.: 0.4455 ± 
0.1422, N = 11) vs. vehicle (mean ± s.e.m.: 0.5077 ± 0.1422, N = 39); Fig. 2l (right panel)). 
We investigated the effects of substrate-selective COX-2 inhibition on stress-induced 
anhedonia and hyponeophagia in the NIH test after mice were subjected to acute footshock stress 
4 h, 24 h, and 72 h prior to testing (see APPENDIX Fig. A).  We found that the SSCI, LM-4131, 
decreased anhedonia and hyponeophagia in juvenile male mice 24 h and 72 h after acute footshock 
stress exposure.  We compared these findings to another SSCI, LMX, and found similar results as 
regards to the 24 h post-footshock stress time point.  According to the cumulative frequency 
distribution percentile plot of mice feeding in the NIFS assay 4h post-footshock stress (Fig. Ad 
(left panel)), 75% of vehicle-treated mice consumed ≤ 1.425 g of the shake (75th percentile) and 
75% of LM-4131-treated mice consumed ≤ 1.175 g of the shake in the novel cage environment.  
A Kolmogorov-Smirnov test of the shake consumption data presented in the percentile plot 
revealed a significant difference between the cumulative frequency distribution for the LM-4131 
treatment group and the cumulative frequency distribution for the vehicle treatment group (D = 
0.2088, p = 0.0379, *p < 0.05, LM-4131 at 10 mg/kg vs. vehicle).  However, a Mann Whitney test 
indicated that the shake consumption was similar for the vehicle-treated mice (median = 0.9000 g) 
and the LM-4131-treated mice (median = 0.8500 g), U = 48.50, p = 0.9259, ns (Fig. Ad (right 
panel)).  According to the cumulative frequency distribution percentile plot of mice feeding in the 
NIFS assay 24h post-footshock stress (Fig. Ae (left panel)), 100% of vehicle-treated mice 
consumed ≤ 1.1 g of the shake (e.g., 100th percentile), 100% of LM-4131-treated mice consumed 
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≤ 2.1 g of the shake, and 100% of LMX-treated mice consumed ≤ 0.8 g of the shake in the novel 
cage environment.  A Kolmogorov-Smirnov test of the shake consumption data presented in the 
percentile plot revealed a significant difference between the cumulative frequency distribution for 
the LM-4131 and LMX treatment groups and the cumulative frequency distribution for the vehicle 
treatment group (D = 0.3465, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle; D = 0.2970, p = 
0.0003, ***p < 0.001, LMX at 1 mg/kg vs. vehicle).  Thus, 24 hours post-footshock stress LM-
4131 caused an increase in shake consumption whereas LMX caused a decrease in shake 
consumption in mice.  A Mann Whitney test indicated that the shake consumption was greater for 
LM-4131-treated mice than for the vehicle-treated mice (U = 117.0, p = 0.0007, ***p < 0.001; 
LM-4131 (median = 1.100 g) vs. vehicle (median = 0.6500 g)) and lesser for the LMX-treated 
mice than for the vehicle-treated mice (U = 58.00, p = 0.0141, *p < 0.05; LMX (median = 0.2500 
g) vs. vehicle (median = 0.6500 g); Fig. Ae (right panel)).  According to the cumulative frequency 
distribution percentile plot of mice feeding in the NIFS assay 72h post-footshock stress (Fig. Af 
(left panel)), 100% of vehicle-treated mice consumed ≤ 0.7 g of the shake and 100% of LM-4131-
treated mice consumed ≤ 1.3 g of the shake in the novel cage environment.  A Kolmogorov-
Smirnov test of the shake consumption data presented in the percentile plot revealed a significant 
difference between the cumulative frequency distribution for the LM-4131 treatment group and 
the cumulative frequency distribution for the vehicle treatment group (D = 0.3125, p = 0.0002, 
***p < 0.001, LM-4131 at 10 mg/kg vs. vehicle).  Thus, 72 hours post-footshock stress LM-4131 
increased shake consumption in the mice.  A Mann Whitney test indicated that the shake 
consumption was lesser for vehicle-treated mice (median = 0.5000 g) and for the LM-4131-treated 
mice (median = 0.7000 g), U = 20.00, p = 0.0178, *p < 0.05 (Fig. Af (right panel)).  As observed 
in our findings regarding the anxiolytic potential of SSCI on stress-induced anxiety-like behavior 
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in the NIH test, we saw in these results that the SSCI, LM-4131, was more efficacious when mice 
were exposed to a form of physical stress.  These results may again imply that COX-2 catalytic 
activity and expression levels may be differentially regulated by the severity of an external stressor, 
whether it’s a physical form or an environmental form of stress.  Further investigation into how 
various stressors affect COX-2’s catalytic activity and expression levels in the brain is needed to 
determine the relationship between COX-2 catalytic activity and expression levels and anxiogenic 
behaviors in animals after stress exposure. 
Next, we performed the tail suspension test and the sucrose preference test under basal and 
stressed conditions to measure the effects of LM-4131 on despair-like behavior in juvenile male 
ICR mice.  Although previous studies in both humans and rodents have illustrated the 
antidepressive effects of the selective COX-2 inhibitor, celecoxib185-191, we found no changes in 
behavioral despair between the mice treated with vehicle or a COX-2 inhibitor.  At first glance, 
LM-4131 at 10 mg/kg appeared to increase despair-like behavior in the mice under non stressed 
conditions compared to vehicle-treated mice.  Two-way ANOVA revealed no effect of 1 min time 
bins x drug interaction (F(11, 336) = 0.7055, p = 0.7333, ns; Fig. 3a (1
st left panel)) but a significant 
main effect of drug dose (F(1, 336) = 12.26, p = 0.0005, ***p < 0.001 (LM-4131 vs vehicle); Fig. 3a  
(1st left panel)) on duration of immobility over all 1 min bins in the tail suspension test.  However, 
further statistical analysis of the main treatment group effect on duration of immobility for each 
minute of behavioral testing revealed no differences between the vehicle-treated and LM-4131-
treated mice (unpaired t test: p = 0.0929, t = 1.757, df = 22, LM-4131 vs. vehicle; Fig. 3a (2nd left 
panel)).  Neither LMX at 1 mg/kg or celecoxib at 10 mg/kg affected duration of immobility over 
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all 1 min bins (two-way ANOVA: main effect of drug dose, F(1, 276) = 1.394, p = 0.2387, ns (LMX 
vs vehicle) and F(1, 264) = 3.239, p = 0.0730, ns (celecoxib vs. vehicle); effect of 1 min time bins x 
drug interaction, F(11, 276) = 0.3841, p = 0.9616, ns (LMX vs vehicle) and F(11, 264) = 0.1927, p = 
0.9979, ns (celecoxib vs. vehicle); Fig. 3a  (left panel)).  None of the COX-2 inhibitors affected 
total immobility duration (one-way ANOVA: F(3, 45) = 0.8929, p = 0.4521, ns; t = 1.610, df = 45, 
p < 0.05, ns, LM-4131 vs. vehicle; t = 0.5363, df = 45, p < 0.05, ns, LMX vs. vehicle; t = 0.8352, 
df = 45, p < 0.05, ns, celecoxib vs. vehicle; Fig. 3a (right panel)) under control (no stress) 
conditions in the tail suspension test.  Acute footshock stress subjected to the mice 8h prior to 
Figure 3. Effects of SSCI on despair-like behavior in the tail suspension test. (a) Effects of LM-4131, 
Lumiracoxib (LMX), and Celecoxib on immobility duration in the tail suspension test under control non-stressed 
conditions. (b, c) Effects of LM-4131 on immobility duration in the tail suspension test 8 and 24 hours after acute 
foot-shock exposure (1 day). (d, e) Effects of LM-4131 on immobility duration in the tail suspension test 8 and 24 
hours after chronic foot-shock exposure (5 days). No drug effects on immobility were observed under any 
condition, except 8 hours after chronic stress exposure.  Data are shown as the mean ± s.e.m.  Stress (e.g., stress 
exposure in the form of an electric footshock administered 8h or 24h prior to testing).  Statistical significance was 
calculated by two-tailed unpaired Student's t-test or two-way ANOVA with post hoc Holm-Sidak’s multiple 
comparisons test. 
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behavioral testing did not affect duration of immobility over all 1 min bins  (two-way ANOVA: 
main effect of drug dose, F(1, 216) = 0.9427, p = 0.3327, ns; effect of 1 min time bins x drug 
interaction, F(11, 216) = 0.4010, p = 0.9546, ns; Fig. 3b (left panel)) or total immobility duration 
(unpaired t test: p = 0.6888, t = 0.4070, df = 18, LM-4131 at 10 mg/kg vs. vehicle; Fig. 3b (right 
panel)).  Increasing the time length between the acute stress exposure and start of behavioral testing 
to 24 h did not affect duration of immobility over all 1 min bins (two-way ANOVA: main effect 
of drug dose, F(1, 216) = 0.5606, p = 0.4548, ns; effect of 1 min time bins x drug interaction, F(11, 
216) = 0.5363, p = 0.8773, ns; Fig. 3c (left panel)) or total immobility duration (unpaired t test: p = 
0.7258, t = 0.3563, df = 18, LM-4131 at 10 mg/kg vs. vehicle; Fig. 3c   (right panel)).  Nevertheless, 
increasing the intensity of the stress exposure from 1 day to 5 days if behavioral testing occurred 
8 h after stress exposure slightly decreased duration of immobility over the 6 min testing period 
(two-way ANOVA: main effect of drug dose, F(1, 216) = 5.311, p = 0.0221, *p < 0.05; 1 min time 
bin x drug interaction, F(11, 216) = 0.2150, p = 0.9965, ns; Fig. 3d (left panel)) but caused no changes 
in total immobility duration (unpaired t test: p = 0.2519, ns,  t = 1.184, df = 18, LM-4131 at 10 
mg/kg vs. vehicle; Fig. 3d (right panel)).  Thus, regardless of the time at which despair-like 
behavior was measured in the tail suspension test or occurred in the mice, LM-4131 at a dose of 
10 mg/kg significantly decreased despair-like behavior in the mice only 8 hours after being 
subjected to 5 days of footshock stress (e.g., 6 footshocks/day separated by 58 seconds with each 
footshock lasting 2 seconds).  Chronic stress exposure subjected to the mice 24 h prior to testing 
did not affect duration of immobility over time (two-way ANOVA: main effect of drug dose, F(1, 
96) = 2.000, p = 0.1605, ns; 1 min time bin x drug interaction, F(11, 96) = 0.4539, p = 0.9266, ns; Fig. 
3e (left panel)) or total immobility duration (unpaired t test: p = 0.6055, t = 0.5376, df = 8, LM-
4131 at 10 mg/kg vs. vehicle; Fig. 3e (right panel)). 
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In regard to the sucrose preference test, we found no changes in percentage sucrose 
preference (two-way ANOVA: effect of drug dose, F(1, 28) = 1.062, p = 0.3115, ns; effect of stress 
exposure, F(1, 28) = 0.005594, p = 0.9409, ns; stress exposure condition x drug interaction, F(1, 28) = 
0.7839, p = 0.3835, ns; Fig. 4a) or the amount of sucrose consumed (two-way ANOVA: effect of 
drug dose, F(1, 28) = 0.7734, p = 0.3867, ns; effect of stress exposure, F(1, 28) = 2.828, p = 0.1037, 
ns; stress exposure condition x drug interaction, F(1, 28) = 0.4820, p = 0.4932, ns; Fig. 4b) between 
the LM-4131 and vehicle treatment groups under both control, non-stressed and 8 hours after acute 
footshock stress exposure.  LM-4131 treatment did restore the amount of water consumed (two-
way ANOVA: effect of drug dose, F(1, 28) = 4.287, p = 0.0477, *p < 0.05; effect of stress exposure, 
Figure 4. Effects of SSCI in the sucrose preference test. (a-c) 2 hour cumulative sucrose preference, 
sucrose consumption, and water consumption after vehicle or LM-4131 treatment in control non-stressed 
mice and in mice tested 8 hours after acute footshock exposure.  Testing was conducted during the light 
phase of the circadian cycle. (d-f) Effects of LM-4131 or vehicle on sucrose consumption during the light 
and dark phase of the circadian cycle.  Mice were treated with LM-4131 or vehicle 8 hours after acute foot 
shock exposure and tested time interval increments of 2 or 4 hours during the light cycle and the dark cycle. 
No drug effects on sucrose preference were observed under any condition. Data are shown as the mean ± 
s.e.m.  NS = no stress, S = stress (e.g., stress exposure in the form of an electric footshock administered 8h 
prior to testing).  Statistical significance was calculated by two-way ANOVA with post hoc Holm-Sidak’s 
multiple comparisons test. 
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F(1, 28) = 3.252, p = 0.0821, ns; stress exposure condition x drug interaction, F(1, 28) = 2.360, p = 
0.1357, ns; Fig. 4c) back to control, non-stressed levels since the amount of water consumed 
decreased in the vehicle treatment group 8 hours after acute footshock stress exposure.  Even 
though the mice appeared to consume more sucrose than water in general, we found similar results 
irrespective of the time of day 8 hours after acute footshock stress exposure in percentage sucrose 
preference (two-way ANOVA: effect of drug dose, F(1, 108) = 3.670, p = 0.0580, ns; time of day x 
drug interaction, F(5, 108) = 0.1616, p = 0.9760, ns; Fig. 4d), the amount of sucrose consumed (two-
way ANOVA: effect of drug dose, F(1, 108) = 0.07044, p = 0.7912, ns; time of day x drug interaction, 
F(5, 108) = 0.1685, p = 0.9737, ns; Fig. 4e), or the amount of water consumed (two-way ANOVA: 
effect of drug dose, F(1, 108) = 0.8032, p = 0.3721, ns; time of day x drug interaction, F(5, 108) = 
0.2183, p = 0.9540, ns; Fig. 4f) between the LM-4131 and vehicle treatment groups. 
Surprisingly, LM-4131 appeared to have some antidepressant properties only when the 
intensity of the stressor was increased.  This finding is in line with previous studies that have 
shown chronic stress exposure instead of basal conditions can reverse depressive-like behavior in 
rodents administered the selective COX-2 inhibitor, celecoxib188,191.  One plausible reason for this 
effect may be due to the ability of specific stress exposure protocols to upregulate PGE2, a 
biomarker of COX-2 activity, and COX-2 transcript and protein expression levels, thus increasing 
the availability of COX-2 protein to be acted upon by COX-2 inhibitors.  If this is so then LM-
4131 may be more efficacious in treating despair-like behavior in animals when COX-2 expression 
is elevated compared to control levels.  Studies have shown that upregulated COX-2 expression is 
found in patients with a depressive disorder192 and COX-2 inhibitors are efficacious in the 
treatment of depressive disorders in humans185,187,189,190.  Nevertheless, prolonged treatment with 
the SSCI, LM-4131, or a higher dose of LM-4131 may be necessary to rescue changes in 
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depressive-like behavior in animals exposed to no stress or acute stress.  Santiago and others 
illustrated that prolonged treatment with celecoxib (e.g., up to 3 weeks) in an animal model of 
chronic mild stress restored sucrose preference in the sucrose preference test to control levels.  Yet, 
these authors also demonstrated that acute administration of celecoxib at a dose of 10 mg/kg was 
sufficient to exhibit antidepressant-like properties in the forced swim test in rodents under basal 
conditions. Discrepancies between our finding that acute administration of celecoxib at a dose of 
10 mg/kg does not improve despair-like behavior in mice under control (no stress) conditions and 
this study may depend on the time interval between drug administration and behavioral testing of 
despair-like behavior in the mice191.  We administered the COX-2 inhibitor, celecoxib, 2 hours 
before behavioral testing whereas Santiago and others administered celecoxib 1 hour before 
behavioral testing. 
Moreover, we may not have been able to observe robust changes in despair-like behavior 
in the mice due to COX-2 inhibition because our stress exposure protocols were not able to induce 
despair-like behavior in the mice in comparison to controls.  This is evident in the sucrose 
preference test where our acute stress protocol did not cause a significant decrease but a decreasing 
trend (if not due to variability in animal behavioral responses and low sample size) in total sucrose 
consumption in the mice (see Fig. 4b).  Even though our stress exposure protocols can induce 
anhedonia, which is a core symptom of depression, in the NIFS assay, modeling depression in 
animals is quite difficult.  Depression is a complex affective disorder characterized by phenotypic 
heterogeneity and symptoms (e.g., anhedonia or loss of interest or pleasure, depressed mood, 
insomnia, fatigue, feelings of worthlessness, and diminished ability to concentrate) that are not 
pathognomonic but present in other neuropsychiatric disorders193.  Depression has also been 
associated with dysregulation of the HPA axis due to previous studies finding increased cortisol 
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levels in depressed humans or corticosterone levels in animals exhibiting despair-like behavior194-
197.  Our stress exposure protocols did not induce any changes in plasma corticosterone (CORT) 
levels in mice when administered vehicle or LM-4131 (see APPENDIX Fig. F; unpaired t test: p 
= 0.6345, t = 0.4836, df = 18, LM-4131 at 10 mg/kg vs. vehicle; Fig. Aa (left panel); p = 0.3805, 
t = 0.8873, df = 38, LM-4131 at 10 mg/kg vs. vehicle; Fig. Ab (middle panel); p = 0.6186, t = 
0.5066, df = 18, LM-4131 at 10 mg/kg vs. vehicle; Fig. Ac (right panel)), suggesting our animal 
model of stress-induced anxiety maybe a poor example for modeling depression when despair-like 
behavior in the mice is measured at least 8 hours after stress exposure.  In fact, one-way ANOVA 
revealed no significant differences in plasma CORT levels in the mice subjected to acute stress (1 
day) and chronic stress (5 days) conditions when compared to controls (one-way ANOVA: F(2, 37) 
= 0.2392, p = 0.7885, ns; Holm-Sidak’s multiple comparisons test: t = 0.5446, df = 37, S + 8h 
(1D) vs. control; t = 0.6415, df = 37, S + 8h (5D) vs. control).   
Effects of age and sex on the anxiolytic potential of substrate-selective COX-2 inhibition 
Previously, we have shown that the SSCI, LM-4131, can reduce anxiety-like behavior in 
juvenile male mice under basal and stressed conditions (see Fig. 2).  Nevertheless, we wanted to 
examine the generalizability of these findings pertaining to the age and sex of mice.  Thus, we 
determined if the anxiolytic potential of LM-4131 could be observed in aged male mice and 
juvenile and aged female mice.  According to the cumulative frequency distribution percentile plot 
of adult (12-15 weeks of age) ICR male mice feeding in the NIFS assay (Fig. 5a (left panel)), 100% 
of vehicle-treated mice had a feeding latency ≤ 675 s, 100% of LM-4131-treated mice had a 
feeding latency ≤ 255 s, and 100% of LMX-treated mice had a feeding latency ≤ 135 s in the novel 
cage environment.  A Kolmogorov-Smirnov test of these findings revealed a significant difference 
between both substrate-selective COX-2 inhibitor treatment groups, LM-4131 and LMX, and the 
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vehicle treatment group (Kolmogorov-Smirnov test: p = 0.0031, **p < 0.01, LM-4131 at 10 mg/kg 
vs. vehicle; ****p < 0.0001, LMX at 1 mg/kg vs. vehicle; Fig. 5a (left panel)).  There was no 
significant difference among the means for feeding latency between the COX-2 inhibitor treatment 
groups and the vehicle treatment group (one-way ANOVA: F(2, 34) = 1.623, p = 0.2122, ns; Holm-
Figure 5.  Anxiolytic effects of COX-2 inhibitors in aged and female mice and after chronic stress exposure.  
(a,b) Cumulative frequency of male adult mice feeding and latency to feed in novelty-induced feeding suppression 
(NIF test under non-stressful and acute stress conditions (six tone-shock pairings in one day).  (c,d) Cumulative 
frequency of female juvenile mice feeding and latency to feed in novelty-induced feeding suppression (NIFS) test 
under non-stressful and acute stress conditions. (e,f) Cumulative frequency of male juvenile mice feeding and 
latency to feed in novelty-induced feeding suppression (NIFS) test under chronic non-stressful and stress 
conditions (six tone-shock pairings/day over five days).  Data are shown as the mean ± s.e.m.  NS = no stress, S = 
stress (e.g., stress exposure in the form of an electric footshock administered 8h prior to testing), *P < 0.05, **P < 
0.01, ****P < 0.0001 (COX-2 inhibitor compared to vehicle).  Statistical significance was calculated by two-tailed 
unpaired Student's t-test or Kolmogorov-Smirnov test (only for frequency plots) or one-way ANOVA with post 
hoc Holm-Sidak’s multiple comparisons test.   
 48 
Sidak’s multiple comparisons test: ns, t = 1.395, df = 34, LM-4131 vs. vehicle; ns, t = 1.526, df = 
34, LMX vs. vehicle; Fig. 5a (right panel)).  When the adult male mice were subjected to acute 
footshock stress and tested for anxiety-like behavior in the NIFS assay 8 hours after stress 
exposure, the adult male mice exhibited a greater decrease in feeding latency in the novel cage 
environment.  Similar effects were observed in adult mice administered by i.p. the SSCI, LMX, 
and the selective COX-2 inhibitor, celecoxib.    According to the cumulative frequency distribution 
percentile plot of stressed adult male mice feeding in the NIFS assay (Fig. 5b (left panel)), 100% 
of vehicle-treated mice had a feeding latency ≤ 735 s, 100% of LM-4131-treated mice had a 
feeding latency ≤ 30 s, 100% of LMX-treated mice had a feeding latency ≤ 90 s, and 100% of 
celecoxib-treated mice had a feeding latency ≤ 60 s in the novel cage environment.  A 
Kolmogorov-Smirnov test of these findings revealed a significant difference between all COX-2 
inhibitor treatment groups, LM-4131, LMX, and celecoxib, and the vehicle treatment group 
(Kolmogorov-Smirnov test: p < 0.0001, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle; p < 
0.0001, ****p < 0.0001, LMX at 1 mg/kg vs. vehicle; p < 0.0001, ****p < 0.0001, celecoxib at 
10 mg/kg vs. vehicle; Fig. 5b (left panel)).  The means for feeding latency between the COX-2 
inhibitor treatment groups and the vehicle treatment group were significantly different (one-way 
ANOVA: F(3, 26) = 6.965, p = 0.0014, **p < 0.01; Holm-Sidak’s multiple comparisons test: **p < 
0.01, t = 3.705, df = 26, LM-4131 vs. vehicle; **p < 0.01, t = 3.504, df = 26, LMX vs. vehicle; 
**p < 0.01, t = 3.392, df = 26, celecoxib vs. vehicle). 
The effect of the SSCI, LM-4131, on feeding latency in juvenile ICR female mice in the 
novel cage environment was less pronounced compared to that in juvenile ICR male mice under 
both non stressed (control)  and stressed conditions (see Fig. 2d, e).  According to the cumulative 
frequency distribution percentile plot of juvenile (5-7 weeks of age) ICR female mice feeding in 
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the NIFS assay (Fig. 5c (left panel)), 100% of vehicle-treated mice had a feeding latency ≤ 825 s 
and 100% of LM-4131-treated mice had a feeding latency ≤ 225 s in the novel cage environment.  
A Kolmogorov-Smirnov test of these findings revealed a significant difference between the 
substrate-selective COX-2 inhibitor treatment group, LM-4131, and the vehicle treatment group 
(Kolmogorov-Smirnov test: p < 0.0001, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle; Fig. 
5c (left panel)).  In contrast to that found in juvenile male mice (see Fig. 2d), there was no 
significant difference among the means for feeding latency between the COX-2 inhibitor treatment 
group and the vehicle treatment group (unpaired t test: p = 0.1575, ns, t = 1.475, df = 18, LM-4131 
vs. vehicle; Fig. 5c (right panel)).  When the juvenile female mice were subjected to acute 
footshock stress and tested for anxiety-like behavior in the NIFS assay 8 hours after stress 
exposure, the juvenile female mice treated with LM-4131 exhibited a small decrease in feeding 
latency in the novel cage environment compared to vehicle-treated mice.  According to the 
cumulative frequency distribution percentile plot of stressed adult male mice feeding in the NIFS 
assay (Fig. 5d (left panel)), 100% of vehicle-treated mice had a feeding latency ≤ 675 s and 100% 
of LM-4131-treated mice had a feeding latency ≤ 225 s in the novel cage environment.  A 
Kolmogorov-Smirnov test of these findings revealed a significant difference between the LM-
4131 treatment group and the vehicle treatment group (Kolmogorov-Smirnov test: p = 0.0012, **p 
< 0.01, LM-4131 at 10 mg/kg vs. vehicle; Fig. 5d (left panel)).  The means for feeding latency 
between the COX-2 inhibitor treatment group and the vehicle treatment group were significantly 
different (unpaired t test: p = 0.0154, *p < 0.05, t = 2.587, df = 27, LM-4131 vs. vehicle; Fig. 5d 
(right panel)). 
From these findings, we can conclude that the anxiolytic potential of LM-4131 in the 
female mice was less robust as observed previously in male mice of the same age in the NIFS 
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assay.  To determine if these effects could be observed in female mice regardless of age, we 
measured anxiety-like behavior of adult female ICR mice in the elevated plus maze (EPM) under 
non stressed and acute stress conditions after i.p. administration of the COX-2 inhibitors, LM-
4131, LMX, or celecoxib (see APPENDIX Fig. C).  All COX-2 inhibitors decreased anxiety-like 
behaviors in the EPM only after the mice were exposed to acute footshock stress, with the 
exception of celecoxib which exhibited anxiolytic effects under both basal and stressed conditions.  
With respect to open arm time in the EPM, two-way ANOVA factoring drug dose and stress 
exposure revealed no effect of drug dose x stress exposure interaction (F(3, 76) = 0.2028; p = 0.8941, 
ns), but a significant effect of stress exposure (F(1, 76) = 21.62, ****p < 0.0001), or drug dose (F(3, 
76) = 9.458, ****p < 0.0001; Fig. Cc).  Post hoc Holm-Sidak’s multiple comparisons test revealed 
a significant increase in open arm time of the EPM at the 10 mg/kg dose of celecoxib compared to 
the vehicle treatment under basal conditions (**p < 0.01, t = 3.610, df = 76) and acute stress 
conditions (**p < 0.01, t = 3.479, df = 76).  Relating to open arm latency in the EPM, two-way 
ANOVA factoring drug dose and stress exposure revealed no effect of drug dose x stress exposure 
interaction (F(3, 75) = 0.8824; p = 0.4542, ns), but a significant effect of stress exposure (F(1, 75) = 
4.750, p = 0.0324, *p < 0.05), or drug dose (F(3, 75) = 7.046, p = 0.0003, ***p < 0.001; Fig. Cf).  
Post hoc Holm-Sidak’s multiple comparisons test revealed a significant decrease in open arm 
latency of the EPM at the 10 mg/kg dose of LM-4131, 1 mg/kg dose of LMX, and 10 mg/kg dose 
of celecoxib compared to the vehicle treatment only under acute stress conditions (***p < 0.001, 
t = 3.689, df = 75, LM-4131 vs. vehicle; ***p < 0.001, t = 3.981, df = 75, LMX vs. vehicle; **p < 
0.01, t = 2.739, df = 75, celecoxib vs. vehicle).  Concerning the closed arm latency in the EPM, 
two-way ANOVA factoring drug dose and stress exposure revealed no effect of drug dose x stress 
exposure interaction (F(3, 76) = 0.8551; p = 0.4682, ns) and no effect of stress exposure (F(1, 76) = 
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0.01881, p = 0.8913, ns), but a significant effect of drug dose (F(3, 76) = 5.490, **p = 0.0018; Fig. 
Cg).  Post hoc Holm-Sidak’s multiple comparisons test revealed a significant increase in closed 
arm latency of the EPM at the 10 mg/kg dose of LM-4131, 1 mg/kg dose of LMX, and the 10 
mg/kg dose of celecoxib compared to the vehicle treatment only under acute stress conditions 
(***p < 0.001, t = 3.932, df = 76, LM-4131 vs. vehicle; **p < 0.01, t = 2.848, df = 76, LMX vs. 
vehicle; **p < 0.01, t = 3.054, df = 76, celecoxib vs. vehicle).  With respect to the start of the first 
freezing episode in the EPM, two-way ANOVA factoring drug dose and stress exposure revealed 
no effect of drug dose x stress exposure interaction (F(3, 76) = 1.086; p = 0.3604, ns) and effect of 
stress exposure (F(1, 76) = 0.006470, p = 0.9361, ns), but a significant effect of drug dose (F(3, 76) = 
3.960, p = 0.0111, *p < 0.05; Fig. Ch).  Post hoc Holm-Sidak’s multiple comparisons test revealed 
a significant increase in the start of the first freezing episode in the EPM at the 10 mg/kg dose of 
celecoxib compared to the vehicle treatment only under basal (no stress) conditions (*p < 0.05, t 
= 1.874, df = 76). 
Also, LM-4131 at a dose of 10 mg/kg did not affect the anhedonic nature of the mice in 
the novel cage environment of the NIFS assay.  There were no changes in the amount of the 
palatable shake consumed under basal (no stress) (unpaired t test: p = 0.2186, ns, t = 1.275, df = 
18, LM-4131 vs. vehicle; see APPENDIX Fig. Ba (right panel)) or acute footshock stress (unpaired 
t test: p = 0.3421, ns, t = 0.9671, df = 27, LM-4131 vs. vehicle; see APPENDIX Fig. Bb (right 
panel)) conditions between vehicle and LM-4131 treatment groups.   
Next, we determined if the anxiolytic potential of LM-4131 could be observed also in 
juvenile (5-7 weeks of age) ICR male mice subjected to no stress or electric footshock stress over 
5 days.  According to the cumulative frequency distribution percentile plot of juvenile male mice 
feeding in the NIFS assay (Fig. 5e (left panel)), 100% of vehicle-treated mice had a feeding latency 
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≤ 510 s, 100% of LM-4131-treated mice had a feeding latency ≤ 465 s, and 100% of LMX-treated 
mice had a feeding latency ≤ 165 s in the novel cage environment under basal (no stress) 
conditions.  A Kolmogorov-Smirnov test of these findings revealed a significant difference only 
between the substrate-selective COX-2 inhibitor treatment group, LMX, and the vehicle treatment 
group (Kolmogorov-Smirnov test: p > 0.9999, ns, LM-4131 at 10 mg/kg vs. vehicle; p = 0.0253, 
*p < 0.05, LMX at 1 mg/kg vs. vehicle; Fig. 5e (left panel)).  There was no significant difference 
among the means for feeding latency between the COX-2 inhibitor treatment groups and the 
vehicle treatment group (one-way ANOVA: F(2, 41) = 0.7657, p = 0.4715, ns; Holm-Sidak’s 
multiple comparisons test: ns, t = 0.1673, df = 41, LM-4131 vs. vehicle; ns, t = 1.062, df = 41, 
LMX vs. vehicle; Fig. 5e (right panel)).  When the juvenile male mice were subjected to chronic 
footshock stress and tested for anxiety-like behavior in the NIFS assay 8 hours after stress 
exposure, the juvenile male mice exhibited a greater decrease in feeding latency in the novel cage 
environment.  Similar effects were observed in juvenile male mice administered by i.p. the SSCI, 
LMX.  According to the cumulative frequency distribution percentile plot of stressed juvenile male 
mice feeding in the NIFS assay (Fig. 5f (left panel)), 100% of vehicle-treated mice had a feeding 
latency ≤ 1455 s, 100% of LM-4131-treated mice had a feeding latency ≤ 345 s, and 100% of 
LMX-treated mice had a feeding latency ≤ 495 s in the novel cage environment 8 hours after 
chronic stress exposure.  A Kolmogorov-Smirnov test of these findings revealed a significant 
difference between all COX-2 inhibitor treatment groups, LM-4131 and LMX, and the vehicle 
treatment group (Kolmogorov-Smirnov test: p < 0.0001, ****p < 0.0001, LM-4131 at 10 mg/kg 
vs. vehicle; p < 0.0001, ****p < 0.0001, LMX at 1 mg/kg vs. vehicle; Fig. 5f (left panel)).  The 
means for feeding latency between the COX-2 inhibitor treatment group, LM-4131, and the vehicle 
treatment group was significantly different (one-way ANOVA: F(2, 52) = 4.518, p = 0.0155, *p < 
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0.05; Holm-Sidak’s multiple comparisons test: p = 0.0114, *p < 0.05, t = 2.883, df = 52, LM-4131 
vs. vehicle; p = 0.0921, ns, t = 1.716, df = 52, LMX vs. vehicle; Fig. 5f (right panel)). 
Previous studies have suggested that increased CB1R availability in humans that suffer 
from trauma-related disorders and animals subjected to stress paradigms may result from 
decreased stress-induced synaptic AEA levels.  These studies also propose that basal AEA levels 
differ with regard to the age of an animal (e.g., aged animals have greater AEA levels than young 
animals)198-200.  This could explain why our findings suggest that the SSCI, LM-4131, is more 
efficacious in reducing stress-induced anxiety and anhedonia in juvenile male mice as opposed to 
adult male mice and female mice.  In addition, animal studies have noted sex differences in CB1R 
regulation, with stress-induced upregulation of CB1Rs seen mainly in limbic structures of female 
animals201.  Moreover, since estradiol, the primary female sex hormone, has been suggested to not 
only alter emotionality in rodents but as well increase endocannabinoid signaling and AEA 
synthesis or release202,203, the female mice may exhibit a less robust inverse relationship between 
brain AEA levels and stress-induced anxiety in the NIH assay in comparison with the male mice.  
Nevertheless, to gain an in-depth understanding of the mechanisms that govern stress-induced 
anxiety-like and anhedonic behaviors in male and female mice regardless of age, the availability 
of the receptors targeted by anandamide and anandamide levels in brain tissue should be examined 
before and after stress exposure. 
The anxiolytic and hedonic potential of subchronic substrate-selective COX-2 inhibition 
Since acute administration of the SSCIs, LM-4131 and LMX, exhibited anxiolytic potential 
in the NIFS assay, we wanted to determine if the same effect could be observed with subchronic 
i.p. administration of an SSCI.  Thus, we administered by i.p. LMX daily for five days to juvenile 
male mice and tested them for anxiety-like behavior in the NIFS assay under basal and 8h after 
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acute footshock stress exposure.  We chose to use LMX instead of LM-4131 since LM-4131 has 
less metabolic stability than LMX.  Thus, the elimination half-life for LMX (e.g., 4-8 h) is longer 
than that for LM-4131 (e.g., 2-3 h)125,204-208.  Only after exposure to a stressful external stimulus, 
the mice demonstrated a reduction in feeding latency in the NIFS test (Fig. 7b).  According to the 
cumulative frequency distribution percentile plot of juvenile male mice feeding in the NIFS assay 
(Fig. 6a (1st left panel)), 100% of vehicle-treated mice had a feeding latency ≤ 990 s and 100% of 
subchronic LMX-treated mice had a feeding latency ≤ 435 s in the novel cage environment under 
Figure 6.  Anxiolytic and anti-hedonic effects of subchronic dose of COX-2 inhibitors in juvenile male mice.  
(a) Cumulative frequency of mice feeding, latency to feed, cumulative frequency of amount of palatable shake 
consumed, and total amount of shake consumption in novelty-induced feeding suppression (NIFS) test under non-
stressful conditions (left to right).  Body weight measured over five days of subchronic dosing of lumiracoxib or 
LMX (1 mg/kg).  (b,c) Cumulative frequency of mice feeding, latency to feed, cumulative frequency of amount 
of palatable shake consumed, and total amount of shake consumption in novelty-induced feeding suppression 
(NIFS) test under acute stress conditions (six tone-shock pairings/day over five days) (left to right).  Body weight 
measured over five days of subchronic dosing of lumiracoxib (1 mg/kg).  Data are shown as the mean ± s.e.m.  NS 
= no stress, S = stress (e.g., stress exposure in the form of an electric footshock administered 8h prior to testing), 
*P < 0.05, ****P < 0.0001 (LMX compared to vehicle).  Statistical significance was calculated by two-tailed 
unpaired Student's t-test or Kolmogorov-Smirnov test (only for frequency plots).   
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basal (no stress) conditions.  A Kolmogorov-Smirnov test of these findings revealed a significant 
difference between the subchronic LMX and the vehicle treatment groups (Kolmogorov-Smirnov 
test: p > 0.0001, ****p > 0.0001, subchronic LMX at 1 mg/kg vs. vehicle; Fig. 6a (1st left panel)).  
There was no significant difference among the means for feeding latency between the subchronic 
LMX and the vehicle treatment groups (unpaired t test: p = 0.0628, ns, t = 1.920, df = 36, 
subchronic LMX vs. vehicle; Fig. 6a (2nd left panel)).  Subchronic LMX treatment caused no 
changes in anhedonia in the mice in the NIFS assay.  According to the cumulative frequency 
distribution percentile plot of juvenile male mice feeding in the NIFS assay (Fig. 6a (1st middle 
panel)), 100% of vehicle-treated mice consumed ≤ 2.4 g of the palatable shake and 100% of 
subchronic LMX-treated mice consumed ≤ 2.8 g in the novel cage environment under basal (no 
stress) conditions.  A Kolmogorov-Smirnov test of these findings revealed no difference between 
the subchronic LMX and vehicle treatment groups (Kolmogorov-Smirnov test: p = 0.9251, ns, 
subchronic LMX at 1 mg/kg vs. vehicle; Fig. 6a (1st middle panel)).  There was no significant 
difference among the means for the amount of the palatable shake consumed between the COX-2 
inhibitor treatment group and the vehicle treatment group (unpaired t test: p = 0.0670, ns, t = 1.889, 
df = 36, subchronic LMX vs. vehicle; Fig. 6a (2nd middle panel)).  Also, these findings were not 
confounded by changes in body weight due to subchronic administration of the COX-2 inhibitor 
or stress and physical discomfort caused by multiple i.p. injections (Fig. 6a (right panel)). 
When the juvenile male mice were subjected to acute footshock stress and tested for 
anxiety-like behavior in the NIFS assay 8 hours after stress exposure, the juvenile male mice 
treated with subchronic LMX exhibited a significant decrease in feeding latency in the novel cage 
environment compared to vehicle-treated mice.  According to the cumulative frequency 
distribution percentile plot of stressed juvenile male mice feeding in the NIFS assay (Fig. 6b (1st 
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left panel)), 100% of vehicle-treated mice had a feeding latency ≤ 1800 s and 100% of subchronic 
LMX-treated mice had a feeding latency ≤ 165 s in the novel cage environment 8 hours after acute 
stress exposure (6 footshocks in 1 day).  A Kolmogorov-Smirnov test of these findings revealed a 
significant difference between the subchronic LMX and the vehicle treatment groups 
(Kolmogorov-Smirnov test: p < 0.0001, ****p < 0.0001, subchronic LMX at 1 mg/kg vs. vehicle; 
Fig. 6b (1st left panel)).  The means for feeding latency between the subchronic LMX and vehicle 
treatment groups was significantly different (unpaired t test: p = 0.0128, *p < 0.05, t = 2.733, df = 
20, subchronic LMX vs. vehicle; Fig. 6b (2nd left panel)).  Regarding the effect of subchronic LMX 
on anhedonic behavior in the stressed mice, the cumulative frequency distribution percentile plot 
of juvenile male mice feeding in the NIFS assay (Fig. 6b (1st middle panel)) demonstrated that 
100% of vehicle-treated mice consumed ≤ 1.22 g of the palatable shake whereas 100% of 
subchronic LMX-treated mice consumed a greater amount of the shake (e.g., ≤ 1.90 g) in the novel 
cage environment 8 hours after acute footshock stress exposure.  A Kolmogorov-Smirnov test of 
these findings revealed a significant difference between the subchronic LMX and vehicle treatment 
groups (Kolmogorov-Smirnov test: p < 0.0001, ****p < 0.0001, subchronic LMX at 1 mg/kg vs. 
vehicle; Fig. 6b (1st middle panel)).  There was no significant difference among the means for the 
amount of the palatable shake consumed between the COX-2 inhibitor treatment group and the 
vehicle treatment group (unpaired t test: p = 0.3014, ns, t = 1.058, df = 22, subchronic LMX vs. 
vehicle; Fig. 6b (2nd middle panel)).  Also, these results were not affected by changes in body 
weight caused by multiple i.p. drug injections or subchronic LMX dosing (Fig. 6b (right panel)). 
Also, the subchronic administration of the SSCI, LMX, before stress exposure was not able 
to prevent stress-induced anxiety or stress-induced hedonic deficits 8h after acute stress exposure 
in the NIFS assay (Fig. 6c).  According to the cumulative frequency distribution percentile plot of 
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juvenile male mice feeding in the NIFS assay (Fig. 6c (1st left panel)), 100% of vehicle-treated 
mice had a feeding latency ≤ 1800 s and 100% of subchronic LMX-treated mice had a feeding 
latency ≤ 780 s in the novel cage environment under stressed conditions.  A Kolmogorov-Smirnov 
test of these findings revealed a significant difference between the subchronic LMX and the vehicle 
treatment groups (Kolmogorov-Smirnov test: p < 0.0001, ****p < 0.0001, LMX at 1 mg/kg vs. 
vehicle; Fig. 6c (1st left panel)).  However, there was no significant difference among the means 
for feeding latency between the COX-2 inhibitor treatment group and the vehicle treatment group 
(unpaired t test: p = 0.1754, ns, t = 1.393, df = 26, subchronic LMX vs. vehicle; Fig. 6c (2nd left 
panel)).  Subchronic LMX treatment before acute stress exposure caused no changes in anhedonia 
in the mice in the NIFS assay.  According to the cumulative frequency distribution percentile plot 
of juvenile male mice feeding in the NIFS assay (Fig. 6c (1st middle panel)), 100% of vehicle-
treated and subchronic LMX-treated mice consumed the same amount of the palatable shake (e.g., 
≤ 1.70 g) in the novel cage environment under acute stress conditions.  Differences in the 
percentage of mice that consumed the palatable shake between the treatment groups occurred at 
lower amounts of the shake consumed.  For instance, 29% of vehicle-treated mice consumed ≤ 
0.10 g of the shake whereas 29% of subchronic LMX-treated mice consumed ≤ 0.50 g of the shake.  
A Kolmogorov-Smirnov test of these findings revealed a significant difference between the 
subchronic LMX and vehicle treatment groups (Kolmogorov-Smirnov test: p = 0.0310, *p < 0.05, 
subchronic LMX at 1 mg/kg vs. vehicle; Fig. 6c (1st middle panel)).  There was no significant 
difference among the means for the amount of the palatable shake consumed between the COX-2 
inhibitor treatment group and the vehicle treatment group (unpaired t test: p = 0.7891, ns, t = 
0.2702, df = 26, subchronic LMX vs. vehicle; Fig. 6c (2nd middle panel)).  Also, these results were 
not confounded by changes in body weight between the drug treatments (Fig. 6c (right panel)). 
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Effects of substrate-selective COX-2 inhibition on sensorimotor gating and locomotor activity 
To ensure that the anxiolytic potential of the SSCIs was not an artifact or confounded by 
deficits in sensorimotor gating or increased locomotor activity in the mice when performing the 
NIFS assay or other behavioral tests of anxiety, we examined the effects of the SSCIs on 
sensorimotor function and locomotion in juvenile ICR male mice.  We found no changes in 
sensorimotor function caused by the COX-2 inhibitors under basal (no stress) or acute stress 
conditions in the mice.  With respect to percentage prepulse inhibition (%PPI) between the vehicle 
and COX-2 inhibitor treatment groups, two-way ANOVA factoring drug dose and stress exposure 
revealed no effect of drug dose x stress exposure interaction (F(3, 118) = 0.7896; p = 0.5020, ns) and 
stress exposure (F(1, 118) = 0.9218, p = 0.3390, ns), but a significant effect of drug dose (F(3, 118) = 
3.086, p = 0.0299, *p < 0.05; Fig. 7a) under basal conditions.  Post hoc Holm-Sidak’s multiple 
comparisons test revealed no significant increase or decrease in %PPI at any dose of the COX-2 
inhibitors compared to the vehicle treatment under control (no stress) conditions.  Moreover, none 
of the COX-2 inhibitors compared to vehicle affected average startle responses in the mice under 
non stressed conditions or 8 hours after acute footshock stress exposure.  Two-way ANOVA 
factoring drug dose and the prepulse intensity revealed no effect of drug dose x prepulse intensity 
interaction (F(3, 174) = 1.520; p = 0.2111, ns) and drug dose (F(3, 174) = 0.2578, p = 0.8557, ns), but 
a significant effect of prepulse intensity (F(1, 174) = 195.4, p < 0.0001, ****p < 0.0001; Fig. 7b) 
under basal conditions.  Two-way ANOVA factoring drug dose and stress exposure revealed no 
effect of drug dose x stress exposure interaction (F(3, 64) = 0.6285; p = 0.5993, ns) and drug dose 
(F(3, 64) = 0.2440, p = 0.8553, ns), but a significant effect of prepulse intensity (F(1, 64) = 143.6, p < 
0.0001, ****p < 0.0001; Fig. 7c) under acute stress conditions. 
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To determine if the effect of the COX-2 inhibitors on feeding latency was not due to 
increased movement or average speed in the novel cage while undergoing testing in the NIFS 
assay, we replaced the Allentown mouse cages with larger rat cages in the NIFS assay and tested 
the mice for anxiety-like behavior.  We first ensured that the modifications made to the NIFS assay 
did not affect the anxiolytic potential of the COX-2 inhibitors observed previously in the original 
NIFS set up.  We found a trending decrease in feeding latency (unpaired t test: p = 0.0525, ns, t = 
2.119, df = 14, LM-4131 vs. vehicle; Fig. 7d) in mice treated with LM-4131 under control (no 
stress) conditions and a significant decrease in feeding latency (unpaired t test: p = 0.0371, *p < 
0.05, t = 2.161, df = 38, LM-4131 vs. vehicle; Fig. 7e) in mice treated with LM-4131 8 hours after 
exposure to acute footshock stress.  In addition, LM-4131 treated mice compared to vehicle treated 
Figure 7.  Sensorimotor effects of COX-2 inhibitors.  (a) Percentage of composite prepulse inhibition (PPI) 
score collapsed across prepulse intensities under non-stressful and acute stress conditions.  (b, c) Mean startle 
behavioral responses under non-stressful and acute stress conditions.  (d, e) Latency to feed behavior in novelty-
induced feeding suppression (NIFS) test using rat cages under non-stressful and acute stress conditions.  (f, g) 
Distance traveled and mean speed in the rat cages during the NIFS test.  Data are shown as the mean ± s.e.m.  NS 
= no stress, S = stress (e.g., stress exposure in the form of an electric footshock administered 8h prior to testing), 
*P < 0.05 (LM-4131 compared to vehicle).  Statistical significance was calculated by two-tailed unpaired Student's 
t-test or two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test.   
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mice did not exhibit any signs of hyperactivity or increased average speed in the modified NIFS 
assay.  Two-way ANOVA factoring drug dose and stress exposure revealed no effect of drug dose 
x stress exposure interaction (F(1, 32) = 0.3073; p = 0.5832, ns), stress exposure (F(1, 32) = 2.458, p 
= 0.1267, ns), or drug dose (F(1, 32) = 1.729, p = 0.1979, ns; Fig. 7f) under basal conditions.  Two-
way ANOVA factoring drug dose and stress exposure also revealed no effect of drug dose x stress 
exposure interaction (F(1, 32) = 0.3057; p = 0.5842, ns), stress exposure (F(1, 32) = 2.432, p = 0.1287, 
ns), or drug dose (F(1, 32) = 1.664, p = 0.2063, ns 5; Fig. 7g) under acute stress conditions.  Thus, 
the reduction in the amount of time to approach and take the first sip of the palatable shake is not 
due to LM-4131 increasing the locomotion or speed of the mice under basal or stressed conditions.   
To validate these findings, we examined the effect of the COX-2 inhibitors on locomotor 
activity in the open field assay under all stress exposures.  We found no changes in locomotor 
activity caused by the COX-2 inhibitors under control (non-stressed), acute stress, or chronic stress 
conditions in the mice.  One-way ANOVA did not reveal any effect of LM-4131 at 10 mg/kg, 
LMX at 1 mg/kg, or celecoxib at 10 mg/kg on total ambulatory or horizontal distance traveled in 
the open field test under basal conditions (F(3, 46) = 2.566, p = 0.0660, ns; Holm-Sidak’s multiple 
comparisons test: ns, t = 0.2944, df = 46, LM-4131 vs. vehicle; ns, t = 2.249, df = 46, LMX vs. 
vehicle; ns, t = 2.052, df = 46, celecoxib vs. vehicle; Fig. 8a), 8 hours after acute stress exposure  
(F(3, 33) = 0.9202, p = 0.4418, ns; Holm-Sidak’s multiple comparisons test: ns, t = 0.03829, df = 
33, LM-4131 vs. vehicle; ns, t = 0.9307, df = 33, LMX vs. vehicle; ns, t = 1.372, df = 33, celecoxib 
vs. vehicle; Fig. 8a), and 8 hours after chronic stress exposure (F(3, 34) = 1.416, p = 0.2551, ns; 
Holm-Sidak’s multiple comparisons test: ns, t = 0.1432, df = 34, LM-4131 vs. vehicle; ns, t = 
0.5044, df = 34, LMX vs. vehicle; ns, t = 1.848, df = 34, celecoxib vs. vehicle; Fig. 8a). 
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Concerning the effect of LM-4131 on distance traveled over all 5 min bins (60 min), two-
way ANOVA factoring drug dose and time revealed no effect of drug dose (F(11, 336) = 0.5604, p = 
0.4546, ns) and drug dose x time interaction (F(11, 336) = 0.5480; p = 0.8697, ns), but a significant 
effect of time (F(11, 336) = 44.17, ****p < 0.0001; Fig. 8b) under no stress exposure.  In regard to 
the effect of LMX on distance traveled over all 5 min bins (60 min), two-way ANOVA factoring 
drug dose and time revealed no effect of drug dose x time interaction (F(11, 335) = 0.5972; p = 
0.8311, ns), but a significant effect of drug dose (F(1, 336) = 27.61, ****p < 0.0001) and time (F(11, 
336) = 45.42, ****p < 0.0001; Fig. 8b) under no stress exposure.  Post hoc Holm-Sidak’s multiple 
comparisons test revealed a slight increase in distance traveled during the 10 min bin of the open 
field assay at the 1 mg/kg dose of LMX  compared to the vehicle treatment under basal conditions 
(*p < 0.05, t = 3.042, df = 336, LMX vs. vehicle; Fig. 8b).  Pertaining to the effect of celecoxib on 
distance traveled over all 5 min bins (60 min), two-way ANOVA factoring drug dose and time 
Figure 8.  Effects of COX-2 Inhibitors on locomotor activity in the novel-open field assay. (a) Effects of LM-
4131, Lumiracoxib (LMX), and Celecoxib under no stress (control) or 8h after acute (1 day) or chronic (5 days) 
stress exposure on total distance travelled in the open-field assay. (b-d) Effects of LM-4131, LMX, and Celecoxib 
compared to vehicle under no stress conditions (b) and 8h after acute stress exposure (c) or chronic stress exposure 
(d) on total distance travelled in the open-field assay over 60 minutes (data point/5 min).  Data are shown as the 
mean ± s.e.m.  NS = no stress, S = stress (e.g., stress exposure in the form of an electric footshock administered 
8h prior to testing).  Statistical significance was calculated by one-way or two-way ANOVA with post hoc Holm-
Sidak’s multiple comparisons test and time x treatment interaction as a source of variation between groups.   
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revealed no effect of dose x time interaction (F(11, 336) = 1.372; p = 0.1846, ns), but a significant 
effect of drug dose (F(1, 336) = 23.62, ****p < 0.0001) and time (F(11, 336) = 56.26, ****p < 0.0001; 
Fig. 8b) under no stress exposure.  Post hoc Holm-Sidak’s multiple comparisons test revealed an 
increase in distance traveled during the first 5 min (*p < 0.05, t = 2.884, df = 336, celecoxib vs. 
vehicle; Fig. 8b) and 10 min (****p < 0.0001, t = 4.025, df = 336, celecoxib vs. vehicle; Fig. 8b) 
bins of the open field assay at the 10 mg/kg dose of celecoxib compared to the vehicle treatment 
under basal conditions. 
With respect to the effect of LM-4131 on distance traveled over all 5 min bins (60 min), 
two-way ANOVA factoring drug dose and time revealed no effect of drug dose (F(1, 312) = 
0.005497, p = 0.9409, ns) and drug dose x time interaction (F(11, 312) = 0.4555; p = 0.9291, ns), but 
a significant effect of time (F(11, 312) = 29.67, ****p < 0.0001; Fig. 8c) 8 hours after acute stress 
exposure.  With regard to the effect of LMX on distance traveled over all 5 min bins (60 min), 
two-way ANOVA factoring drug dose and time revealed no effect of drug dose x time interaction 
(F(11, 204) = 0.8993; p = 0.5420, ns), but a significant effect of drug dose (F(1, 204) = 4.909, p = 
0.0278, *p < 0.05) and time (F(11, 204) = 12.15, ****p < 0.0001; Fig. 8c) 8 hours after acute stress 
exposure.  Post hoc Holm-Sidak’s multiple comparisons test revealed a decrease in distance 
traveled during the first 5 min bin (*p < 0.05, t = 3.010, df = 204, LMX vs. vehicle; Fig. 8c) of the 
open field assay at the 1 mg/kg dose of LMX compared to the vehicle treatment under acute stress 
conditions.  In connection with the effect of celecoxib on distance traveled over all 5 min bins (60 
min), two-way ANOVA factoring drug dose and time revealed no effect of drug dose x time 
interaction (F(11, 228) = 0.7039; p = 0.7343, ns), but a significant effect of drug dose (F(1, 228) = 8.749, 
p = 0.0034, **p < 0.01) and time (F(11, 228) = 19.68, ****p < 0.0001; Fig. 8c) 8 hours after acute 
stress exposure.  Post hoc Holm-Sidak’s multiple comparisons test revealed no changes in distance 
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traveled during all 5 min bins over a 60 min time frame of the open field assay at the 10 mg/kg 
dose of celecoxib compared to the vehicle treatment under acute stress conditions. 
Pertaining to the effect of LM-4131 and LMX on distance traveled over all 5 min bins (60 
min), two-way ANOVA factoring drug dose and time revealed no effect of drug dose (LM-4131: 
F(1, 204) = 0.1097, p = 0.7408, ns; LMX: F(1, 216) = 1.603, p = 0.2069, ns) and drug dose x time 
interaction (LM-4131: F(11, 204) = 0.1661; p = 0.9989, ns; LMX: F(11, 216) = 0.2508, p = 0.9931, ns), 
but a significant effect of time (LM-4131: F(11, 204) = 12.43, ****p < 0.0001; LMX: F(11, 216) = 
17.48, ****p < 0.0001; Fig. 8d) 8 hours after chronic stress exposure.  As regards to the effect of 
celecoxib on distance traveled over all 5 min bins (60 min), two-way ANOVA factoring drug dose 
and time revealed no effect of drug dose x time interaction (F(11, 180) = 0.2240; p = 0.9958, ns), but 
a significant effect of drug dose (F(1, 180) = 16.76, ****p < 0.0001) and time (F(11, 180) = 8.951, 
****p < 0.0001; Fig. 8d) 8 hours after chronic stress exposure.  Post hoc Holm-Sidak’s multiple 
comparisons test revealed no changes in distance traveled during all 5 min bins over a 60 min time 
frame of the open field assay at the 10 mg/kg dose of celecoxib compared to the vehicle treatment 
under chronic stress conditions. 
Effects of substrate-selective COX-2 inhibition on neurotransmitter levels 
Since cannabinoid receptor agonists or endocannabinoids, such as AEA, can affect synaptic 
neurotransmission when activating or inhibiting their receptor or ion channel targets209,210, we 
examined the effects of the SSCI, LM-4131, on monoamine content in three brain regions known 
to modulate anxiety-like behaviors and fear responses in animals and humans (e.g., the amygdala, 
the prefrontal cortex, and the hippocampus).  We found that our acute stress paradigm (8h post-
footshock stress) compared to control (no stress) significantly increased dopamine (unpaired t test: 
p = 0.0051, **p < 0.01, t = 3.168, df = 19; Fig. 8a), noradrenaline (unpaired t test: p = 0.0486, *p 
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Figure 9.  Receptor mechanisms mediating anxiolytic effects of COX-2 inhibition. (a) Dopamine levels in 
amygdala tissue sections determined by HPLC with electrochemical or fluorescent detection.  (b) Cumulative 
feeding latency distribution curves for vehicle and LM-4131 treated mice in the presence of vehicle, Rimonabant 
(2 mg/kg) or Rimonabant (5 mg/kg) co-treatment. Mean ± S.E.M feeding latency for each group tested under non-
stressful conditions. (c) Cumulative feeding latency distribution curves for vehicle, LM-4131, and Lumiracoxib 
(LMX) treated mice in the presence of vehicle, Rimonabant (2 mg/kg), or Rimonabant (5 mg/kg) co-treatment. 
Effects of the CB1 receptor antagonist Rimonabant (2 mg/kg and 5 mg/kg) on LM-4131- and LMX-induced 
reductions in feeding latency tested 8hours after stress exposure.  Mean ± S.E.M feeding latency for each group 
tested 8h after stress exposure.  (d) Cumulative feeding latency distribution curves for vehicle and LM-4131 treated 
mice in the presence of vehicle, Apamin (0.4 mg/kg), or 1-EBIO (5 mg/kg) co-treatment.  Effects of the SK channel 
inhibitor Apamin (0.4 mg/kg), and SK channel activator 1-EBIO (5 mg/kg), on LM-4131-induced reductions in 
feeding latency tested 8h after stress exposure.  Mean ± S.E.M feeding latency for each group tested 8h after stress 
exposure.  (e) Cumulative food consumption distribution curves for vehicle, LM-4131, and LMX treated mice in 
the presence of vehicle or Rimonabant (2 mg/kg and 5 mg/kg) co-treatment.  Effects of Rimonabant (2 mg/kg and 
5 mg/kg) on LM-4131- or LMX-induced increases in shake consumption tested 8h after stress exposure. Mean ± 
S.E.M amount of shake consumed for each group tested 8h after stress exposure.  Data are shown as the mean ± 
s.e.m.  *P < 0.05, **P < 0.01, ***P<0.001, ****P<0.0001.  Statistical significance was calculated by two-tailed 
unpaired Student's t-test or Kolmogorov-Smirnov test (only for frequency plots).   
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< 0.05, t = 2.100, df = 20; Fig. 8b), and serotonin (unpaired t test: p = 0.0011, **p < 0.01, t = 3.791, 
df = 20; Fig. 8c) levels in amygdala tissue sections.  LM-4131 only reversed stress-induced 
increases in dopamine levels in the amygdala tissues sections back to control levels (unpaired t 
test: p = 0.0397, *p < 0.05, t = 2.228, df = 17, LM-4131 (acute S + 8h) vs. vehicle (acute S + 8h); 
unpaired t test: p = 0.1892, ns, t = 1.359, df = 20, LM-4131 (acute S + 8h) vs. vehicle (no stress); 
Fig. 8a).  LM-4131 at a dose of 10 mg/kg did not alter levels of dopamine under chronic stress 
conditions (unpaired t test: p = 0.1168, ns, t = 1.643, df = 19, LM-4131 vs. vehicle; see APPENDIX 
Fig. Da).  The SSCI was not able to affect the levels of other monoamines, such as noradrenaline 
and serotonin, under all stress exposures in the amygdala (Fig. Db, c) and the hippocampus (Fig. 
Dh, i).  Also, there was no effect of LM-4131 on dopamine levels in the prefrontal cortex or the 
hippocampus (see APPENDIX Fig. Dd, g).  In addition, LM-4131 did not affect the levels of the 
dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), the serotonin metabolite, 5-
hydroxyindoleacetic acid (5-HIAA), or the DOPAC metabolite, homovanillic acid (HVA) levels 
in the amygdala (see APPENDIX Fig. Ea-c), even though our acute stress paradigm increased 
DOPAC levels in the amygdala (unpaired t test: p = 0.0051, **p < 0.01, t = 3.168, df = 19; Fig. 
Ea).  In the prefrontal cortex, LM-4131 significantly decreased serotonin levels under basal 
conditions (unpaired t test: p = 0.0004, ***p < 0.001, t = 4.360, df = 18, LM-4131 at 10 mg/kg vs. 
vehicle; see APPENDIX Fig. Df).  Our chronic stress paradigm also decreased serotonin levels in 
the prefrontal cortex (unpaired t test: p = 0.0015, **p<0.01, t = 3.725, df = 18, vehicle (no stress) 
vs. vehicle (chronic S + 8h); Fig. Df).  LM-4131 reversed these effects and increased serotonin 
levels back to control levels 8 hours after 5 days of footshock stress (unpaired t test: p = 0.0225, 
*p < 0.05, t = 2.497, df = 18, LM-4131 (chronic S + 8h) vs. vehicle (chronic S + 8h); unpaired t 
test: p = 0.1672, ns, t = 1.429, df = 22, LM-4131 (chronic S + 8h) vs. vehicle (no stress); Fig. Df).  
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Our findings are consistent with previous studies that stress exposure can increase dopamine levels 
and its metabolism and decrease serotonin levels in the brain211-213.  Interestingly, the SSCI, LM-
4131, was able to restore these changes in neurotransmitter levels back to non-stressed or control 
levels.  What remains unclear is whether or not these changes in neurotransmitter levels as a 
consequence of stress exposure directly correlates to anxiogenic behaviors in animals even though 
previous studies have suggested that serotonin and dopamine receptors can modulate anxiety-like 
behavior in animals214-216.   
Receptor-mediated mechanisms of SSCI on stress-induced anxiety and anhedonia 
We have previously shown that under basal conditions SSCIs result in increased AEA 
levels in the brain and reduced anxiety-like behaviors in juvenile male ICR mice that were assessed 
for anxious behavior with the open field assay and the light-dark box.  These effects were removed 
when the mice were co-administered by i.p. injection the SSCI, LM-4131 (10 mg/kg), and the 
CB1R antagonist, rimonabant.  These studies suggested that increased AEA levels and anxiolytic 
behaviors as a result of COX-2 inhibition was cannabinoid-receptor mediated125.  Thus, we 
assumed that SSCIs can reduce anxiety-like behaviors in mice subjected to acute and chronic 
traumatic stress through a cannabinoid-receptor mediated mechanism.  In order to examine this 
hypothesis, we subjected the same acute and chronic stress paradigms mentioned previously to 
juvenile ICR mice of both sexes and tested the mice for anxiety-like behavior in the NIH test.  
Before testing, we treated different cohorts of mice with either vehicle, LM-4131 (10 mg/kg), the 
CB1R antagonist, rimonabant (2 mg/kg or 5 mg/kg), or both LM-4131 and rimonabant.  We 
observed that the anxiolytic effects of the SSCI, LM-4131, is CB1R-mediated under basal 
conditions.  According to the cumulative frequency distribution percentile plots of mice feeding 
in the NIH test under basal (no stress) conditions (Fig. 9b (2 left panels)), 100% of vehicle-treated 
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mice had a feeding latency ≤ 327 s, 100% of LM-4131-treated mice had a feeding latency ≤ 176 
s, 100% of rimonabant-treated mice had a feeding latency ≤ 998 s, and 100% of LM-4131 and 
rimonabant co-treated mice had a feeding latency ≤ 401 s in the novel cage environment.  An 
independent samples (unpaired) t test revealed a significant difference between the vehicle and 
LM-4131 treatment groups, t (18) = 2.507; p = 0.0220, *p < 0.05.  The sample means are displayed 
in Figure 9b (right panel), which shows that the mice treated with LM-4131 (10 mg/kg) scored 
significantly lesser on feeding latency than did the mice treated with vehicle (for LM-4131 
treatment group, means ± s.e.m. = 55.40 ± 17.88, N = 10; for vehicle treatment group, means ± 
s.e.m. = 146.7 ± 31.73, N = 10).  An independent samples t test also revealed no significant 
difference between the vehicle treatment group and LM-4131 and rimonabant co-treatment group 
(t (18) = 0.2215; p = 0.8272, ns) and between the rimonabant treatment group and the rimonabant 
and rimonabant and LM-4131 treatment group (t (18) = 0.1653; p = 0.8705, ns).  The sample 
means in Figure 9b (right panel) show that the vehicle-treated mice demonstrated scores on feeding 
latency similar to mice co-treated with rimonabant and LM-4131 (for vehicle treatment group, 
means ± s.e.m. = 146.7 ± 31.73, N = 10; for LM-4131 and rimonabant co-treatment group, means 
± s.e.m. = 158.7 ± 43.92, N = 10).  It also shows that the rimonabant-treated mice demonstrated 
scores on feeding latency similar to mice co-treated with rimonabant and LM-4131 (for rimonabant 
treatment group, means ± s.e.m. = 175.8 ± 93.64, N = 10; for LM-4131 and rimonabant co-
treatment group, means ± s.e.m. = 158.7 ± 43.92, N = 10). 
We found that the anxiolytic effects of the SSCIs, LM-4131 and LMX, was non-CB1R-
mediated under acute stress conditions.  According to the cumulative frequency distribution 
percentile plots of mice feeding in the NIH test 8h after exposure to acute electric footshock stress 
(Fig. 9c (2 left panels)), 100% of vehicle-treated mice had a feeding latency ≤ 890 s, 100% of LM-
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4131-treated mice had a feeding latency ≤ 150 s, 100% of LMX-treated mice had a feeding latency 
≤ 221 s, 100% of rimonabant-treated mice had a feeding latency ≤ 1800 s, and 100% of LM-4131 
and rimonabant co-treated mice had a feeding latency ≤ 716 s in the novel cage environment.  A 
Kolmogorov-Smirnov test of the feeding latency data presented in the percentile plots revealed a 
significant difference between the cumulative frequency distribution for the LM-4131 or LMX 
treatment group and the cumulative frequency distribution for the vehicle treatment group (D = 
0.4050, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle; D = 0.3636, ****p < 0.0001, LMX at 
1 mg/kg vs. vehicle) and a significant difference between the cumulative frequency distribution 
for the rimonabant treatment group and the rimonabant and LM-4131 co-treatment group (D = 
0.6942, ****p < 0.0001, rimonabant + LM-4131 vs. rimonabant at 2 mg/kg).  An independent 
samples (unpaired) t test revealed a significant difference between the vehicle and LM-4131 or 
LMX treatment group (t (14) = 2.879; p = 0.0121, *p < 0.05, LM-4131 vs. vehicle; t (14) = 2.448, 
p = 0.0281, *p < 0.05, LMX vs. vehicle).  The sample means are displayed in Figure 9b (right 
panel), which shows that the mice treated with LM-4131 (10 mg/kg) or LMX (1 mg/kg) scored 
significantly lesser on feeding latency than did the mice treated with vehicle (for LM-4131 
treatment group, means ± s.e.m. = 87.00 ± 19.99, N = 8; for LMX treatment group, means ± s.e.m. 
= 125.0 ± 25.10, N = 8; for vehicle treatment group, means ± s.e.m. = 360.6 ± 92.91, N = 8).  An 
independent samples t test also revealed a significant difference between the rimonabant treatment 
group and the rimonabant and rimonabant and LM-4131 treatment group (t (39) = 2.146; p = 
0.0382, *p < 0.05), suggesting the CB1R antagonist, rimonabant was not able to block the 
anxiolytic effects of LM-4131.  The sample means in Figure 9b (right panel) show that the 
rimonabant-treated mice demonstrated scores on feeding latency which were significantly greater 
than those shown by mice co-treated with rimonabant and LM-4131 (for rimonabant treatment 
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group, means ± s.e.m. = 408.0 ± 96.96, N = 20; for LM-4131 and rimonabant co-treatment group, 
means ± s.e.m. = 188.0 ± 38.71, N = 21).  We have previously shown that anxiety-like behavior 
exhibited by mice in the novel cage environment of the NIH test is dependent upon the dose of the 
CB1R antagonist, rimonabant
115.  Thus, we increased our rimonabant dose from 2 mg/kg to 5 
mg/kg and performed the NIH test in another cohort of juvenile male mice to determine whether 
or not the anxiolytic action of SSCIs is CB1R-mediated.  This enabled us to ensure the rimonabant 
dose we used in our behavioral testing was sufficient enough to produce anxiogenic effects in the 
mildly stressful, novel cage environment of the NIH test and block the anxiolytic effects of the 
SSCIs if they involve the CB1R.  Even treating the mice with a higher dose of rimonabant still did 
not block the anxiolytic effects of the SSCI, LM-4131, as well as LMX under acute stress 
conditions.  According to the cumulative frequency distribution percentile plots of mice feeding 
in the NIH test 8h after exposure to acute electric footshock stress (Fig. 9c (3rd left panel)), 100% 
of rimonabant-treated mice had a feeding latency ≤ 1800 s, 100% of LM-4131 and rimonabant co-
treated mice had a feeding latency ≤ 242 s, and 100% of LMX and rimonabant co-treated mice 
had a feeding latency ≤ 584 s in the novel cage environment.  A Kolmogorov-Smirnov test of the 
feeding latency data presented in the percentile plots revealed a significant difference between the 
cumulative frequency distribution for the rimonabant treatment group and the rimonabant and 
LMX or LM-4131 co-treatment group (D = 0.8760, ****p < 0.0001, rimonabant + LM-4131 vs. 
rimonabant at 5 mg/kg; D = 0.8347, ****p < 0.0001, rimonabant + LMX vs. rimonabant at 5 
mg/kg).  An independent samples t test also revealed a significant difference between the 
rimonabant treatment group and LM-4131 and rimonabant co-treatment group (t (13) = 2.707; p = 
0.0179, *p < 0.05) and between the rimonabant treatment group and the rimonabant and 
rimonabant and LMX treatment group (t (14) = 2.415; p = 0.0300, *p < 0.05).  The sample means 
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in Figure 9b (right panel) show that the rimonabant-treated mice demonstrated scores on feeding 
latency which were greater than those shown by mice co-treated with rimonabant and LM-4131 
(for rimonabant treatment group, means ± s.e.m. = 867.0 ± 242.0, N = 8; for LM-4131 and 
rimonabant co-treatment group, means ± s.e.m. = 160.3 ± 26.10, N = 7).  It also shows that the 
rimonabant-treated mice demonstrated scores on feeding latency which were greater than those 
shown by mice co-treated with rimonabant and LMX (for rimonabant treatment group, means ± 
s.e.m. = 867.0 ± 242.0, N = 8; for LMX and rimonabant co-treatment group, means ± s.e.m. = 
271.0 ± 48.48, N = 8). 
Anandamide (AEA) is an agonist of both cannabinoid type 1 and 2 receptors as well as the 
transient receptor potential cation channel subfamily V member 1 (TRPV1) and can activate other 
targets besides the cannabinoid receptors, such as small conductance calcium-activated potassium 
(SK) channels217-219.  Thus, we repeated the NIH test in juvenile male ICR mice to rule out the 
contribution of theses receptors or ion channels in the anxiolytic behaviors illustrated by the mice 
after stress exposure as a result of substrate-selective COX-2 inhibition.  We treated the mice with 
a CB2R antagonist, SR144528 (3 mg/kg), the TRPV1 antagonist, capsazepine (10 mg/kg), or the 
SK channel antagonist, apamin (0.4 mg/kg) and examined the anxiolytic potential of the SSCI, 
LM-4131, after acute and chronic stress exposure as to whether or not it can be mediated by other 
receptors or ion channels besides the CB1R.  We found that the SSCI, LM-4131, can reduce 
anxiety-like behaviors after acute stress exposure through a non-CB1 receptor-mediated 
mechanism in male ICR mice, specifically SK channels.  This finding is in accordance with a 
recent study that has suggested that SK channels can modulate anxiogenic behaviors in animals 
after stress exposure.  In particular, Rau and others showed that SK channel activation in the 
amygdala can reduce stress-induced anxiety-like behavior in an animal model of chronic early-life 
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stress220.  According to the cumulative frequency distribution percentile plots of mice feeding in 
the NIH test 8h after exposure to acute electric footshock stress (Fig. 9d (3 left panels)), 100% of 
vehicle-treated mice had a feeding latency ≤ 946 s, 100% of LM-4131-treated mice had a feeding 
latency ≤ 482 s, 100% of apamin-treated mice had a feeding latency ≤ 1800 s, and 100% of apamin 
and LM-4131 co-treated mice had a feeding latency ≤ 1800 s in the novel cage environment.  A 
Kolmogorov-Smirnov test of the feeding latency data presented in the percentile plots revealed a 
significant difference between the cumulative frequency distribution for the LM-4131 treatment 
group and the cumulative frequency distribution for the vehicle treatment group (D = 0.3306, 
****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle) and no difference between the cumulative 
frequency distribution for the apamin treatment group and the apamin and LM-4131 co-treatment 
group (D = 0.2000, p = 0.8186, ns, apamin + LM-4131 vs. apamin at 0.4 mg/kg).  An independent 
samples (unpaired) t test revealed a significant difference between the vehicle and LM-4131 
treatment group (t (57) = 4.055; p = 0.0002, ***p < 0.001, LM-4131 vs. vehicle).  The sample 
means are displayed in Figure 9d (right panel), which shows that the mice treated with LM-4131 
(10 mg/kg) scored significantly lesser on feeding latency than did the mice treated with vehicle 
(for LM-4131 treatment group, means ± s.e.m. = 140.9 ± 17.20, N = 32; for vehicle treatment 
group, means ± s.e.m. = 320.9 ± 43.87, N = 27).  An independent samples t test also revealed no 
significant difference between the apamin treatment group and LM-4131 and apamin co-treatment 
group (t (38) = 0.7658; p = 0.4485, ns) and between the vehicle treatment group and LM-4131 and 
apamin co-treatment group (t (45) = 1.074; p = 0.2884, ns).  The sample means in Figure 9d (right 
panel) show that the apamin-treated mice demonstrated scores on feeding latency similar to mice 
co-treated with apamin and LM-4131 (for apamin treatment group, means ± s.e.m. = 537.3 ± 131.2, 
N = 20; for LM-4131 and apamin co-treatment group, means ± s.e.m. = 417.2 ± 85.86, N = 20).  It 
 72 
also shows that the vehicle-treated mice demonstrated scores on feeding latency similar to mice 
co-treated with apamin and LM-4131 (for vehicle treatment group, means ± s.e.m. = 320.9 ± 43.87, 
N = 27; for LM-4131 and apamin co-treatment group, means ± s.e.m. = 417.2 ± 85.86, N = 20).  
To further validate that the anxiolytic action of the SSCI, LM-4131, is mediated through the SK 
channels once mice have been subjected to acute stress exposure, we treated another cohort of 
juvenile male ICR mice with the SK channel agonist, 1-EBIO, to determine if it could mimic the 
anxiolytic effects of LM-4131 in the NIH test.  We found that activating the SK channels reduced 
stress-induced anxiety-like behavior in the mice similar to LM-4131.  According to the cumulative 
frequency distribution percentile plots of mice feeding in the NIH test 8h after exposure to acute 
electric footshock stress (Fig. 9d (3rd left panels)), 100% of 1-EBIO-treated mice had a feeding 
latency ≤ 287 s and 100% of 1-EBIO and LM-4131 co-treated mice had a feeding latency ≤ 280 s 
in the novel cage environment.  A Kolmogorov-Smirnov test of the feeding latency data presented 
in the percentile plots revealed no difference between the cumulative frequency distribution for 
the 1-EBIO treatment group and the 1-EBIO and LM-4131 co-treatment group (D = 0.04132, p > 
0.9999, ns, 1-EBIO + LM-4131 vs. 1-EBIO at 5 mg/kg).  An independent samples t test also 
revealed no significant difference between the 1-EBIO treatment group and LM-4131 and 1-EBIO 
co-treatment group (t (8) = 0.2948; p = 0.7756, ns) and between the LM-4131 treatment group and 
LM-4131 and 1-EBIO co-treatment group (t (35) = 0.8318; p = 0.4112, ns).  The sample means in 
Figure 9d (right panel) show that the 1-EBIO-treated mice demonstrated scores on feeding latency 
similar to mice co-treated with 1-EBIO and LM-4131 (for 1-EBIO treatment group, means ± s.e.m. 
= 163.8 ± 35.60, N = 5; for LM-4131 and 1-EBIO co-treatment group, means ± s.e.m. = 179.4 ± 
39.15, N = 5).  It also shows that the LM-4131-treated mice demonstrated scores on feeding latency 
similar mice co-treated with 1-EBIO and LM-4131 (for LM-4131 treatment group, means ± s.e.m. 
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= 140.9 ± 17.20, N = 32; for LM-4131 and 1-EBIO co-treatment group, means ± s.e.m. = 179.4 ± 
39.15, N = 5).   
We also investigated whether or not the effects of substrate-selective COX-2 inhibition on 
stress-induced anhedonia and hyponeophagia in the NIH test after mice were subjected to acute 
footshock stress 8 h prior to testing as mediated by the CB1R.  Both SSCIs, LM-4131 and LMX, 
decreased anhedonia and hyponeophagia when the mice were tested in the aversive, novel cage 
environment 8 hours after exposure to acute footshock stress.  However, these effects were 
reversed when the mice were co-treated with LM-4131 or LMX and the CB1R antagonist, 
rimonabant.  Thus, the SSCIs, LM-4131 and LMX, decreased stress-induced anhedonia and 
hyponeophagia when the mice in a CB1R-mediated manner.  According to the cumulative 
frequency distribution percentile plots of juvenile ICR male mice feeding in the NIFS assay (Fig. 
9e (3 left panels)), 100% of vehicle-treated mice consumed ≤ 1.0 g of the shake, 100% of LM-
4131-treated mice consumed ≤ 1.8 g of the shake, 100% of LMX-treated mice consumed ≤ 1.7 g 
of the shake, 100% of rimonabant-treated mice consumed ≤ 0.8 g (for rimonabant at 2 or 5 mg/kg) 
of the shake, 100% of LM-4131 and rimonabant co-treated mice consumed ≤ 0.9 g (for rimonabant 
at 2 mg/kg) or ≤ 1.0 g (for rimonabant at 5 mg/kg) of the shake, and 100% of LMX and rimonabant 
co-treated mice consumed ≤ 0.9 g (for rimonabant at 5 mg/kg) of the shake in the novel cage 
environment.  A Kolmogorov-Smirnov test of the shake consumption data presented in the 
percentile plots revealed a significant difference between the cumulative frequency distributions 
for the LM-4131 and LMX treatment groups and the cumulative frequency distribution for the 
vehicle treatment group (D = 0.7143, ***p < 0.001, LM-4131 at 10 mg/kg vs. vehicle; D = 0.6593, 
****p < 0.0001, LMX at 1 mg/kg vs. vehicle).  It also revealed no difference between the 
cumulative frequency distribution for the rimonabant treatment group and the cumulative 
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frequency distribution for the LM-4131 or LMX and rimonabant co-treatment group (D = 0.09901, 
p = 7052, ns, rimonabant at 2 mg/kg vs. rimonabant + LM-4131 at 10 mg/kg; D = 0.09901, p = 
0.7052, ns, rimonabant at 5 mg/kg vs. rimonabant + LM-4131; D = 0.04950, p = 0.9997, 
rimonabant at 5 mg/kg vs. rimonabant + LMX at 1 mg/kg).  An independent samples (unpaired) t 
test revealed a significant difference between the vehicle and LM-4131 or LMX treatment group 
(t (13) = 4.427, p = 0.0007, ***p < 0.001, LM-4131 vs. vehicle; t (14) = 3.155, p = 0.0070, **p < 
0.01, LMX vs. vehicle).  The sample means are displayed in Figure 9e (right panel), which shows 
that the mice treated with LM-4131 (10 mg/kg) or LMX (1 mg/kg) scored significantly greater on 
shake consumption than did the mice treated with vehicle (for LM-4131 treatment group, means 
± s.e.m. = 1.129 ± 0.1409, N = 7; for LMX treatment group, means ± s.e.m. = 1.063 ± 0.1954, N 
= 8; for vehicle treatment group, means ± s.e.m. = 0.3625 ± 0.1051, N = 8).  An independent 
samples t test also revealed no significant difference between the rimonabant treatment group and 
LM-4131 or LMX and rimonabant co-treatment group (t (39) = 0.2758; p = 0.7841, ns, LM-4131 
+ rimonabant at 2 mg/kg vs. rimonabant; t (14) = 0.5670; p = 0.5797, ns, LM-4131 + rimonabant 
at 5 mg/kg vs. rimonabant; t (14) = 0.2590; p = 0.7994, ns, LMX + rimonabant at 5 mg/kg vs. 
rimonabant) and between the vehicle treatment group and LM-4131 or LMX and rimonabant co-
treatment group (t (27) = 0.1630; p = 0.8717, ns, vehicle vs. LM-4131 + rimonabant at 2 mg/kg; t 
(14) = 1.002; p = 0.3335, ns, vehicle vs. LM-4131 + rimonabant at 5 mg/kg; t (14) = 0.7345; p = 
0.4748, ns, vehicle vs. LMX + rimonabant at 5 mg/kg).  The sample means in Figure 9e (right 
panel) show that the rimonabant-treated mice demonstrated scores on shake consumption similar 
to mice co-treated with rimonabant and LM-4131 or LMX (for 
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rimonabant (2 mg/kg) treatment group, means ± s.e.m. = 0.3200 ± 0.05361, N = 20; for LM-4131 
and rimonabant (2 mg/kg) co-treatment group, means ± s.e.m. = 0.3429 ± 0.06271, N = 21; for 
rimonabant (5 mg/kg) treatment group, means ± s.e.m. = 0.4375 ± 0.09246, N = 8; for LM-4131 
and rimonabant (5 mg/kg) co-treatment group, means ± s.e.m. = 0.5250 ± 0.1236, N = 8; for LMX 
Figure 10.  Anxiolytic effects of COX-2 inhibition is non-CB1R mediated only in male mice.  (a) 
Cumulative feeding latency distribution curves for vehicle and LM-4131 treated male mice in the presence of 
vehicle or CB2 antagonist SR144528 (3 mg/kg) co-treatment. Mean ± S.E.M feeding latency for each group 
tested under acute footshock stress conditions. (b) Cumulative feeding latency distribution curves for vehicle 
and LM-4131 treated male mice in the presence of vehicle or TRPV1 antagonist capsazepine (10 mg/kg) co-
treatment. Mean ± S.E.M feeding latency for each group tested under acute footshock stress conditions. (c) 
Cumulative feeding latency distribution curves for vehicle and LM-4131 treated female mice in the presence 
of vehicle or CB1 antagonist Rimonabant (2 mg/kg) co-treatment. Mean ± S.E.M feeding latency for each 
group tested under acute footshock stress conditions.  Mean ± S.E.M amount of shake consumed for each 
group tested 8h after stress exposure.  Data are shown as the mean ± s.e.m.  *P < 0.05, **P < 0.01, 
****P<0.0001.  Statistical significance was calculated by two-tailed unpaired Student's t-test or Kolmogorov-
Smirnov test (only for frequency plots).   
 76 
and rimonabant (5 mg/kg) co-treatment group, means ± s.e.m. = 0.4750 ± 0.1114, N = 8).  It also 
shows that the vehicle-treated mice demonstrated scores on shake consumption were similar to 
those shown by mice co-treated with rimonabant and LM-4131 or LMX (for vehicle treatment 
group, means ± s.e.m. = 0.3625 ± 0.1051, N = 8; for LM-4131 and rimonabant at 2 mg/kg co-
treatment group, means ± s.e.m. = 0.3429 ± 0.06271, N = 20; for LM-4131 and rimonabant at 5 
mg/kg co-treatment group, means ± s.e.m. = 0.5250 ± 0.1236, N = 8; for LMX and rimonabant at 
5 mg/kg co-treatment group, means ± s.e.m. = 0.4750 ± 0.1114, N = 8).  
Although the CB2R or TRPV1 has been suggested to modulate anxiety-like behavior in 
rodents221-226, we found that the SSCI, LM-4131, does not reduce anxiety-like behaviors after acute 
stress exposure through a CB2 receptor-mediated mechanism in juvenile male ICR mice.  
According to the cumulative frequency distribution percentile plots of mice feeding in the NIH 
test 8h after exposure to acute electric footshock stress (Fig. 10a (2 left panels)), 100% of vehicle-
treated mice had a feeding latency ≤ 1081 s, 100% of LM-4131-treated mice had a feeding latency 
≤ 245 s, 100% of SR144528-treated mice had a feeding latency ≤ 297 s, and 100% of SR144528 
and LM-4131 co-treated mice had a feeding latency ≤ 271 s in the novel cage environment.  A 
Kolmogorov-Smirnov test of the feeding latency data presented in the percentile plots revealed a 
significant difference between the cumulative frequency distribution for the LM-4131 treatment 
group and the cumulative frequency distribution for the vehicle treatment group (D = 0.4628, 
****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle) and no difference between the cumulative 
frequency distribution for the SR144528 treatment group and the SR144528 and LM-4131 co-
treatment group (D = 0.05785, p = 0.9874, ns, SR144528 + LM-4131 vs. SR144528 at 3 mg/kg).  
An independent samples (unpaired) t test revealed a significant difference between the vehicle and 
LM-4131 treatment group (t (32) = 3.555; p = 0.0012, **p < 0.01, LM-4131 vs. vehicle).  The 
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sample means are displayed in Figure 10a (right panel), which shows that the mice treated with 
LM-4131 (10 mg/kg) scored significantly lesser on feeding latency than did the mice treated with 
vehicle (for LM-4131 treatment group, means ± s.e.m. = 125.6 ± 16.90, N = 16; for vehicle 
treatment group, means ± s.e.m. = 374.9 ± 64.26, N = 18).  An independent samples t test also 
revealed no significant difference between the SR144528 treatment group and LM-4131 and 
SR144528 co-treatment group (t (28) = 0.1819; p = 0.8569, ns), but a significant difference 
between the vehicle treatment group and LM-4131 and SR144528 co-treatment group (t (30) = 
3.595; p = 0.0011, **p < 0.01).  The sample means in Figure 10a (right panel) show that the 
SR144528-treated mice demonstrated scores on feeding latency similar to mice co-treated with 
SR144528 and LM-4131 (for SR144528 treatment group, means ± s.e.m. = 95.50 ± 19.24, N = 16; 
for LM-4131 and SR144528 co-treatment group, means ± s.e.m. = 101.1 ± 24.27, N = 14).  It also 
shows that the vehicle-treated mice demonstrated greater scores on feeding latency than mice co-
treated with SR144528 and LM-4131 (for vehicle treatment group, means ± s.e.m. = 374.9 ± 64.26, 
N = 18; for LM-4131 and SR144528 co-treatment group, means ± s.e.m. = 101.1 ± 24.27, N = 14).   
We also found that the SSCI, LM-4131, does not reduce anxiety-like behaviors after acute 
stress exposure through a TRPVI-mediated mechanism in juvenile male ICR mice.  According to 
the cumulative frequency distribution percentile plots of mice feeding in the NIH test 8h after 
exposure to acute electric footshock stress (Fig. 10b (2 left panels)), 100% of vehicle-treated mice 
had a feeding latency ≤ 1081 s, 100% of LM-4131-treated mice had a feeding latency ≤ 245 s, 
100% of capsazepine-treated mice had a feeding latency ≤ 219 s, and 100% of capsazepine and 
LM-4131 co-treated mice had a feeding latency ≤ 323 s in the novel cage environment.  A 
Kolmogorov-Smirnov test of the feeding latency data presented in the percentile plots revealed a 
significant difference between the cumulative frequency distribution for the LM-4131 treatment 
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group and the cumulative frequency distribution for the vehicle treatment group (D = 0.4628, 
****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle) and no difference between the cumulative 
frequency distribution for the capsazepine treatment group and the capsazepine and LM-4131 co-
treatment group (D = 0.06612, p = 0.9541, ns, capsazepine + LM-4131 vs. capsazepine at 10 
mg/kg).  An independent samples (unpaired) t test revealed a significant difference between the 
vehicle and LM-4131 treatment group (t (32) = 3.555; p = 0.0012, **p < 0.01, LM-4131 vs. 
vehicle).  The sample means are displayed in Figure 10a (right panel), which shows that the mice 
treated with LM-4131 (10 mg/kg) scored significantly lesser on feeding latency than did the mice 
treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 125.6 ± 16.90, N = 16; for 
vehicle treatment group, means ± s.e.m. = 374.9 ± 64.26, N = 18).  An independent samples t test 
also revealed no significant difference between the capsazepine treatment group and LM-4131 and 
capsazepine co-treatment group (t (19) = 1.180; p = 0.2525, ns), but a significant difference 
between the vehicle treatment group and LM-4131 and capsazepine co-treatment group (t (28) = 
2.724; p = 0.0110, *p < 0.05).  The sample means in Figure 10b (right panel) show that the 
capsazepine-treated mice demonstrated scores on feeding latency similar to mice co-treated with 
capsazepine and LM-4131 (for capsazepine treatment group, means ± s.e.m. = 117.7 ± 17.12, N = 
9; for LM-4131 and capsazepine co-treatment group, means ± s.e.m. = 153.4 ± 22.79, N = 12).  It 
also shows that the vehicle-treated mice demonstrated scores on feeding latency which were 
greater than those shown by mice co-treated with capsazepine and LM-4131 (for vehicle treatment 
group, means ± s.e.m. = 374.9 ± 64.26, N = 18; for LM-4131 and capsazepine co-treatment group, 
means ± s.e.m. = 153.4 ± 22.79, N = 12).   
In addition, we found that these findings were sex-specific since the anxiolytic behaviors 
displayed by female mice as a result of SSCI was CB1R mediated after the juvenile female ICR 
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mice were exposed to acute footshock stress (Fig. 10c).  This may be due to there being sex 
differences in CB1R regulation, with stress-induced upregulation of CB1Rs seen mainly in limbic 
structures of female animals201.  According to the cumulative frequency distribution percentile 
plots of juvenile female ICR mice feeding in the NIH test 8 h after exposure to acute electric 
footshock stress (Fig. 10c (3 left panels)), 100% of vehicle-treated mice had a feeding latency ≤ 
655 s, 100% of LM-4131-treated mice had a feeding latency ≤ 219 s, 100% of rimonabant-treated 
mice had a feeding latency ≤ 1800 s, and 100% of rimonabant and LM-4131 co-treated mice had 
a feeding latency ≤ 1800 s in the novel cage environment.  A Kolmogorov-Smirnov test of the 
feeding latency data presented in the percentile plots revealed a significant difference between the 
cumulative frequency distribution for the LM-4131 treatment group and the cumulative frequency 
distribution for the vehicle treatment group (D = 0.2479, p = 0.0012, **p < 0.01, LM-4131 at 10 
mg/kg vs. vehicle) and no difference between the cumulative frequency distribution for the 
rimonabant treatment group and the rimonabant and LM-4131 co-treatment group (D = 0.1000, p 
> 0.9999, ns, rimonabant + LM-4131 vs. rimonabant at 2 mg/kg).  An independent samples 
(unpaired) t test revealed a significant difference between the vehicle and LM-4131 treatment 
group (t (27) = 2.587; p = 0.0154, *p < 0.05, LM-4131 vs. vehicle).  The sample means are 
displayed in Figure 10c (right panel), which shows that the mice treated with LM-4131 (10 mg/kg) 
scored significantly lesser on feeding latency than did the mice treated with vehicle (for LM-4131 
treatment group, means ± s.e.m. = 124.6 ± 16.48, N = 14; for vehicle treatment group, means ± 
s.e.m. = 268.7 ± 51.51, N = 15).  An independent samples t test also revealed no significant 
difference between the rimonabant treatment group and LM-4131 and rimonabant co-treatment 
group (t (18) = 0.2684; p = 0.7915, ns) and between the vehicle treatment group and LM-4131 and 
rimonabant co-treatment group (t (23) = 1.855; p = 0.0764, ns).  The sample means in Figure 10c 
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(right panel) show that the rimonabant-treated mice demonstrated scores on feeding latency similar 
to mice co-treated with rimonabant and LM-4131 (for rimonabant treatment group, means ± s.e.m. 
= 509.5 ± 153.8, N = 10; for LM-4131 and rimonabant co-treatment group, means ± s.e.m. = 574.8 
± 188.5, N = 10).  It also shows that the vehicle-treated mice demonstrated scores on feeding 
latency similar to mice co-treated with rimonabant and LM-4131 (for vehicle treatment group, 
means ± s.e.m. = 268.7 ± 51.51, N = 15; for LM-4131 and rimonabant co-treatment group, means 
± s.e.m. = 574.8 ± 188.5, N = 10).    
Moreover, the chronic stress-induced anxiogenic and anhedonic effects in the NIFS assay 
were decreased in a non-cannabinoid-receptor and cannabinoid-receptor mediated manner, 
respectively, demonstrating a context-dependent dissociation between stress-induced anxiety-like 
and anhedonic behaviors concerning cannabinoid-receptor mediated mechanisms.  We found that 
the SSCI, LM-4131, can reduce anxiety-like behaviors after chronic stress exposure through a non-
CB1 receptor-mediated mechanism in juvenile male ICR mice, specifically SK channels.  
According to the cumulative frequency distribution percentile plots of mice feeding in the NIH 
test 8h after exposure to chronic (5 days) electric footshock stress (Fig. 11a (2 left panels)), 100% 
of vehicle-treated mice had a feeding latency ≤ 1800 s, 100% of LM-4131-treated mice had a 
feeding latency ≤ 345 s, 100% of rimonabant-treated mice had a feeding latency ≤ 1800 s, and 
100% of rimonabant and LM-4131 co-treated mice had a feeding latency ≤ 1800 s in the novel 
cage environment.  A Kolmogorov-Smirnov test of the feeding latency data presented in the 
percentile plots revealed a significant difference between the cumulative frequency distribution 
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for the LM-4131 treatment group and the cumulative frequency distribution for the vehicle 
treatment group (D = 0.8017, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle) and between the 
cumulative frequency distribution for the rimonabant treatment group and the rimonabant and LM-
4131 co-treatment group (D = 0.5537, ****p < 0.0001, rimonabant + LM-4131 vs. rimonabant at 
2 mg/kg).  An independent samples (unpaired) t test revealed a significant difference between the 
vehicle and LM-4131 treatment group (t (51) = 3.233; p = 0.0022, **p < 0.01, LM-4131 vs. 
Figure 11.  Receptor mechanisms mediating anxiolytic and hedonic effects of COX-2 inhibition after 
chronic stress exposure. (a) Cumulative feeding latency distribution curves for vehicle and LM-4131 treated 
mice in the presence of vehicle or Rimonabant (2 mg/kg) co-treatment. Mean ± S.E.M feeding latency for each 
group tested under acute stress conditions. (b) Cumulative feeding latency distribution curves for vehicle and 
LM-4131treated mice in the presence of vehicle or Rimonabant (2 mg/kg) co-treatment. Effects of the CB1 
receptor antagonist Rimonabant (2 mg/kg on LM-4131-induced increases in shake consumption tested 8hours 
after 5 days of daily electric footshock stress exposure.  Mean ± S.E.M feeding latency for each group tested 
8h after stress exposure.  (c) Cumulative feeding latency distribution curves for vehicle and LM-4131 treated 
mice in the presence of vehicle, Apamin (0.4 mg/kg), or 1-EBIO (5 mg/kg) co-treatment.  Effects of the SK 
channel inhibitor Apamin (0.4 mg/kg), and SK channel activator 1-EBIO (5 mg/kg), on LM-4131-induced 
reductions in feeding latency tested 8h after5 days of daily electric footshock stress exposure.  Mean ± S.E.M 
feeding latency/amount consumed for each group tested 8h after chronic stress exposure.  Data are shown as 
the mean ± s.e.m.  **P < 0.01, ****P<0.0001.  Statistical significance was calculated by two-tailed unpaired 
Student's t-test or Kolmogorov-Smirnov test (only for frequency plots).   
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vehicle).  The sample means are displayed in Figure 11a (right panel), which shows that the mice 
treated with LM-4131 (10 mg/kg) scored significantly lesser on feeding latency than did the mice 
treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 115.8 ± 18.78, N = 22; for 
vehicle treatment group, means ± s.e.m. = 391.6 ± 70.44, N = 31).  An independent samples t test 
also revealed a significant difference between the rimonabant treatment group and LM-4131 and 
rimonabant co-treatment group (t (18) = 3.060; p = 0.0067, **p < 0.01) and no significant 
difference between the vehicle treatment group and LM-4131 and rimonabant co-treatment group 
(t (37) = 0.1879; p = 0.8520, ns).  The sample means in Figure 10a (right panel) show that the 
rimonabant-treated mice demonstrated scores on feeding latency which were significantly greater 
than those shown by mice co-treated with rimonabant and LM-4131 (for rimonabant treatment 
group, means ± s.e.m. = 909.2 ± 119.7, N = 12; for LM-4131 and rimonabant co-treatment group, 
means ± s.e.m. = 418.9 ± 76.62, N = 8).  It also shows that the vehicle-treated mice demonstrated 
scores on feeding latency similar to mice co-treated with rimonabant and LM-4131 (for vehicle 
treatment group, means ± s.e.m. = 391.6 ± 70.44, N = 31; for LM-4131 and rimonabant co-
treatment group, means ± s.e.m. = 418.9 ± 76.62, N = 8). 
 We also examined whether or not the effects of substrate-selective COX-2 inhibition on 
chronic stress-induced anhedonia and hyponeophagia in the NIH test after mice were subjected to 
chronic (5 days) footshock stress 8 h prior to testing was mediated by the CB1R.  The SSCI, LM-
4131, decreased anhedonia and hyponeophagia when the mice were tested in the aversive, novel 
cage environment 8 hours after exposure to chronic footshock stress.  However, these effects were 
reversed when the mice were co-treated with LM-4131 and the CB1R antagonist, rimonabant.  
Thus, the SSCI, LM-4131, decreased chronic stress-induced anhedonia and hyponeophagia in the 
mice in a CB1R-mediated manner.  According to the cumulative frequency distribution percentile 
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plots of juvenile ICR male mice feeding in the NIFS assay 8h after chronic stress exposure (Fig. 
11b (2 left panels)), 50% (50th percentile) of vehicle-treated mice consumed ≤ 0.4 g of the shake, 
50% of LM-4131-treated mice consumed ≤ 0.7 g of the shake, 50% of rimonabant-treated mice 
consumed ≤ 0.05 g of the shake, and 50% of LM-4131 and rimonabant co-treated mice consumed 
≤ 0.2 g of the shake in the novel cage environment.  A Kolmogorov-Smirnov test of the shake 
consumption data presented in the percentile plots revealed a significant difference between the 
cumulative frequency distributions for the LM-4131 treatment group and the cumulative frequency 
distribution for the vehicle treatment group (D = 0.3465, ****p < 0.0001, LM-4131 at 10 mg/kg 
vs. vehicle).  It also revealed no difference between the cumulative frequency distribution for the 
rimonabant treatment group and the cumulative frequency distribution for the LM-4131 and 
rimonabant co-treatment group (D = 0.1485, p = 0.2153, ns, rimonabant at 2 mg/kg vs. rimonabant 
+ LM-4131 at 10 mg/kg).  An independent samples (unpaired) t test revealed a significant 
difference between the vehicle and LM-4131 treatment group (t (51) = 3.016, p = 0.0040, **p < 
0.01, LM-4131 vs. vehicle).  The sample means are displayed in Figure 11b (right panel), which 
shows that the mice treated with LM-4131 (10 mg/kg) scored significantly greater on shake 
consumption than did the mice treated with vehicle (for vehicle treatment group, means ± s.e.m. = 
0.4903 ± 0.06884, N = 31; for LM-4131 treatment group, means ± s.e.m. = 0.8273 ± 0.09050, N = 
22).  An independent samples t test also revealed a significant difference between the rimonabant 
treatment group and LM-4131 and rimonabant co-treatment group (t (17) = 2.974; p = 0.0085, **p 
< 0.01, LM-4131 + rimonabant at 2 mg/kg vs. rimonabant), but no significant difference between 
the vehicle treatment group and LM-4131 and rimonabant co-treatment group (t (36) = 1.274; p = 
0.2108, ns, vehicle vs. LM-4131 + rimonabant at 2 mg/kg).  The sample means in Figure 11b (right 
panel) show that the rimonabant-treated mice demonstrated scores on shake consumption which 
 84 
were lesser than those shown by mice co-treated with rimonabant and LM-4131 (for rimonabant 
(2 mg/kg) treatment group, means ± s.e.m. = 0.1000 ± 0.03482, N = 12; for LM-4131 and 
rimonabant (2 mg/kg) co-treatment group, means ± s.e.m. = 0.3000 ± 0.06547, N = 7).  It also 
shows that the vehicle-treated mice demonstrated scores on shake consumption were similar to 
those shown by mice co-treated with rimonabant and LM-4131 (for vehicle treatment group, 
means ± s.e.m. = 0.4903 ± 0.06884, N = 31; for LM-4131 and rimonabant at 2 mg/kg co-treatment 
group, means ± s.e.m. = 0.3000 ± 0.06547, N = 7).  
We found that the SSCI, LM-4131, can reduce anxiety-like behaviors after chronic (5 days) 
stress exposure through a non-CB1 receptor-mediated mechanism in male ICR mice, specifically 
SK channels.  According to the cumulative frequency distribution percentile plots of mice feeding 
in the NIH test 8h after exposure to acute electric footshock stress (Fig. 11c (3 left panels)), 100% 
of vehicle-treated mice had a feeding latency ≤ 1800 s, 100% of LM-4131-treated mice had a 
feeding latency ≤ 269 s, 100% of apamin-treated mice had a feeding latency ≤ 1800 s, and 100% 
of apamin and LM-4131 co-treated mice had a feeding latency ≤ 1800 s in the novel cage 
environment.  A Kolmogorov-Smirnov test of the feeding latency data presented in the percentile 
plots revealed a significant difference between the cumulative frequency distribution for the LM-
4131 treatment group and the cumulative frequency distribution for the vehicle treatment group 
(D = 0.9174, ****p < 0.0001, LM-4131 at 10 mg/kg vs. vehicle) and between the cumulative 
frequency distribution for the apamin treatment group and the apamin and LM-4131 co-treatment 
group (D = 0.8099, ****p < 0.0001, apamin + LM-4131 vs. apamin at 0.4 mg/kg).  An independent 
samples (unpaired) t test revealed a significant difference between the vehicle and LM-4131 
treatment group (t (24) = 2.330; p = 0.0285, *p < 0.05, LM-4131 vs. vehicle).  The sample means 
are displayed in Figure 11c (right panel), which shows that the mice treated with LM-4131 (10 
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mg/kg) scored significantly lesser on feeding latency than did the mice treated with vehicle (for 
LM-4131 treatment group, means ± s.e.m. = 91.23 ± 19.25, N = 13; for vehicle treatment group, 
means ± s.e.m. = 397.3 ± 129.9, N = 13).  An independent samples t test also revealed no significant 
difference between the apamin treatment group and LM-4131 and apamin co-treatment group (t 
(23) = 1.084, p = 0.2896, ns) and between the vehicle treatment group and LM-4131 and apamin 
co-treatment group (t (22) = 0.6064; p = 0.5505, ns).  The sample means in Figure 11c (right panel) 
show that the apamin-treated mice demonstrated scores on feeding latency similar to mice co-
treated with apamin and LM-4131 (for apamin treatment group, means ± s.e.m. = 865.6 ± 225.0, 
N = 14; for LM-4131 and apamin co-treatment group, means ± s.e.m. = 534.1 ± 191.6, N = 11).  It 
also shows that the vehicle-treated mice demonstrated scores on feeding latency similar to mice 
co-treated with apamin and LM-4131 (for vehicle treatment group, means ± s.e.m. = 397.3 ± 129.9, 
N = 13; for LM-4131 and apamin co-treatment group, means ± s.e.m. = 534.1 ± 191.6, N = 11).  
To further validate that the anxiolytic action of the SSCI, LM-4131, is mediated through the SK 
channels once mice have been subjected to chronic stress exposure, we treated another cohort of 
juvenile male ICR mice with the SK channel agonist, 1-EBIO, to determine if it could mimic the 
anxiolytic effects of LM-4131 in the NIH test.  We found that activating the SK channels reduced 
chronic stress-induced anxiety-like behavior in the mice similar to LM-4131.  According to the 
cumulative frequency distribution percentile plots of mice feeding in the NIH test 8h after exposure 
to chronic electric footshock stress (Fig. 11c (3rd left panel)), 100% of 1-EBIO-treated mice had a 
feeding latency ≤ 355 s and 100% of 1-EBIO and LM-4131 co-treated mice had a feeding latency 
≤ 324 s in the novel cage environment.  A Kolmogorov-Smirnov test of the feeding latency data 
presented in the percentile plots revealed no difference between the cumulative frequency 
distribution for the 1-EBIO treatment group and the 1-EBIO and LM-4131 co-treatment group (D 
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= 0.03306, p > 0.9999, ns, 1-EBIO + LM-4131 vs. 1-EBIO at 5 mg/kg).  An independent samples 
t test also revealed no significant difference between the 1-EBIO treatment group and LM-4131 
and 1-EBIO co-treatment group (t (10) = 0.2418; p = 0.8138, ns) and between the vehicle treatment 
group and LM-4131 and 1-EBIO co-treatment group (t (22) = 1.125; p = 0.2762, ns).  The sample 
means in Figure 11c (right panel) show that the 1-EBIO-treated mice demonstrated scores on 
feeding latency similar to mice co-treated with 1-EBIO and LM-4131 (for 1-EBIO treatment 
group, means ± s.e.m. = 193.2 ± 52.16, N = 6; for LM-4131 and 1-EBIO co-treatment group, means 
± s.e.m. = 175.7 ± 50.17, N = 6).  It also shows that the vehicle-treated mice demonstrated scores 
on feeding latency similar to mice co-treated with 1-EBIO and LM-4131 (for vehicle treatment 
group, means ± s.e.m. = 397.3 ± 129.9, N = 13; for LM-4131 and 1-EBIO co-treatment group, 
means ± s.e.m. = 175.7 ± 50.17, N = 6).   
Our finding that SK channels are able to facilitate the anxiolytic effects of the SSCI, LM-
4131, after acute stress exposure was not confounded by increased locomotor activity in the mice 
as a result of i.p. administration with the SK channel antagonist, apamin, or the SK channel agonist, 
1-EBIO.  Administration of the SK channel antagonist, apamin, did not cause any changes in 
horizontal activity under control (no stress) conditions (Fig. 12a).  One-way ANOVA did not 
reveal any effect of apamin at 0.2, 0.4, or 1 mg/kg on horizontal counts (F (3, 36) = 2.688, p = 0.0608; 
Fig. 12a (left panel)) or horizontal time (F(3, 36) = 2.245, p = 0.0997; Fig. 12a (middle panel)) in 
the open field assay.  Horizontal or ambulatory distance traveled was only decreased at the highest 
dose of apamin (one-way ANOVA: F(3, 36) = 2.929, p = 0.0467; 1 mg/kg vs. vehicle, p<0.05 by 
Holm-Sidak post hoc test; Fig. 12a (right panel)), which was not used in the experiments aimed at 
determining the mechanism of action of LM-3131 in reducing stress-induced anxiety in the NIFS 
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test.  Also, post hoc Holm-Sidak’s test revealed no differences in horizontal distance traveled 
Figure 12.  Locomotor effects of SK channel antagonists and agonists.  Horizontal activity, vertical activity, 
average velocity, groom behavior, resting time, and jump counts measured in the open field assay under non-
stressful conditions for the SK channel antagonist, apamin (a-f), and the SK channel agonist, 1-EBIO (g-l), at 
varying concentrations in juvenile male mice. Data are shown as the mean ± s.e.m.  NS = no stress, S = stress 
(e.g., stress exposure in the form of an electric footshock administered 8h prior to testing), *P < 0.05 (SK channel 
antagonist/agonist compared to vehicle).  Statistical significance was calculated by two-tailed unpaired Student's 
t-test.   
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during the 60 min testing period in the open-field assay at the 0.2 mg/kg and 0.4 mg/kg doses of 
apamin compared to the vehicle treatment.  Moreover, administration of apamin did not cause any 
changes in vertical activity under control (no stress) conditions (Fig. 12b).  One-way ANOVA did 
not reveal any effect of apamin at 0.2, 0.4, or 1 mg/kg on vertical counts (F (3, 36) = 0.1038, p = 
0.9573; Fig. 12b (left panel)) in the open field assay.  Vertical time was only decreased at the 
highest dose of apamin (one-way ANOVA: F(3, 36) = 4.868, p = 0.0061; 1 mg/kg vs. vehicle, p<0.01 
by Holm-Sidak post hoc test; Fig. 12b (right panel)).  Also, post hoc Holm-Sidak’s test revealed 
no differences in vertical time during the 60 min testing period in the open-field assay at the 0.2 
mg/kg and 0.4 mg/kg doses of apamin compared to the vehicle treatment.  Apamin did not affect 
average velocity (one-way ANOVA: F(3, 36) = 1.794, p = 0.1657; Fig. 12c) at any dose tested.  
Apamin only reduced grooming or stereotypic counts (one-way ANOVA: F(3, 36) = 3.919, p = 
0.0161; 1 mg/kg vs. vehicle, p<0.01 by Holm-Sidak post hoc test; Fig. 12d (left panel)) and 
stereotypic time (one-way ANOVA: F(3, 36) = 4.848, p = 0.0062; 1 mg/kg vs. vehicle, p<0.01 by 
Holm-Sidak post hoc test; Fig. 12d (right panel)) at the highest dose.  Apamin appeared to make 
the mice slightly lethargic by increasing resting time at the highest dose tested (one-way ANOVA: 
F(3, 36) = 5.067, p = 0.0050; 1 mg/kg vs. vehicle, p<0.01 by Holm-Sidak post hoc test; Fig. 12de).  
Also, apamin decreased total jump counts at the highest dose tested in the open-field assay time 
(one-way ANOVA: F(3, 36) = 4.763, p = 0.0067; 1 mg/kg vs. vehicle, p<0.05 by Holm-Sidak post 
hoc test; Fig. 12f). 
Although administration of the SK channel agonist, 1-EBIO, at 5 mg/kg decreased 
horizontal counts (one-way ANOVA: F(3, 36) = 4.610, p = 0.0079; 5 mg/kg vs. vehicle, p<0.05 by 
Holm-Sidak post hoc test; Fig. 12g (left panel)) and time (one-way ANOVA: F(3, 36) = 4.070, p = 
0.0137; 5 mg/kg vs. vehicle, p<0.05 by Holm-Sidak post hoc test; Fig. 12g (right panel)), this dose 
 89 
of 1-EBIO did not cause any changes in horizontal distance traveled under control (no stress) 
conditions (one-way ANOVA: F(3, 36) = 3.217, p = 0.0341; 5 mg/kg vs. vehicle, ns by Holm-Sidak 
post hoc test; Fig. 12g) in the open-field test.  Also, post hoc Holm-Sidak’s test revealed no 
differences in horizontal distance traveled during the 60 min testing period in the open-field assay 
at the 1 mg/kg and 10 mg/kg doses of 1-EBIO compared to the vehicle treatment.  Moreover, 
administration of 1-EBIO did not cause any changes in vertical activity counts under control (no 
stress) conditions (one-way ANOVA: F(3, 36) = 2.141, p = 0.1121; Fig. 12h) at any dose tested.  
Vertical time was only decreased at the 5 mg/kg dose of apamin (one-way ANOVA: F(3, 36) = 
3.144, p = 0.0369; 5 mg/kg vs. vehicle, p<0.05 by Holm-Sidak post hoc test; Fig. 12h (right panel)).  
Also, post hoc Holm-Sidak’s test revealed no differences in vertical time during the 60 min testing 
period in the open-field assay at the 1 mg/kg and 10 mg/kg doses of 1-EBIO compared to the 
vehicle treatment.  1-EBIO did not affect average velocity (one-way ANOVA: F(3, 36) = 0.8780, p 
= 0.4616; Fig. 12i),  grooming or stereotypic counts (one-way ANOVA: F(3, 36) = 0.6029, p = 
0.6174; Fig. 12j (left panel)), stereotypic time (one-way ANOVA: F(3, 36) = 0.1697, p = 0.9162; 
Fig. 12j (right panel)), or resting time (one-way ANOVA: F(3, 36) = 0.9059, p = 0.4478; Fig. 12k) 
at any dose tested.   Also, 1-EBIO decreased total jump counts at the 5 mg/kg dose tested in the 
open-field assay time (one-way ANOVA: F(3, 36) = 4.952, p = 0.0056; 5 mg/kg vs. vehicle, p<0.01 
by Holm-Sidak post hoc test; Fig. 12l). 
Effects of substrate-selective COX-2 inhibition on stress-induced fear-related behavior 
When a human or an animal encounters an aversive or stressful life event, a fear response 
can be produced until the aversion subsides.  Fear responses can develop into pathological anxiety 
when they are chronically dysfunctional or exaggerated227,228.  Lesion studies have shown that the 
amygdala is one of several brain structures involved in modulating fear-related behaviors in 
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animals, such as phasic immobility or freezing.  In particular, these studies have illustrated that 
lesions of the lateral, basolateral, and central nuclei of the amygdala can disrupt fear responses 
conditioned to a cue (e.g., a tone paired with an electric footshock) and a context (e.g., a chamber 
in which tone-electric footshock pairings occur) and disrupt subsequent expression of stress-
induced freezing229-233.  Our study suggests that COX-2 inhibitors can reduce anxiety in mice after 
being subjected to an acute aversive life event, such as a series of electric footshocks in one day.  
Thus, one would expect that COX-2 inhibitors may as well be able to enhance extinction of 
conditioned fear responses in mice to the same acute aversive life event in an amygdala-dependent 
manner.  To test this hypothesis, we examined the effects of the SSCI, LM-4131 (10 mg/kg), on 
freezing behavior in mice when we returned them to the same chamber they experienced the acute 
aversive life event (e.g., six tone-electric footshock pairings) in the presence of a conditioned 
stimulus (e.g., a 30 second tone repeated 15 times).  We found no significant differences in the 
freezing behavior of the mice before i.p. administration of vehicle or LM-4131 after subjecting the 
mice to six tone-footshock pairings.  Relating to the effect of six tone-electric footshock pairings 
on freezing behavior, two-way ANOVA factoring drug dose and time revealed no effect of drug 
dose x time interaction (F(6, 308) = 1.446; p = 0.1967, ns), but a significant effect of drug dose (F(1, 
308) = 6.843, p = 0.0093, **p < 0.01) and time (F(6, 308) = 53.38, ****p < 0.0001; Fig. 13a (left 
panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed a slight decrease in percentage 
freezing after the administration of the last tone-footshock pairing in a cohort of mice that will be 
treated with LM-4131 at a dose of 10 mg/kg compared to the mice that will be treated with vehicle 
(*p < 0.05, t = 3.200, df = 308, LM-4131 vs. vehicle; for vehicle treatment group, means ± s.e.m. 
= 62.06 ± 5.181, N = 23; for LM-4131 treatment group, means ± s.e.m. = 45.48 ± 5.181, N = 23).  
We also found no significant differences in the freezing 
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behavior of the vehicle-treated or LM-4131-treated mice elicited by a tone that was paired with 
the electric footshock once we placed the mice in the same chamber in which the aversive electric 
footshock was previously experienced.  Two-way ANOVA factoring drug dose and time revealed 
no significant effect of drug dose (F(1, 484) = 1.136; p = 0.2870, ns) and dose x time interaction (F(10, 
484) = 0.6668; p = 0.7555, ns), but a significant effect of time (F(10, 484) = 3.056; p = 0.0009, ***p 
< 0.001; Fig.13a (middle top panel)).  An independent samples (unpaired) t test revealed no 
Figure 13.  Cognitive effects of substrate-selective COX-2 inhibition.  (a, b) Diagrams (top) of experimental 
design for context conditioning and cued or contextual fear extinction and retrieval.  (a) Freezing behavior 
during context conditioning (left) and cued fear extinction (middle) and retrieval (right).  During context 
conditioning, a tone, the conditional stimulus (CS), was paired with a footshock, the unconditional stimulus 
(US), six times.  (b) Freezing behavior during context conditioning (left) and contextual fear extinction (middle) 
and retrieval (right). (c) Number of entries in each arm, number of total arm entries, percentage of spontaneous 
alternations, mean speed, and total distance traveled in the Y-maze (left to right).  Data are shown as the mean 
± s.e.m.  NS = no stress, S = stress (e.g., stress exposure in the form of an electric footshock administered 8h 
prior to testing), *P < 0.05, **P < 0.01.  Statistical significance was calculated by two-tailed unpaired Student's 
t-test or two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test and time x treatment 
interaction as a source of variation between groups.   
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significant difference in total freezing time during the fear extinction test between the vehicle and 
LM-4131 treatment group (t (44) = 0.4572, p = 0.6498, ns, LM-4131 vs. vehicle).  The sample 
means are displayed in Figure 13a (right bottom panel), which shows that the mice treated with 
LM-4131 (10 mg/kg) scored similar on total freezing time to the mice treated with vehicle (for 
LM-4131 treatment group, means ± s.e.m. = 84.97 ± 13.42, N = 23; for vehicle treatment group, 
means ± s.e.m. = 92.14 ± 8.133, N = 23).  We obtained similar results in the freezing behavior of 
the mice when we examined the effects of LM-4131 on the recovery of the extinguished fear (e.g., 
fear retrieval or recall) in the mice.  Two-way ANOVA factoring drug dose and time revealed a 
significant effect of drug dose (F(1, 144) = 10.61; p = 0.0014, **p < 0.01) and time (F(5, 144) = 2.279; 
p = 0.0498, *p < 0.05), but no significant effect of dose x time interaction (F(5, 144) = 0.1014; p = 
0.9917, ns; Fig.13a (right top panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed 
no changes in percentage freezing at any time point in the vehicle-treated mice compared to the 
LM-4131-treated mice.  An independent samples (unpaired) t test revealed no significant 
difference in total freezing time during the fear retrieval test between the vehicle and LM-4131 
treatment group (t (24) = 1.913, p = 0.0678, ns, LM-4131 vs. vehicle).  The sample means are 
displayed in Figure 13a (right bottom panel), which shows that the mice treated with LM-4131 (10 
mg/kg) scored similar on total freezing time to the mice treated with vehicle (for LM-4131 
treatment group, means ± s.e.m. = 60.49 ± 8.851, N = 13; for vehicle treatment group, means ± 
s.e.m. = 39.96 ± 6.078, N = 13).  These results suggest that the SSCI, LM-4131, does not affect 
stress-induced fear-related behavior in an amygdala-dependent fashion.  LM-4131 may be 
selectively affecting subregions of the amygdala after an animal has been exposed to a stressful 
external stimulus, such as a series of electric footshocks, or only affects fear-related behavior in 
animals in a context-dependent manner.  Several studies have suggested that the basolateral 
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subregion of the amygdala is not restricted to a single sensory modality and is required for 
memories of contextual representations of an environment, especially in the case of memories 
acquired after contextual fear conditioning where an environment is associated with an aversive 
electric footshock234-236. 
Since impaired extinction of contextual fear memories is thought to contribute to the 
development and maintenance of anxiety, trauma-related, and stressor-related disorders, we next 
assessed whether or not COX-2 inhibitors could enhance contextual fear extinction and recall.  To 
investigate the effects of LM-4131 on contextual fear extinction, we measured freezing behavior 
in vehicle-treated and LM-4131-treated mice when we returned them to the same chamber they 
experienced the acute aversive life event (e.g., six tone-electric footshock pairings).  We found no 
significant differences in the freezing behavior of the mice before i.p. administration of vehicle or 
LM-4131 after subjecting the mice to six tone-footshock pairings.  Concerning the effect of six 
tone-electric footshock pairings on freezing behavior, two-way ANOVA factoring drug dose and 
time revealed no effect of drug dose x time interaction (F(18, 385) = 0.4368, p = 0.9795, ns) and drug 
dose (F(13 385) = 0.8664, p = 0.4586, ns), but a significant effect of time (F(6, 385) = 63.69, ****p < 
0.0001; Fig. 13b (left panel)).  We found that the SSCI, LM-4131, significantly increased 
contextual fear extinction by decreasing freezing behavior in the mice only 8 hours after exposure 
to the acute stress paradigm.  Two-way ANOVA factoring drug dose and time revealed a 
significant effect of drug dose (F(1, 567) = 89.09, ****p < 0.0001), time (F(20, 567) = 3.495, ****p < 
0.0001), and dose x time interaction (F(20, 567) = 1.697, p = 0.0298, *p < 0.05; Fig.13b (middle top 
panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed a significant decrease in 
percentage freezing in the juvenile male ICR mice during the 1.5 min (t (567) = 3.948, **p < 0.01, 
for LM-4131 treatment group, means ± s.e.m. = 12.51 ± 6.746, N = 15; for vehicle treatment group, 
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means ± s.e.m. = 39.14 ± 6.746, N = 14), 2.0 min (t (567) = 5.100, ****p < 0.0001, for LM-4131 
treatment group, means ± s.e.m. = 10.05 ± 6.746; for vehicle treatment group, means ± s.e.m. = 
44.45 ± 6.746), 2.5 min (t (567) = 3.983, **p < 0.01, for LM-4131 treatment group, means ± s.e.m. 
= 11.55 ± 6.746; for vehicle treatment group, means ± s.e.m. = 38.41 ± 6.746), 3.0 min (t (567) = 
3.322, *p < 0.05, for LM-4131 treatment group, means ± s.e.m. = 7.163 ± 6.746; for vehicle 
treatment group, means ± s.e.m. = 29.57 ± 6.746), and 3.5 min (t (567) = 3.358, *p < 0.05, for LM-
4131 treatment group, means ± s.e.m. = 9.245 ± 6.746; for vehicle treatment group, means ± s.e.m. 
= 31.90 ± 6.746) bins of the fear extinction test at the 10 mg/kg dose of LM-4131 compared to 
vehicle treatment.  An independent samples (unpaired) t test revealed a significant difference in 
total freezing time during the fear extinction test between the vehicle and LM-4131 treatment 
group (t (27) = 3.356, p = 0.0024, **p < 0.01, LM-4131 vs. vehicle).  The sample means are 
displayed in Figure 13b (middle bottom panel), which shows that the mice treated with LM-4131 
(10 mg/kg) scored significantly lesser on total freezing time than did the mice treated with vehicle 
(for LM-4131 treatment group, means ± s.e.m. = 66.31 ± 8.775, N = 15; for vehicle treatment 
group, means ± s.e.m. = 153.8 ± 25.33, N = 14).  We found no significant differences in the freezing 
behavior of the mice during fear retrieval 24 hours after exposure to the acute stress protocol.  
Two-way ANOVA factoring drug dose and time revealed a significant effect of drug dose (F(1, 297) 
= 6.559, p = 0.0109, *p < 0.05), but no significant effect of time (F(10, 297) = 0.8374, p = 0.5928, 
ns) and dose x time interaction (F(10, 297) = 0.6363, p = 0.7824, ns; Fig.13b (middle top panel)).  
Post hoc Holm-Sidak’s multiple comparisons test revealed no significant difference in percentage 
freezing at any time point in the juvenile male ICR mice of the fear retrieval test at the 10 mg/kg 
dose of LM-4131 compared to vehicle treatment.  An independent samples (unpaired) test revealed 
no significant difference in total freezing time during the fear retrieval test between the vehicle 
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and LM-4131 treatment group (t (27) = 0.9954, p = 0.3284, ns, LM-4131 vs. vehicle).  The sample 
means are displayed in Figure 13b (right bottom panel), which shows that the mice treated with 
LM-4131 (10 mg/kg) scored similar on total freezing time to the mice treated with vehicle (for 
LM-4131 treatment group, means ± s.e.m. = 68.26 ± 9.947, N = 15; for vehicle treatment group, 
means ± s.e.m. = 88.08 ± 17.66, N = 14).  These results suggest that LM-4131 can decrease stress-
induced fear in a context-dependent manner.  Also, the effects of LM-4131 on contextual fear 
extinction is dependent upon not only the amygdala, but as well as the hippocampus, since we did 
not find similar changes with cued fear extinction and recall, which is mainly amygdala-dependent 
(Fig. 13a (middle panel)).  Phillips and LeDoux illustrated in rats that both the amygdala and the 
hippocampus are involved in the conditioning of fear-related behavior as a consequence of 
complex, polymodal sensory stimuli.  When they lesioned the amygdala and hippocampus, both 
brain regions disrupted conditioning of fear responses in the rats when the stress-induced fear 
responses were associated with a particular environment (e.g., the chamber where an electric 
footshock occurred)230. 
The effects of the SSCI, LM-4131, on stress-induced fear-related behavior in the mice were 
not confounded by cognitive deficits in spatial learning and memory or an animal’s willingness to 
explore a novel environment.  LM-4131 at a dose of 10 mg/kg compared to vehicle did not cause 
any changes in the number of entries in each arm in the Y-maze test under both basal and acute 
stress exposure conditions (Fig, 13c, left panel).  With respect to the effect of LM-4131 on the 
number of entries in each arm of the Y-maze under basal (no stress) conditions, two-way ANOVA 
factoring drug dose and time revealed no significant effect of drug dose (F(1, 48) = 0.3075, p = 
0.5818, ns) and dose x arm interaction (F(2, 48) = 0.1829, p = 0.8334, ns), but a significant effect of 
which arm was entered (F(2, 48) = 3.196, p = 0.0498, *p < 0.05).  Relating to the effect of LM-4131 
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on the number of entries in each arm of the Y-maze 8h after acute stress exposure, two -way 
ANOVA factoring drug dose and time also revealed no significant effect of drug dose (F(1, 48) = 
1.836, p = 0.1818, ns) and dose x arm interaction (F(2, 48) = 0.4066, p = 0.6682, ns), but a significant 
effect of which arm was entered (F(2, 48) = 8.511, p = 0.0007, ***p < 0.001).  LM-4131 at a dose 
of 10 mg/kg compared to vehicle did not cause any changes in the total number of arm entries in 
the Y-maze test under both basal and acute stress exposure conditions (Fig, 13c, middle left panel).  
Pertaining to the effect of LM-4131 on the total number of arm entries in the Y-maze under basal 
conditions, an independent samples (unpaired) t test revealed no significant difference between the 
vehicle and LM-4131 treatment groups (t (16) = 0.5525; p = 0.5883, ns).  The sample means are 
displayed in Figure 13c, which shows that the mice treated with LM-4131 (10 mg/kg) scored 
similar on the total number of arm entries in the Y-maze to the mice treated with vehicle (for LM-
4131 treatment group, means ± s.e.m. = 59.75 ± 4.515, N = 8; for vehicle treatment group, means 
± s.e.m. = 64.40 ± 6.580, N = 10).  In connection with the effect of LM-4131 on the total number 
of arm entries in the Y-maze 8h after acute stress exposure, an independent samples (unpaired) t 
test revealed no significant difference between the vehicle and LM-4131 treatment groups (t (16) 
= 1.090; p = 0.2921, ns).  The sample means are displayed in Figure 13c, which shows that the 
mice treated with LM-4131 (10 mg/kg) scored similar on the total number of arm entries in the Y-
maze to the mice treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 54.00 ± 
7.461, N = 9; for vehicle treatment group, means ± s.e.m. = 63.11 ± 3.777, N = 9).  LM-4131 at a 
dose of 10 mg/kg compared to vehicle did not cause any changes in percentage spontaneous 
alternation in the Y-maze test under both basal and acute stress exposure conditions (Fig, 13c, 
middle panel).  About the effect of LM-4131 on percentage spontaneous alternation in the Y-maze 
under basal conditions, an independent samples (unpaired) t test revealed no significant difference 
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between the vehicle and LM-4131 treatment groups (t (16) = 1.255; p = 0.2274, ns).  The sample 
means are displayed in Figure 13c, which shows that the mice treated with LM-4131 (10 mg/kg) 
scored similar on percentage spontaneous alternation in the Y-maze to the mice treated with 
vehicle (for LM-4131 treatment group, means ± s.e.m. = 27.50 ± 3.410, N = 8; for vehicle treatment 
group, means ± s.e.m. = 21.60 ± 3.201, N = 10).  In regard to the effect of LM-4131 on percentage 
spontaneous alternation in the Y-maze 8h after acute stress exposure, an independent samples 
(unpaired) t test revealed no significant difference between the vehicle and LM-4131 treatment 
groups (t (16) = 0.1551; p = 0.8787, ns).  The sample means are displayed in Figure 13c, which 
shows that the mice treated with LM-4131 (10 mg/kg) scored similar on percentage spontaneous 
alternation in the Y-maze to the mice treated with vehicle (for LM-4131 treatment group, means 
± s.e.m. = 23.30 ± 4.291, N = 9; for vehicle treatment group, means ± s.e.m. = 22.55 ± 2.140, N = 
9).  LM-4131 at a dose of 10 mg/kg compared to vehicle did not cause any changes in mean speed 
in the Y-maze test under both basal and acute stress exposure conditions (Fig, 13c, middle right 
panel).  In connection with the effect of LM-4131 on mean speed in the Y-maze under basal 
conditions, an independent samples (unpaired) t test revealed no significant difference between the 
vehicle and LM-4131 treatment groups (t (16) = 1.844; p = 0.0838, ns).  The sample means are 
displayed in Figure 13c, which shows that the mice treated with LM-4131 (10 mg/kg) scored 
similar on mean speed in the Y-maze to the mice treated with vehicle (for LM-4131 treatment 
group, means ± s.e.m. = 0.02825 ± 0.002102, N = 8; for vehicle treatment group, means ± s.e.m. 
= 0.0328 ± 0.001436, N = 10).  With respect to the effect of LM-4131 on mean speed in the Y-
maze 8h after acute stress exposure, an independent samples (unpaired) t test revealed no 
significant difference between the vehicle and LM-4131 treatment groups (t (16) = 0.3315; p = 
0.7446, ns).  The sample means are displayed in Figure 13c, which shows that the mice treated 
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with LM-4131 (10 mg/kg) scored similar on mean speed in the Y-maze to the mice treated with 
vehicle (for LM-4131 treatment group, means ± s.e.m. = 0.02978 ± 0.004146, N = 9; for vehicle 
treatment group, means ± s.e.m. = 0.03122 ± 0.001341, N = 9).  LM-4131 at a dose of 10 mg/kg 
compared to vehicle did not cause any changes in total distance traveled in the Y-maze test under 
both basal and acute stress exposure conditions (Fig, 13c, right panel).  Pertaining to the effect of 
LM-4131 on total distance traveled in the Y-maze under basal conditions, an independent samples 
(unpaired) t test revealed no significant difference between the vehicle and LM-4131 treatment 
groups (t (16) = 1.887; p = 0.0775, ns).  The sample means are displayed in Figure 13c, which 
shows that the mice treated with LM-4131 (10 mg/kg) scored similar on total distance traveled in 
the Y-maze to the mice treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 16.90 
± 1.271, N = 8; for vehicle treatment group, means ± s.e.m. = 19.68 ± 0.8419, N = 10).  In regard 
to the effect of LM-4131 on total distance traveled in the Y-maze 8h after acute stress exposure, 
an independent samples (unpaired) t test revealed no significant difference between the vehicle 
and LM-4131 treatment groups (t (16) = 0.3526; p = 0.7290, ns).  The sample means are displayed 
in Figure 13c, which shows that the mice treated with LM-4131 (10 mg/kg) scored similar on total 
distance traveled in the Y-maze to the mice treated with vehicle (for LM-4131 treatment group, 
means ± s.e.m. = 17.93 ± 2.474, N = 9; for vehicle treatment group, means ± s.e.m. = 18.84 ± 
0.7769, N = 9). 
Next, we wanted to ensure that the effect of the SSCI, LM-4131, on stress-induced fear-
related behavior was not dependent upon the time cued fear extinction and retrieval was performed 
after fear conditioning.  Thus, we performed cued fear extinction 24 hours after fear conditioning 
and cued fear retrieval 48 hours after fear conditioning.  During the cued fear extinction and 
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retrieval tests, we found no changes in the freezing behavior of the mice treated with LM-4131 
compared to mice treated with vehicle.  We found no significant differences in the freezing 
Figure 14.  COX-2 inhibitors do not affect amygdala-dependent fear memory processes.  (a-d) Diagram 
(top) of experimental design for context conditioning and cued fear extinction and retrieval. Freezing behavior 
(beneath diagram) during context conditioning (left) and cued fear extinction (middle) and retrieval (right).  Data 
are shown as the mean ± s.e.m.  Statistical significance was calculated by two-tailed unpaired Student's t-test or 
two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test and time x treatment effect as a source 
of variation between vehicle and COX-2 inhibitor treatment groups (LM-4131, LMX, or celecoxib).   
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behavior of the mice before i.p. administration of vehicle or LM-4131 after subjecting the mice to 
six tone-footshock pairings.  Concerning the effect of six tone-electric footshock pairings on 
freezing behavior, two-way ANOVA factoring drug dose and time revealed no effect of drug dose 
x time interaction (F(6, 245) = 0.4506; p = 0.8442, ns), but a significant effect of drug dose (F(1, 245) 
= 4.075, p = 0.0446, *p < 0.05) and time (F(6, 245) = 35.37, ****p < 0.0001; Fig. 14a (left panel)).  
Post hoc Holm-Sidak’s multiple comparisons test revealed no difference in percentage freezing 
after the administration of each tone-footshock pairing in a cohort of mice that will be treated with 
LM-4131 at a dose of 10 mg/kg compared to mice that will be treated with vehicle.  We also found 
no significant differences in the freezing behavior of the vehicle-treated or LM-4131-treated mice 
elicited by a tone that was paired with the electric footshock once we placed the mice in the same 
chamber in which the aversive electric footshock was previously experienced but with a white 
smooth floor contextual insert that was positioned over the grid floor and a white curved wall 
contextual insert.  Two-way ANOVA factoring drug dose and time revealed a significant effect of 
drug dose (F(1, 407) = 7.356; p = 0.0070, **p < 0.01) and time (F(10, 407) = 3.651; p = 0.0001, ***p 
< 0.001), but no significant effect of dose x time interaction (F(10, 407) = 0.7554; p = 0.6719, ns; 
Fig.14a (middle top panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed no 
difference in percentage freezing during any time point of the fear extinction test in LM-4131-
treated mice compared to vehicle-treated mice.  An independent samples (unpaired) t test revealed 
no significant difference in total freezing time during the fear extinction test between the vehicle 
and LM-4131 treatment group (t (37) = 1.160, p = 0.2536, ns, LM-4131 vs. vehicle).  The sample 
means are displayed in Figure 14a (right bottom panel), which shows that the mice treated with 
LM-4131 (10 mg/kg) scored similar on total freezing time to the mice treated with vehicle (for 
LM-4131 treatment group, means ± s.e.m. = 111.5 ± 11.72, N = 20; for vehicle treatment group, 
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means ± s.e.m. = 132.3 ± 13.74, N = 19).  We obtained similar results in the freezing behavior of 
the mice when we examined the effects of LM-4131 on the recovery of the extinguished fear (e.g., 
fear retrieval or recall) in the mice.  Two-way ANOVA factoring drug dose and time revealed a 
significant effect of drug dose (F(1, 108) = 5.493; p = 0.0209, *p < 0.05) and time (F(5, 108) = 6.785; 
****p < 0.0001), but no significant effect of dose x time interaction (F(5, 108) = 0.3130; p = 0.9043, 
ns; Fig.13a (right top panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed no 
changes in percentage freezing at any time point in the vehicle-treated mice compared to the LM-
4131-treated mice.  An independent samples (unpaired) t test revealed no significant difference in 
total freezing time during the fear retrieval test between the vehicle and LM-4131 treatment group 
(t (18) = 1.176, p = 0.2550, ns, LM-4131 vs. vehicle).  The sample means are displayed in Figure 
14a (right bottom panel), which shows that the mice treated with LM-4131 (10 mg/kg) scored 
similar on total freezing time to the mice treated with vehicle (for LM-4131 treatment group, means 
± s.e.m. = 56.20 ± 10.83, N = 10; for vehicle treatment group, means ± s.e.m. = 74.10 ± 10.71, N 
= 10). 
We also investigated if the effect of the SSCI, LM-4131, on stress-induced fear-related 
behavior was dependent upon when the SSCI was administered after fear conditioning.  Thus, we 
performed cued fear extinction 24 hours after fear conditioning and cued fear retrieval 48 hours 
after fear conditioning, but administered LM-4131 two hours before performing the fear retrieval 
test.  During the cued fear retrieval test, we found no changes in the freezing behavior of the mice 
treated with LM-4131 compared to mice treated with vehicle.  We found no significant differences 
in the freezing behavior of the mice before i.p. administration of vehicle or LM-4131 after 
subjecting the mice to six tone-footshock pairings.  With respect to the effect of six tone-electric 
footshock pairings on freezing behavior, two-way ANOVA factoring drug dose and time revealed 
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no effect of drug dose x time interaction (F(6, 112) = 0.3056; p = 0.9329, ns) and drug dose (F(1, 112) 
= 0.4689; p = 0.4949, ns), but a significant effect of time (F(6, 112) = 20.17, ****p < 0.0001; Fig. 
14b (left panel)).  We also found no significant differences in the freezing behavior of the mice 
elicited by a tone that was paired with the electric footshock once we placed the mice in the same 
chamber in which the aversive electric footshock was previously experienced but with a white 
smooth floor contextual insert that was positioned over the grid floor and a white curved wall 
contextual insert.  Two-way ANOVA factoring drug dose and time revealed a significant effect of 
drug dose (F(1, 154) = 5.309; p = 0.0226, *p < 0.05), but no significant effect of time (F(10, 154) = 
1.355; p = 0.2064, ns) and dose x time interaction (F(10, 154) = 0.3267; p = 0.9730, ns; Fig.14b 
(middle top panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed no difference in 
percentage freezing during any time point of the fear extinction test in the LM-4131-treated mice 
compared to the vehicle-treated mice.  An independent samples (unpaired) t test revealed no 
significant difference in total freezing time during the fear extinction test between the vehicle and 
LM-4131 treatment group (t (14) = 0.9080, p = 0.3792, ns, LM-4131 vs. vehicle).  The sample 
means are displayed in Figure 14b (right bottom panel), which shows that the mice that will be 
treated with LM-4131 (10 mg/kg) scored similar on total freezing time to the mice that will be 
treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 146.2 ± 22.79, N = 7; for 
vehicle treatment group, means ± s.e.m. = 178.2 ± 25.45, N = 9).  We obtained similar results in 
the freezing behavior of the mice when we examined the effects of LM-4131 on fear retrieval in 
the mice.  Two-way ANOVA factoring drug dose and time revealed no significant effect of drug 
dose (F(1, 108) = 0.1410, p = 0.7080, ns), time (F(5, 108) = 1.803, p = 0.1183, ns), and dose x time 
interaction (F(5, 108) = 0.1900, p = 0.9658, ns; Fig.14b (right top panel)).  An independent samples 
(unpaired) t test revealed no significant difference in total freezing time during the fear retrieval 
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test between the vehicle and LM-4131 treatment group (t (18) = 0.2173, p = 0.8305, ns, LM-4131 
vs. vehicle).  The sample means are displayed in Figure 14b (right bottom panel), which shows 
that the mice treated with LM-4131 (10 mg/kg) scored similar on total freezing time to the mice 
treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 79.37 ± 11.75, N = 10; for 
vehicle treatment group, means ± s.e.m. = 82.71 ± 9.938, N = 10). 
Since the SSCI, LM-4131, had no effect on cued fear extinction in juvenile male ICR mice 
8h after fear conditioning, we determined if the other COX-2 inhibitors, LMX and celecoxib, 
would have a similar effect on cued fear extinction in the mice.  We found no significant 
differences in the freezing behavior of the mice before i.p. administration of vehicle or LMX after 
subjecting the mice to six tone-footshock pairings.  With regard to the effect of six tone-electric 
footshock pairings on freezing behavior, two-way ANOVA factoring drug dose and time revealed 
no effect of drug dose x time interaction (F(6, 77) = 0.6293; p = 0.7063, ns) or drug dose (F(1, 77) = 
0.9836, p = 0.3244, ns), but a significant effect of time (F(6, 77) = 12.86, ****p < 0.0001; Fig. 14c 
(left panel)).  We also found no significant differences in the freezing behavior of the vehicle-
treated or LMX-treated mice during the fear extinction test.  Two-way ANOVA factoring drug 
dose and time revealed no significant effect of drug dose (F(1, 121) = 3.523; p = 0.0629, ns), dose x 
time interaction (F(10, 121) = 0.4461, p = 0.9206, ns), or time (F(10, 121) = 1.461, p = 0.1622, ns; Fig. 
14c (middle top panel)).  An independent samples (unpaired) t test revealed no significant 
difference in total freezing time during the fear extinction test between the vehicle and LMX 
treatment group (t (11) = 0.7747, p = 0.4549, ns, LMX vs. vehicle).  The sample means are 
displayed in Figure 14c (right bottom panel), which shows that the mice treated with LMX (1 
mg/kg) scored similar on total freezing time to the mice treated with vehicle (for LMX treatment 
group, means ± s.e.m. = 71.40 ± 20.10, N = 7; for vehicle treatment group, means ± s.e.m. = 53.13 
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± 9.680, N = 6).  We obtained similar results in the freezing behavior of the mice when we 
examined the effects of LMX on fear retrieval in the mice.  Two-way ANOVA factoring drug dose 
and time revealed no significant effect of drug dose (F(1, 66) = 1.143, p = 0.2890, ns), time (F(5, 66) 
= 1.539, p = 0.1899, ns), or dose x time interaction (F(5, 66) = 0.7258, p = 0.6065, ns; Fig.14c (right 
top panel)).  An independent samples (unpaired) t test revealed no significant difference in total 
freezing time during the fear retrieval test between the vehicle and LMX treatment group (t (11) = 
0.6171, p = 0.5497, ns, LMX vs. vehicle).  The sample means are displayed in Figure 14c (right 
bottom panel), which shows that the mice treated with LMX (1 mg/kg) scored similar on total 
freezing time to the mice treated with vehicle (for LMX treatment group, means ± s.e.m. = 40.37 
± 8.885, N = 7; for vehicle treatment group, means ± s.e.m. = 32.09 ± 10.14, N = 6).  These results 
suggest that the SSCI, LMX, does not affect stress-induced fear-related behavior in an amygdala-
dependent fashion.   
We also found no significant differences in the freezing behavior of the mice before i.p. 
administration of vehicle or celecoxib after subjecting the mice to six tone-footshock pairings.  
Pertaining to the effect of six tone-electric footshock pairings on freezing behavior, two-way 
ANOVA factoring drug dose and time revealed no effect of drug dose x time interaction (F(6, 77) = 
0.2328; p = 0.9646, ns) or drug dose (F(1, 77) = 0.8567, p = 0.3576, ns), but a significant effect of 
time (F(6, 77) = 15.03, ****p < 0.0001; Fig. 14d (left panel)).  We as well found no significant 
differences in the freezing behavior of the vehicle-treated or celecoxib-treated mice during the fear 
extinction test.  Two-way ANOVA factoring drug dose and time revealed no significant effect of 
drug dose (F(1, 121) = 0.2185, p = 0.6410, ns), dose x time interaction (F(10, 121) = 0.9731, p = 0.4704, 
ns), or time (F(10, 121) = 1.610, p = 0.1115, ns; Fig. 14d (middle top panel)).  An independent samples 
(unpaired) t test revealed no significant difference in total freezing time during the fear extinction 
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test between the vehicle and celecoxib treatment group (t (11) = 0.2272, p = 0.8245, ns, celecoxib 
vs. vehicle).  The sample means are displayed in Figure 14d (right bottom panel), which shows 
that the mice treated with celecoxib (10 mg/kg) scored similar on total freezing time to the mice 
treated with vehicle (for celecoxib treatment group, means ± s.e.m. = 56.16 ± 9.120, N = 7; for 
vehicle treatment group, means ± s.e.m. = 53.13 ± 9.680, N = 6).  We obtained similar results in 
the freezing behavior of the mice when we examined the effects of celecoxib on fear retrieval in 
the mice.  Two-way ANOVA factoring drug dose and time revealed no significant effect of drug 
dose (F(1, 66) = 3.310, p = 0.0734, ns), time (F(5, 66) = 1.088, p = 0.3756, ns), or dose x time 
interaction (F(5, 66) = 1.061, p = 0.3900, ns; Fig.14d (right top panel)).  An independent samples 
(unpaired) t test revealed no significant difference in total freezing time during the fear retrieval 
test between the vehicle and celecoxib treatment group (t (11) = 1.119, p = 0.2870, ns, celecoxib 
vs. vehicle).  The sample means are displayed in Figure 14d (right bottom panel), which shows 
that the mice treated with celecoxib (10 mg/kg) scored similar on total freezing time to the mice 
treated with vehicle (for celecoxib treatment group, means ± s.e.m. = 45.26 ± 6.624, N = 7; for 
vehicle treatment group, means ± s.e.m. = 32.09 ± 10.14, N = 6).  These results suggest that the 
selective COX-2 inhibitor, celecoxib, does not affect stress-induced fear-related behavior in an 
amygdala-dependent fashion.   
Next, we wanted to ensure that the effect of the SSCI, LM-4131, on stress-induced fear-
related behavior was not dependent upon the time contextual fear extinction and retrieval was 
performed after fear conditioning.  Thus, we performed contextual fear extinction 24 hours after 
fear conditioning and contextual fear retrieval 48 hours after fear conditioning.  During the 
contextual fear extinction and retrieval tests, we found no changes in the freezing behavior of the 
mice treated with LM-4131 compared to mice treated with vehicle.  We found a few 
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significant differences in the freezing behavior of the mice before i.p. administration of vehicle or 
LM-4131 after subjecting the mice to six tone-footshock pairings.  About the effect of six tone-
electric footshock pairings on freezing behavior, two-way ANOVA factoring drug dose and time 
Figure 15.  COX-2 inhibitors differentially affect both amygdala-dependent and hippocampal-dependent 
fear memory processes.  (a-d) Diagram (top) of experimental design for context conditioning and contextual 
fear extinction and retrieval. Freezing behavior (beneath diagram) during context conditioning (left) and 
contextual fear extinction (middle) and retrieval (right) in ICR (CD-1) (a-c) and C57Bl/6J (d) juvenile male 
mice.  Data are shown as the mean ± s.e.m.  Statistical significance was calculated by two-tailed unpaired 
Student's t-test or two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test and time x treatment 
effect as a source of variation between vehicle and COX-2 inhibitor treatment groups (LM-4131, LMX, or 
celecoxib).   
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revealed a significant effect of drug dose x time interaction (F(6, 119) = 3.825, p = 0.0016, **p < 
0.01), drug dose (F(1 119) = 47.65, ****p < 0.0001), and time (F(6, 119) = 14.16, ****p < 0.0001; Fig. 
15a (left panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed a significant decrease 
in percentage freezing in the juvenile male ICR mice after the 4th tone-footshock pairing (t (119) 
= 3.521, **p < 0.01, for LM-4131 treatment group, means ± s.e.m. = 32.77 ± 7.838, N = 10; for 
vehicle treatment group, means ± s.e.m. = 5.172 ± 7.838, N = 9), the 5th tone-footshock pairing (t 
(119) = 5.644, ****p < 0.0001, for LM-4131 treatment group, means ± s.e.m. = 52.52 ± 7.838; for 
vehicle treatment group, means ± s.e.m. = 8.286 ± 7.838), and the 6th tone-footshock pairing (t 
(119) = 4.505, ****p < 0.0001, for LM-4131 treatment group, means ± s.e.m. = 57.88 ± 7.838; for 
vehicle treatment group, means ± s.e.m. = 22.57 ± 7.838) of the fear conditioning session that will 
be treated at the 10 mg/kg dose of LM-4131 compared to the vehicle treatment.  We found that the 
SSCI, LM-4131, did not affect contextual fear extinction in the mice 24 hours after exposure to 
the acute stress paradigm.  Two-way ANOVA factoring drug dose and time revealed a significant 
effect of drug dose (F(1, 367) = 16.98, ****p < 0.0001) and time (F(20, 367) = 6.783, ****p < 0.0001), 
but no significant effect of dose x time interaction (F(20, 367) = 0.5172, p = 0.9593, ns; Fig.15a 
(middle top panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed no significant 
changes in percentage freezing in the juvenile male ICR mice during the fear extinction test at the 
10 mg/kg dose of LM-4131 compared to the vehicle treatment.  An independent samples 
(unpaired) t test revealed no significant difference in total freezing time during the fear extinction 
test between the vehicle and LM-4131 treatment group (t (18) = 1.348, p = 0.1943, ns, LM-4131 
vs. vehicle).  The sample means are displayed in Figure 15a (middle bottom panel), which shows 
that the mice treated with LM-4131 (10 mg/kg) scored similar on total freezing time compare to 
the mice treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 273.3 ± 26.29, N = 
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10; for vehicle treatment group, means ± s.e.m. = 230.2 ± 18.12, N = 10).  We found no significant 
differences in the freezing behavior of the mice during fear retrieval 24 hours after exposure to the 
acute stress protocol.  Two-way ANOVA factoring drug dose and time revealed a significant effect 
of drug dose (F(1, 198) = 6.974, p = 0.0089, **p < 0.01) and time (F(10, 198) = 3.846, p = 0.5928, ns), 
but no significant effect of dose x time interaction (F(10, 297) = 0.6363, ****p < 0.0001; Fig.15a 
(middle top panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed no significant 
difference in percentage freezing at any time point in the juvenile male ICR mice of the fear 
retrieval test at the 10 mg/kg dose of LM-4131 compared to the vehicle treatment.  An independent 
samples (unpaired) t test revealed no significant difference in total freezing time during the fear 
retrieval test between the vehicle and LM-4131 treatment group (t (18) = 0.9704, p = 0.3447, ns, 
LM-4131 vs. vehicle).  The sample means are displayed in Figure 15a (right bottom panel), which 
shows that the mice treated with LM-4131 (10 mg/kg) scored similar on total freezing time to the 
mice treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 111.8 ± 27.45, N = 10; 
for vehicle treatment group, means ± s.e.m. = 74.60 ± 26.69, N = 10). 
Since the SSCI, LM-4131, had a significant effect on contextual fear extinction in juvenile 
male ICR mice 8h after fear conditioning, we determined if the other COX-2 inhibitors, LMX and 
celecoxib, would have a similar effect on contextual fear extinction in the mice.  We found no 
significant differences in the freezing behavior of the mice before i.p. administration of vehicle or 
LMX after subjecting the mice to six tone-footshock pairings.  With respect to the effect of six 
tone-electric footshock pairings on freezing behavior, two-way ANOVA factoring drug dose and 
time revealed no effect of drug dose x time interaction (F(6, 189) = 0.1034, p = 0.9960, ns) and drug 
dose (F(1 189) = 0.1022, p = 0.7496, ns), but a significant effect of time (F(6, 189) = 38.38, ****p < 
0.0001; Fig. 15b (left panel)).  We found that the SSCI, LMX, slightly increased contextual fear 
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extinction by decreasing freezing behavior in the mice only 8 hours after exposure to the acute 
stress paradigm.  Two-way ANOVA factoring drug dose and time revealed a significant effect of 
drug dose (F(1, 693) = 6.576, p = 0.0105, *p < 0.05) and time (F(20, 693) = 7.792, ****p < 0.0001), 
but no significant effect of dose x time interaction (F(20, 693) = 1.131, p = 0.3112, ns; Fig.15b 
(middle top panel)).  An independent samples (unpaired) t test revealed no significant difference 
in total freezing time during the fear extinction test between the vehicle and LM-4131 treatment 
group (t (33) = 0.9626, p = 0.3428, ns, LMX vs. vehicle).  The sample means are displayed in 
Figure 15b (middle bottom panel), which shows that the mice treated with LMX (1 mg/kg) scored 
similar on total freezing time compared to mice treated with vehicle (for LMX treatment group, 
means ± s.e.m. = 113.9 ± 12.92, N = 15; for vehicle treatment group, means ± s.e.m. = 137.3 ± 
18.64, N = 20).  We found no significant differences in the freezing behavior of the mice during 
fear retrieval 24 hours after exposure to the acute stress protocol.  Two-way ANOVA factoring 
drug dose and time revealed a significant effect of drug dose (F(1, 363) = 7.377, p = 0.0069, **p < 
0.01), but no significant effect of time (F(10, 363) = 1.620, p = 0.0989, ns) or dose x time interaction 
(F(10, 363) = 0.6414, p = 0.7782, ns; Fig.15b (middle top panel)).  Post hoc Holm-Sidak’s multiple 
comparisons test revealed no significant difference in percentage freezing at any time point in the 
juvenile male ICR mice of the fear retrieval test at the 1 mg/kg dose of LMX compared to the 
vehicle treatment.  An independent samples (unpaired) t test revealed no significant difference in 
total freezing time during the fear retrieval test between the vehicle and LMX treatment group (t 
(33) = 1.067, p = 0.2939, ns, LMX vs. vehicle).  The sample means are displayed in Figure 15b 
(right bottom panel), which shows that the mice treated with LMX (1 mg/kg) scored similar on 
total freezing time to the mice treated with vehicle (for LMX treatment group, means ± s.e.m. = 
107.1 ± 15.90, N = 15; for vehicle treatment group, means ± s.e.m. = 85.55 ± 12.83, N = 20).   
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Thus, these results suggest that LMX can slightly decrease stress-induced fear-related behavior in 
a context-dependent manner.  We found similar results with the selective COX-2 inhibitor, 
celecoxib.  There were no significant differences in the freezing behavior of the mice before i.p. 
administration of vehicle or celecoxib after subjecting the mice to six tone-footshock pairings.  
Relating to the effect of six tone-electric footshock pairings on freezing behavior, two-way 
ANOVA factoring drug dose and time revealed no effect of drug dose x time interaction (F(6, 189) 
= 0.0.4124, p = 0.8703, ns) and drug dose (F(1 189) = 0.5459, p = 0.4609, ns), but a significant effect 
of time (F(6, 189) = 29.85, ****p < 0.0001; Fig. 15c (left panel)).  We found that celecoxib slightly 
increased contextual fear extinction by decreasing freezing behavior in the mice 8 hours after 
exposure to the acute stress paradigm.  Two-way ANOVA factoring drug dose and time revealed 
a significant effect of drug dose (F(1, 693) = 11.56, p = 0.0007, ***p < 0.001) and time (F(20, 693) = 
5.949, ****p < 0.0001), but no significant effect of dose x time interaction (F(20, 693) = 0.6024, p = 
0.9126, ns; Fig.15c (middle top panel)).  An independent samples (unpaired) t test revealed no 
significant difference in total freezing time during the fear extinction test between the vehicle and 
celecoxib treatment group (t (33) = 1.244, p = 0.2223, ns, celecoxb vs. vehicle).  The sample means 
are displayed in Figure 15c (middle bottom panel), which shows that the mice treated with 
celecoxib (10 mg/kg) scored similar on total freezing time compared to mice treated with vehicle 
(for celecoxib treatment group, means ± s.e.m. = 107.4 ± 12.10, N = 15; for vehicle treatment 
group, means ± s.e.m. = 137.3 ± 18.64, N = 20).  We found no significant differences in the freezing 
behavior of the mice during fear retrieval 24 hours after exposure to the acute stress protocol.  
Two-way ANOVA factoring drug dose and time revealed no significant effect of drug dose (F(1, 
363) = 1.399, p = 0.2377, ns), time (F(10, 363) = 0.8092, p = 0.6199, ns), or dose x time interaction 
(F(10, 363) = 0.6603, p = 0.7612, ns; Fig.15c (middle top panel)).  An independent samples (unpaired) 
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t test revealed no significant difference in total freezing time during the fear retrieval test between 
the vehicle and celecoxib treatment group (t (33) = 0.4881, p = 0.6287, ns, celecoxib vs. vehicle).  
The sample means are displayed in Figure 15c (right bottom panel), which shows that the mice 
treated with celecoxib (10 mg/kg) scored similar on total freezing time to the mice treated with 
vehicle (for celecoxib treatment group, means ± s.e.m. = 77.33 ± 9.144, N = 15; for vehicle 
treatment group, means ± s.e.m. = 85.55 ± 12.83, N = 20).    
Moreover, the effects of LM-4131 on contextual fear extinction and retrieval were not 
restricted to only the ICR mouse strain but could as well be observed in the C57BL/6J mouse 
strain.  LM-4131 enhanced contextual fear extinction and retrieval in juvenile male C57BL/6J 
mice.  We found no significant differences in the freezing behavior of the mice before i.p. 
administration of vehicle or LM-4131 after subjecting the mice to six tone-footshock pairings.  
Concerning the effect of six tone-electric footshock pairings on freezing behavior, two-way 
ANOVA factoring drug dose and time revealed no effect of drug dose x time interaction (F(2, 48) = 
0.7317, p = 0.4864, ns) and drug dose (F(1, 48) = 0.3643, p = 0.5490, ns), but a significant effect of 
time (F(2, 48) = 12.95, ****p < 0.0001; Fig. 15d (left panel)).  We found that the SSCI, LM-4131, 
significantly increased contextual fear extinction by decreasing freezing behavior in the C57BL/6J 
mice only 8 hours after exposure to the acute stress paradigm.  Two-way ANOVA factoring drug 
dose and time revealed a significant effect of drug dose (F(1, 378) = 27.25, ****p < 0.0001) and time 
(F(20, 378) = 1.815, p = 0.0177), but no significant effect of dose x time interaction (F(20, 378) = 0.5734, 
p = 0.9302, ns; Fig.15d (middle top panel)).  An independent samples (unpaired) t test revealed no 
significant difference in total freezing time during the fear extinction test between the vehicle and 
LM-4131 treatment group (t (18) = 1.701, p = 0.1061, ns, LM-4131 vs. vehicle).  The sample 
means are displayed in Figure 15d (middle bottom panel), which shows that the mice treated with 
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LM-4131 (10 mg/kg) scored similar on total freezing time compared to the mice treated with 
vehicle (for LM-4131 treatment group, means ± s.e.m. = 184.7 ± 25.87, N = 10; for vehicle 
treatment group, means ± s.e.m. = 249.8 ± 28.15, N = 10).  We found significant differences in the 
freezing behavior of the C57BL/6J mice during fear retrieval 24 hours after exposure to the acute 
stress protocol.  Two-way ANOVA factoring drug dose and time revealed a significant effect of 
drug dose (F(1, 198) = 7.322, p = 0.0074, **p < 0.01), time (F(10, 198) = 2.729, p = 0.0036, **p < 
0.01), and dose x time interaction (F(10, 198) = 2.341, p = 0.0125, *p < 0.05; Fig.15d (middle top 
panel)).  Post hoc Holm-Sidak’s multiple comparisons test revealed a significant difference in 
percentage freezing at the start of the fear retrieval test (e.g., 0.0 min time bin) (t (198) = 3.823, 
**p < 0.01, ns, LM-4131 vs. vehicle; for LM-4131 treatment group, means ± s.e.m. = 27.46 ± 
7.326, N = 10; for vehicle treatment group, means ± s.e.m. = 55.47 ± 7.326, N = 10) and at the first 
0.5 min time (t (198) = 3.089, *p < 0.05, ns, LM-4131 vs. vehicle; for LM-4131 treatment group, 
means ± s.e.m. = 30.65 ± 7.326, N = 10; for vehicle treatment group, means ± s.e.m. = 53.28 ± 
7.326, N = 10) bin in the juvenile male C57BL/6J mice of the fear retrieval test at the 10 mg/kg 
dose of LM-4131 compared to the vehicle treatment.  An independent samples (unpaired) t test 
revealed no significant difference in total freezing time during the fear retrieval test between the 
vehicle and LM-4131 treatment group (t (18) = 1.183, p = 0.2523, ns, LM-4131 vs. vehicle).  The 
sample means are displayed in Figure 15d (right bottom panel), which shows that the mice treated 
with LM-4131 (10 mg/kg) scored similar on total freezing time to the mice treated with vehicle 
(for LM-4131 treatment group, means ± s.e.m. = 92.86 ± 10.70, N = 10; for vehicle treatment 
group, means ± s.e.m. = 112.6 ± 12.78, N = 10). 
Since the SSCI, LM-4131, had a significant effect on contextual fear extinction, but no 
effect on cued fear extinction, in juvenile male ICR mice 8h after acute (1 day) fear conditioning, 
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we determined if LM-4131 would have a similar effect in the mice 8h after chronic (5 days) fear 
conditioning.  We found no significant differences in the freezing behavior of the mice before i.p. 
administration of vehicle or LM-4131 after subjecting the mice to five days of six tone-footshock 
pairings per day.  With reference to the effect of six tone-electric footshock pairings per day on 
freezing behavior, two-way ANOVA factoring drug dose and time revealed no effect of drug dose 
x time interaction (F(13, 196) = 1.147, p = 0.3220, ns) and drug dose (F(1, 196) = 0.4780, p = 0.4901, 
ns), but a significant effect of time (F(13, 196) = 19.96, ****p < 0.0001; Fig. 16a (left panel)).  We 
found that the SSCI, LM-4131, did not affect cued fear extinction in the mice only 8 hours after 
exposure to the chronic stress paradigm.  Two-way ANOVA factoring drug dose and time revealed 
no significant effect of drug dose (F(1, 154) = 3.451, p = 0.0651, ns) and dose x time interaction (F(10, 
154) = 0.3604, p = 0.9616, ns), but a slightly significant effect of time (F(10, 154) = 2.172, p = 0.0222, 
*p < 0.05; Fig.16a (middle top panel)).  An independent samples (unpaired) t test revealed no 
significant difference in total freezing time during the fear extinction test between the vehicle and 
LM-4131 treatment group (t (14) = 0.9251, p = 0.3706, ns, LM-4131 vs. vehicle).  The sample 
means are displayed in Figure 16a (middle bottom panel), which shows that the mice treated with 
LM-4131 (10 mg/kg) scored similar on total freezing time compared to mice treated with vehicle 
(for LM-4131 treatment group, means ± s.e.m. = 107.7 ± 22.74, N = 8; for vehicle treatment group, 
means ± s.e.m. = 132.9 ± 14.94, N = 8).  We found no significant differences in the freezing 
behavior of the mice during fear retrieval 24 hours after exposure to the chronic stress protocol.  
Two-way ANOVA factoring drug dose and time revealed no significant effect of drug dose (F(1, 
84) = 0.8466, p = 0.3601, ns) or dose x time interaction (F(5, 84) = 0.1843, p = 0.9678, ns), but a 
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significant effect of time (F(5, 84) = 4.210, p = 0.0018, **p < 0.01); Fig.16a (middle top panel)).  An 
Figure 16.  Substrate-selective COX-2 inhibition does not affect amygdala-dependent fear memory 
processes after chronic stress exposure.  (a, b) Diagram (top) of experimental design for context conditioning 
and cued fear extinction and retrieval. Freezing behavior (beneath diagram) during context conditioning (left) and 
cued fear extinction (middle) and retrieval (right). During context conditioning, a tone, the conditional stimulus 
(CS), was paired with a footshock, the unconditional stimulus (US), six times daily for five days. Data are shown 
as the mean ± s.e.m.  Statistical significance was calculated by two-tailed unpaired Student's t-test or two-way 
ANOVA with post hoc Holm-Sidak’s multiple comparisons test and time x treatment effect as a source of variation 
between vehicle and LM-4131 treatment groups.   
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independent samples (unpaired) t test revealed no significant difference in total freezing time 
during the fear retrieval test between the vehicle and LM-4131 treatment group (t (14) = 0.5354, 
p = 0.6008, ns, LM-4131 vs. vehicle).  The sample means are displayed in Figure 16a (right bottom 
panel), which shows that the mice treated with LM-4131 (10 mg/kg) scored similar on total 
freezing time to the mice treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 
44.91 ± 9.142, N = 8; for vehicle treatment group, means ± s.e.m. = 52.78 ± 11.51, N = 8).   Thus, 
these results suggest that LM-4131 does not affect chronic stress-induced fear-related behavior in 
an amygdala-dependent manner.  We found similar results with LM-4131 when mice were 
subjected to chronic fear conditioning and tested for contextual fear extinction and retrieval.  There 
were slight significant differences in the freezing behavior of the mice before i.p. administration 
of vehicle or LM-4131 after subjecting the mice to five days of six tone-footshock pairings per 
day.  With respect to the effect of five days of six tone-electric footshock pairings on freezing 
behavior, two-way ANOVA factoring drug dose and time revealed no effect of drug dose x time 
interaction (F(13, 182) = 1.644, p = 0.0768, ns), but a significant effect of drug dose (F(1, 182) = 26.07, 
****p < 0.0001) and time (F(13, 182) = 20.26, ****p < 0.0001; Fig. 16b (left panel)).  Post hoc 
Holm-Sidak’s multiple comparisons test revealed a significant decrease in percentage freezing in 
the juvenile male ICR mice after the 3rd tone-footshock pairing of the last day (e.g., day 5) of fear 
conditioning (t (182) = 2.977, *p < 0.05, for LM-4131 treatment group, means ± s.e.m. = 41.34 ± 
11.55, N = 7; for vehicle treatment group, means ± s.e.m. = 75.73 ± 11.55, N = 8) and the 5th tone-
footshock pairing of the last day of fear conditioning (t (182) = 3.985, **p < 0.01, for LM-4131 
treatment group, means ± s.e.m. = 34.61 ± 11.55; for vehicle treatment group, means ± s.e.m. = 
80.64 ± 11.55) of the chronic fear conditioning session that will be treated at the 10 mg/kg dose of 
LM-4131 compared to the vehicle treatment.  We found that LM-4131 slightly increased 
 116 
contextual fear extinction by decreasing freezing behavior in the mice 8 hours after exposure to 
the chronic stress paradigm.  Two-way ANOVA factoring drug dose and time revealed a 
significant effect of drug dose (F(1, 273) = 8.992, p = 0.0030, **p < 0.01), but no significant effect 
of time (F(20, 273) = 0.3257, p = 0.9977, ns) and dose x time interaction (F(20, 273) = 1.035, p = 0.4204, 
ns; Fig.16b (middle top panel)).  An independent samples (unpaired) t test revealed no significant 
difference in total freezing time during the fear extinction test between the vehicle and LM-4131 
treatment group (t (13) = 1.232, p = 0.2397, ns, LM-4131 vs. vehicle).  The sample means are 
displayed in Figure 16b (middle bottom panel), which shows that the mice treated with LM-4131 
(10 mg/kg) scored similar on total freezing time compared to mice treated with vehicle (for LM-
4131 treatment group, means ± s.e.m. = 105.2 ± 14.45, N = 7; for vehicle treatment group, means 
± s.e.m. = 144.6 ± 26.95, N = 8).  We found a slight significant difference in the freezing behavior 
of the mice during fear retrieval 24 hours after exposure to the chronic stress protocol.  Two-way 
ANOVA factoring drug dose and time revealed a significant effect of drug dose (F(1, 143) = 5.752, 
p = 0.0178, *p < 0.05), but no significant effect of time (F(10, 143) = 1.279, p = 0.2476, ns) or dose 
x time interaction (F(10, 143) = 0.4936, p = 0.8920, ns; Fig.16b (middle top panel)).  An independent 
samples (unpaired) t test revealed no significant difference in total freezing time during the fear 
retrieval test between the vehicle and LM-4131 treatment group (t (13) = 0.9011, p = 0.3839, ns, 
LM-4131 vs. vehicle).  The sample means are displayed in Figure 16b (right bottom panel), which 
shows that the mice treated with LM-4131 (10 mg/kg) scored similar on total freezing time to the 
mice treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 57.80 ± 21.44, N = 7; 
for vehicle treatment group, means ± s.e.m. = 88.02 ± 25.10, N = 8).    
Since stress-induced anxiety-like behavior reduced by substrate-selective COX-2 
inhibition is mediated in a non-cannabinoid receptor fashion, we wanted to determine if stress-
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induced fear-related behavior was also mediated in a non-cannabinoid receptor manner.  We found 
that regardless of mouse strain, stress-induced fear-related behavior is mediated by the cannabinoid 
type 1 receptor when it is context dependent.  During fear conditioning of juvenile male ICR mice, 
we found no significant differences in the freezing behavior of the mice before i.p. administration 
of the CB1R antagonist, rimonabant (5 mg/kg), or co-administration of rimonabant and LM-4131 
after subjecting the mice to six tone-footshock pairings.  Regarding the effect of six tone-electric 
footshock pairings on freezing behavior, two-way ANOVA factoring drug dose and time revealed 
no effect of drug dose x time interaction (F(6, 252) = 0.4851, p = 0.8192, ns) and drug dose (F(1, 252) 
= 0.6801, p = 0.4103, ns), but a significant effect of time (F(6, 252) = 18.96, ****p < 0.0001; Fig. 
17a (left panel)).  We found that the CB1R antagonist, rimonabant, blocked the previously observed 
increase in contextual fear extinction (see Fig. 13b (middle panel)) by increasing freezing behavior 
Figure 17.  Modulation of contextual fear memory processes by substrate-selective COX-2 inhibition is 
CB
1
 receptor-dependent.  (a, b) Diagram (top) of experimental design for context conditioning and contextual 
fear extinction and retrieval. Freezing behavior (beneath diagram) during context conditioning (left) and 
contextual fear extinction (middle) and retrieval (right) in ICR (CD-1) (a) and C57Bl/6J (b) juvenile male mice.  
Data are shown as the mean ± s.e.m.  Statistical significance was calculated by two-tailed unpaired Student's t-
test or two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test and time x treatment effect as a 
source of variation between rimonbant and co-administered rimonabant and LM-4131 treatment groups.   
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in the mice co-treated with LM-4131 and rimonabant only 8 hours after exposure to the acute stress 
paradigm.  Two-way ANOVA factoring drug dose and time revealed no significant effect of drug 
dose (F(1, 756) = 2.988, p = 0.0843, ns) or dose x time interaction (F(20, 756) = 0.5714, p = 0.9329, 
ns), but a significant effect of time (F(20, 756) = 2.224, **p < 0.01; Fig.17a (middle top panel)).  An 
independent samples (unpaired) t test revealed no significant difference in total freezing time 
during the fear extinction test between the rimonabant treatment group and the rimonabant and 
LM-4131 treatment group (t (36) = 0.5272, p = 0.6013, ns, rimonabant + LM-4131 vs. 
rimonabant).  The sample means are displayed in Figure 17a (middle bottom panel), which shows 
that the mice co-treated with rimonabant (5 mg/kg) and LM-4131 (10 mg/kg) scored similar on 
total freezing time compared to the mice treated with rimonabant (for rimonabant and LM-4131 
co-treatment group, means ± s.e.m. = 132.6 ± 23.02, N = 20; for rimonabant treatment group, 
means ± s.e.m. = 115.6 ± 22.54, N = 18).  We found no significant differences in the freezing 
behavior of the mice during fear retrieval 24 hours after exposure to the acute stress protocol.  
Two-way ANOVA factoring drug dose and time revealed a significant effect of drug dose (F(1, 286) 
= 8.521, p = 0.0038, **p < 0.01), but no significant effect of time (F(10, 286) = 1.438, p = 0.1629, 
ns) and dose x time interaction (F(10, 286) = 0.4615, p = 0.9138, ns; Fig.17a (middle top panel)).  
Post hoc Holm-Sidak’s multiple comparisons test revealed no significant difference in percentage 
freezing at any time point in the juvenile male ICR mice of the fear retrieval test at the 10 mg/kg 
dose of LM-4131 combined with the 5 mg/kg dose of rimonabant compared to the rimonabant 
treatment.  An independent samples (unpaired) t test revealed no significant difference in total 
freezing time during the fear retrieval test between the rimonabant treatment group and the 
rimonabant and LM-4131 co-treatment group (t (26) = 1.338, p = 0.1924, ns, rimonabant + LM-
4131 vs. rimonabant).  The sample means are displayed in Figure 17a (right bottom panel), which 
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shows that the mice co-treated with rimonabant (5 mg/kg) and LM-4131 (10 mg/kg) scored similar 
on total freezing time to the mice treated with rimonabant (for rimonabant and LM-4131 co-
treatment group, means ± s.e.m. = 77.25 ± 12.97, N = 15; for rimonabant treatment group, means 
± s.e.m. = 56.83 ± 6.632, N = 13).  These results suggest that the CB1R mediates LM-4131-induced 
decreases in fear elicited by acute stress exposure in a context-dependent manner. 
In the juvenile male C57BL/6J mice, we found that the CB1R also mediates the action of 
LM-4131 on stress-induced fear-related behavior when it is context dependent.  During fear 
conditioning of juvenile male C57BL/6J mice, we found no significant differences in the freezing 
behavior of the mice before i.p. administration of the CB1R antagonist, rimonabant (5 mg/kg), or 
co-administration of rimonabant and LM-4131 after subjecting the mice to six tone-footshock 
pairings.  As to the effect of six tone-electric footshock pairings on freezing behavior, two-way 
ANOVA factoring drug dose and time revealed no effect of drug dose x time interaction (F(2, 54) = 
0.2055, p = 0.8149, ns) and drug dose (F(1, 54) = 0.002349, p = 0.9615, ns), but a significant effect 
of time (F(2, 54) = 5.993, p = 0.0045, **p < 0.01; Fig. 17b (left panel)).  As seen in the juvenile male 
ICR mice, we found that the CB1R antagonist, rimonabant, blocked the previously observed 
increase in contextual fear extinction (see Fig. 15d (middle panel)) by increasing freezing behavior 
in the C57BL/6J mice co-treated with LM-4131 and rimonabant only 8 hours after exposure to the 
acute stress paradigm.  Two-way ANOVA factoring drug dose and time revealed no significant 
effect of drug dose (F(1, 18) = 0.4501, p = 0.5108, ns), but a slightly significant effect of dose x time 
interaction (F(20, 360) = 1.786, p = 0.0207, *p < 0.05) and time (F(20, 360) = 1.718, , p = 0.0288, *p < 
0.05; Fig.17b (middle top panel)).  An independent samples (unpaired) t test revealed no significant 
difference in total freezing time during the fear extinction test between the rimonabant treatment 
group and the rimonabant and LM-4131 treatment group (t (18) = 0.6712, p = 0.5106, ns, 
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rimonabant + LM-4131 vs. rimonabant).  The sample means are displayed in Figure 17b (middle 
bottom panel), which shows that the mice co-treated with rimonabant (5 mg/kg) and LM-4131 (10 
mg/kg) scored similar on total freezing time compared to the mice treated with rimonabant (for 
rimonabant and LM-4131 co-treatment group, means ± s.e.m. = 321.6 ± 43.29, N = 10; for 
rimonabant treatment group, means ± s.e.m. = 279.0 ± 46.44, N = 10).  We found no significant 
differences in the freezing behavior of the mice during fear retrieval 24 hours after exposure to the 
acute stress protocol.  Two-way ANOVA factoring drug dose and time revealed no significant 
effect of drug dose (F(1, 18) = 2.240, p = 0.1518, ns) or dose x time interaction (F(10, 180) = 0.4587, 
p = 0.9145, ns), but a significant effect of time (F(10, 180) = 5.130, ****p < 0.0001; Fig.17b (middle 
top panel)).  An independent samples (unpaired) t test revealed no significant difference in total 
freezing time during the fear retrieval test between the rimonabant treatment group and the 
rimonabant and LM-4131 co-treatment group (t (18) = 1.497, p = 0.1518, ns, rimonabant + LM-
4131 vs. rimonabant).  The sample means are displayed in Figure 17b (right bottom panel), which 
shows that the mice co-treated with rimonabant (5 mg/kg) and LM-4131 (10 mg/kg) scored similar 
on total freezing time to the mice treated with rimonabant (for rimonabant and LM-4131 co-
treatment group, means ± s.e.m. = 97.71 ± 20.83, N = 10; for rimonabant treatment group, means 
± s.e.m. = 147.0 ± 25.48, N = 10).   
Our acute and chronic stress paradigms using Pavlovian fear conditioning models 
maladaptive fear, which is fear that is continual or easily generalized to a nonthreatening stimulus.  
Maladaptive fear is associated with anxiety-related, trauma-related, and stressor-related disorders 
in humans. In addition, impaired fear extinction can be reversed in mice by pharmacological 
augmentation of AEA signaling22, which is how SSCIs are suggested to reduce anxiety-like 
behaviors in animals237.  Our studies appear to be in line with previous studies that suggest 
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increased AEA signaling through pharmacological manipulation of the endocannabinoid system 
can modulate stress-induced fear-related behaviors in mice.  Moreover, similar to previous 
studies238,239, our findings in this research endeavor suggest that stress-induced fear-related 
behavior in mice is mediated by the cannabinoid type 1 receptor. 
 
Conclusion 
Through our studies, we have observed the potential of substrate-selective COX-2 
inhibitors, such as LM-4131, to not only serve as a therapeutic alternative to reduce anxiety-like 
and anhedonic behaviors in animals under basal conditions but as well after acute and chronic 
stress exposure regardless of sex (only with respect to anxiety-like behaviors).  In particular, the 
SSCI, LM-4131, reduced anxiety-like behavior in the NIFS assay in the juvenile ICR male mice 
subjected to acute stress or under basal conditions only when the mice were exposed to an aversive 
environment.  When we repeated the NIFS assay in another cohort of juvenile male ICR mice 
subjected to no stress or acute footshock stress to compare the efficacy of LM-4131 to the SSCI, 
lumiracoxib (1 mg/kg), and the FDA approved selective COX-2 inhibitor, celecoxib (10 mg/kg), 
which served as a reference drug to increase the translational implications of these experiments, 
we observed similar changes in feeding latency.  However, LM-4131 appeared more efficacious 
at reducing anxiety-like behavior.  Nevertheless, the mechanisms for the anxiolytic and hedonic 
action of these drugs are mediated through cannabinoid receptors under context-dependent 
conditions.  This can be due to differential expression of receptor or ion channel targets in specific 
brain regions as a consequence of the magnitude and length of stress exposure as well as sex 
hormones.  
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CHAPTER III 
SYNAPTIC AND ANXIOLYTIC BEHAVIORAL CORRELATES OF SUBSTRATE-
SELECTIVE COX-2 INHIBITION IN AN ANIMAL MODEL OF ACUTE TRAUMATIC 
STRESS 
 
Introduction 
Excitatory neurotransmission, mediated mostly by glutamate, can be enhanced by stress and 
induce anxiety-like behaviors in animals and humans240-242.  Thus, an increased ratio of synaptic 
excitation/inhibition in the hippocampus or prefrontal cortex-amygdala neural circuits may play a 
role in the pathophysiology of anxiety, trauma-related, and stressor-related disorders.  Enhanced 
AEA signaling, possibly on glutamatergic neurons, has been shown to modulate stress-induced 
anxiety-like behaviors in animals125,133,243.  Thus, SSCIs, which increase AEA levels in the brain, 
may enhance AEA signaling on glutamatergic neurons and, subsequently alter glutamatergic and 
GABAergic neurotransmission in key limbic brain structures, such as the amygdala.  In order to 
examine this, we will discuss in this chapter the effects of SSCI on synaptic changes in the 
amygdala and how such alterations relate to the anxiolytic actions of SSCI observed in our 
previous studies (see CHAPTER II). 
 
Experimental 
Animals.  Male ICR (CD-1) mice between 4-7 weeks of age (juvenile) or between 12-15 weeks of 
age (adult) were used for all experiments (Harlan, Indianapolis, IN) unless otherwise noted.  All 
mice were housed on a 12:12 light-dark cycle (lights on at 6:00 a.m.) with food and water available 
ad libitum.  All studies were carried out in accordance with the National Institute of Health Guide 
for the Care and Use of Laboratory Animals and approved by the Vanderbilt University 
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Institutional Animal Care and Use Committee. All behavioral testing was performed during the 
inactive light phase of the mouse circadian cycle (between 6:00 a.m. and 6:00 p.m.). 
Drugs and treatment. The following drugs were used for the experiments: the COX-2 inhibitors, 
LM-4131 (10 mg/kg; gift from Dr. Lawrence Marnett laboratory) and lumiracoxib (1 mg/kg; 
Selleck Chemicals, Houston, TX). Drugs or vehicle (dimethyl sulfoxide or DMSO) were 
administered by i.p. injection.  Drugs were dissolved in DMSO at a volume of 1 mL/kg.  Drug 
pretreatment times were two hours prior to behavioral testing. 
Behavioral testing. 
Elevated plus maze.  The  elevated plus maze apparatus was elevated 47 cm from the ground, and 
consisted of two open arms (30 × 5 cm; 90 lux) and two closed arms (30 × 5 × 15 cm; 20 lux) 
extending from a 5 × 5 cm central area (San Diego Instruments). The walls and floor were made 
from black ABS (acrylonitrile butadiene styrene) plastic. To begin the 5-min test for animals 
without cannulization or 10-min test for animals cannulized for in vivo electrophysiological 
recordings, each mouse was placed in the center, facing an open arm. Time spent and entries into 
the open and closed arms were recorded using CinePlex Behavioral Research System (Plexon Inc, 
Dallas TX) and scored offline by the experimenter or using Any Maze tracking software. The 
mouse was considered to be in an arm when all four paws were in the arm. “Risk Assessment” 
was defined as when a mouse placed its front paws into an open arm while its back paws were in 
the center, but returned to the center without entering the open arm.    
In vivo electrophysiology.  Male Hsd:ICR (CD-1) outbred mice were obtained from Harlan 
Laboratories (Indianapolis, IN). Mice were 4 weeks of age upon arrival, and were given one week 
to acclimate prior to any surgical or behavioral procedures. They were housed in pairs in a 
temperature (72 ± 5°F) and humidity (45±15%) controlled vivarium, under a 12-hr light/dark cycle 
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(lights on at 0630 h). All experimental procedures carried out were approved by the NIAAA 
Animal Care and Use Committee under animal study protocol #LIN-AH-31 and followed the NIH 
guidelines outlined in Using Animals in Intramural Research and the local Animal Care and Use 
Committees.  
 Mice were anesthetized with 2% Isoflurane (Baxter Healthcare, Deerfield, IL) and 
implanted with 2x8 electrode (35um tungsten) micro-arrays (Innovative Neurophysiology Inc, 
Durham, NC) targeted at the basolateral amygdala (3.1mm lateral, 1.2-2.2mm posterior, and 
4.5mm ventral relative to Bregma). Following surgery, mice were housed singly, and allowed at 
least one week to recover prior to behavioral testing. 
Animals were exposed to stress individually, between the hours of 700 and 930am. Stress 
exposure took place in 27 × 27 × 11cm conditioning chambers (Med Associates, St. Albans, VT), 
with a metal-rod floor. Mice received 6 parings of a pure tone CS with a .7mA foot shock. Stimulus 
presentation and automated motion scoring were controlled by the Med Associates VideoFreeze 
system. 
 Five and a half hours following stress exposure, each animal received a pre-drug baseline 
recording session in its homecage. Individual units were identified and recorded for 5 min using 
Omniplex Neural Data Acquisition System (Plexon Inc, Dallas, TX).  Exactly 6 hours after stress 
exposure, animals received an injection of either LM-4131 (10mg/kg, 1mg/ml in DMSO), or 
vehicle. Two hours following the injection (8 hours after stress exposure), animals received a 5-
min post-drug baseline recording session in its homecage, using the same parameters for cell 
identification as each animal’s pre-drug baseline recording session. Immediately following the 
post-drug baseline session, animals were placed on the elevated plus maze (EPM) for a 10-min 
recorded EPM session. In addition to neural recordings on the EPM, video acquisition monitored 
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behavior using CinePlex Behavioral Research System software (Plexon Inc, Dallas, TX). Neural 
data was sorted using Offline Sorter (Plexon Inc, Dallas, TX) and analyzed using NeuroExplorer 
5.0 (Nex Technologies, Madison, AL). 
Statistical analyses.  For single unit analysis, neural data was acquired and recorded using 
Omniplex Neural Data Acquisition System (Plexon, Inc, Dallas, TX). Waveforms were isolated 
manually, using principal component analysis (Offline Sorter, Plexon Inc). To be included in the 
analyses, spikes had to exhibit a refractory period of at least 1 ms.  Autocorrelograms from 
simultaneously recorded units were examined to ensure that no cell was counted twice. 
“Responsiveness” to arm entries for each unit was analyzed by generating perievent histograms 
(100ms bins) of firing rates in the 2 s surrounding arm entry (NeuroExplorer, Nex Technologies). 
Firing rates were normalized to baseline (1 s prior to entry) using z-score transformation. If z-
scores for any of the time bins in the 1 second following arm entry was greater than 2 or less than 
-2, the cell was considered to be responsive (excitatory or inhibitory, respectively). Analysis of 
arm entry responsiveness included 67 cells in vehicle-treated animals, and 72 cells in LM-4131-
treated animals. Data reported for raw firing rates included only putative principal neurons; any 
unit with a baseline firing rate over 7Hz was excluded (5 veh and 3 LM-4131; see Likhtik, E, et 
al., 2006)244.  Statistical analyses were conducted by either Student’s t-test or by ANOVA followed 
by Holm-Sidak post hoc multiple comparisons test.   
 
Results and Discussion 
Correlates of SSCI in stress-induced anxiety and synaptic transmission 
To correlate our findings described in Chapter II in relation to the anxiolytic potential of 
SSCI after acute stress exposure with synaptic changes in the amygdala, a brain region known to 
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modulate anxiety-like behaviors in animals and humans, we performed in vivo electrophysiology 
in the basolateral nucleus of the amygdala in mice subjected to the elevated plus maze paradigm, 
which is depicted in Figure 18a, after exposure to the acute footshock paradigm and i.p. 
administration of either vehicle or the SSCI, LM-4131 (10 mg/kg).  To ensure implanting of the 
cannula for the in vivo electrophysiology did not interfere with the anxiety-like behaviors exhibited 
by the mice after acute stress exposure, we tested the mice in the EPM with and without 
cannulization to compare findings.  We found that regardless of the cannulization the mice 
exhibited a reduction in stress-induced anxiety-like behavior in the EPM when administered LM-
4131 in comparison to vehicle-treated mice.  Regarding the mice that were not cannulized, all 
substrate-selective COX-2 inhibitors, LM-4131 and LMX, compared to vehicle treatment 
decreased anxiety-like behaviors in the EPM by decreasing the latency to open arm entry and 
increasing the latency to closed arm entry after the mice were exposed to acute footshock stress 
(Fig. 18b).  A one-way ANOVA was conducted to compare the effect of LM-4131 and LMX on 
open arm latency in juvenile male ICR mice 8h after acute stress exposure.  It showed that the 
difference in open arm latency between the vehicle treatment group (means ± s.e.m. = 27.90 ± 
5.355, N = 17), the LM-4131 treatment group (means ± s.e.m. = 0.6000 ± 0.4030, N = 13), and the 
LMX treatment group (means ± s.e.m. = 2.287 ± 1.053, N = 15) were statistically significant (F(2, 
42) = 19.26; ****p < 0.0001).  Post hoc Holm-
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Sidak’s multiple comparisons test revealed a significant decrease in open arm latency of the EPM 
Figure 18.  Synaptic effects of substrate-selective COX-2 inhibition in stress-induced anxiety-like 
behaviors.  (a) Diagram of experimental design using the elevated plus maze (EPM), a behavioral test for 
anxiety.  (b) Open arm latency, closed arm latency, and total distance traveled by mice in the EPM that have not 
undergone cannulization. (c) Closed or open arm entries or time, closed or open arm latency, closed arm exits, 
and risk assessment by ice in the EPM that have undergone cannulization for in vivo electrophysiology.  (d) 
Schematic of heat map of elevated plus for vehicle-treated or LM-4131 treated mouse after stress exposure.  (e) 
Z score of average firing rate of excitatory cells in vehicle-treated and LM-4131-treated mice as the mice enter 
the center of the EPM. (f) Number of cell types in vehicle and LM-4131-treated animals.  (g) Correlation plots 
of open arm latency and Data are shown as the mean ± s.e.m.  *P < 0.05, **P < 0.01, ***P<0.001, ****P<0.0001 
(COX-2 inhibitor compared to vehicle).  Statistical significance was calculated by two-tailed unpaired Student's 
t-test or one-way or two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test.   
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at the 10 mg/kg dose of LM-4131 (****p < 0.0001, t = 5.350, df = 42, LM-4131 vs. vehicle) and 
at the 1 mg/kg dose of LMX (****p < 0.0001, t = 5.220, df = 42, LMX vs. vehicle) compared to 
vehicle treatment under acute stress conditions.  A one-way ANOVA was also conducted to 
compare the effect of LM-4131 and LMX on closed arm latency in the mice 8h after acute stress 
exposure.  It showed that the difference in closed arm latency between the vehicle treatment group 
(means ± s.e.m. = 4.600 ± 1.787, N = 17), the LM-4131 treatment group (means ± s.e.m. = 23.58 
± 2.516, N = 13), and the LMX treatment group (means ± s.e.m. = 23.27 ± 4.150, N = 15) were 
statistically significant (F(2, 42) = 14.37; ****p < 0.0001).  Post hoc Holm-Sidak’s multiple 
comparisons test revealed a significant increase in closed arm latency of the EPM at the 10 mg/kg 
dose of LM-4131 (****p < 0.0001, t = 4.512, df = 42, LM-4131 vs. vehicle) and at the 1 mg/kg 
dose of LMX (****p < 0.0001, t = 4.618, df = 42, LMX vs. vehicle) compared to vehicle treatment 
under acute stress conditions.  These results were not confounded by changes in total distance 
traveled in the EPM, suggesting that the drug effects on anxiety-like behavior in the EPM were 
not an artifact of motor deficits or abnormalities.  A one-way ANOVA was conducted to compare 
the effect of LM-4131 and LMX on total distance traveled in the mice 8h after acute stress 
exposure.  It showed that the difference in total distance traveled between the vehicle treatment 
group (means ± s.e.m. = 10.65 ± 0.5166, N = 17), the LM-4131 treatment group (means ± s.e.m. 
= 11.92 ± 0.9740, N = 13), and the LMX treatment group (means ± s.e.m. = 10.66 ± 0.9433, N = 
15) were not statistically significant (F(2, 42) = 0.7595; p = 0.4742, ns).  Post hoc Holm-Sidak’s 
multiple comparisons test revealed no significant changes in total distance traveled in the EPM at 
the 10 mg/kg dose of LM-4131 (ns, t = 1.104, df = 42, LM-4131 vs. vehicle) and at the 1 mg/kg 
dose of LMX (ns, t = 0.007873, df = 42, LMX vs. vehicle) compared to vehicle treatment under 
acute stress conditions. 
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We also found that the SSCIs, LM-4131 and LMX, reduced anxiety-like behavior in the 
EPM in both juvenile and adult male ICR mice that were not cannulized regardless of stress 
exposure, even though the most robust effects were observed in stressed and juvenile mice (see 
APPENDIX Fig. G).  Non-stressed juvenile male ICR mice showed significant differences in open 
arm entries (one-way ANOVA: F(2, 58) = 4.972, p = 0.0102, *p < 0.05) and closed arm latency (one-
way ANOVA: F(2, 52) = 12.55, ****p < 0.0001) in the EPM.  The sample means are displayed in 
Figure Ga, which shows that the mice treated with an SSCI, LM-4131 (10 mg/kg) or LMX (1 
mg/kg), scored greater on open arm entries and closed arm latency than mice treated with vehicle 
(t (58) = 3.070 (open arm entries), t (51) = 5.006 (closed arm latency); for vehicle treatment group: 
means ± s.e.m. = 6.391 ± 1.895 (open arm entries), 2.576 ± 2.493 (closed arm latency), N = 23; 
for LM-4131 treatment group: means ± s.e.m. = 15.05 ± 2.493 (closed arm latency), N = 13; for 
LMX treatment group: means ± s.e.m. = 12.21 ± 1.895 (open arm entries), N = 24).  Stressed 
juvenile male ICR mice showed significant differences in latency to freeze (one-way ANOVA: 
F(2, 52) = 7.184, p = 0.0018, **p < 0.01) in the EPM.  The sample means are displayed in Figure 
Gb, which shows that the mice treated with the SSCI, LM-4131 (10 mg/kg), scored greater on 
latency to freeze than mice treated with vehicle (t (52) = 3.789, for vehicle treatment group: means 
± s.e.m. = 0.3875 ± 1.910, N = 16; for LM-4131 treatment group: means ± s.e.m. = 7.626 ± 1.910, 
N = 19).  Non-stressed adult male ICR mice showed significant differences in open arm latency 
(one-way ANOVA: F(2, 58) = 17.06, ****p < 0.0001), closed arm latency (one-way ANOVA: F(2, 
64) = 8.275, p = 0.0006, ***p < 0.001), and latency to freeze (one-way ANOVA: F(2, 61) = 8.448, p 
= 0.0006, ***p < 0.001) in the EPM.  The sample means are displayed in Figure Gc, which shows 
that the mice treated with an SSCI, LM-4131 (10 mg/kg) or LMX (1 mg/kg), scored lesser on open 
arm latency and greater on closed arm latency and latency to freeze than mice treated with vehicle 
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(t (52) = 5.188 (LM-4131 vs. vehicle) or 4.942 (LMX vs. vehicle) (open arm latency), t (64) = 
4.056 (LM-4131 vs. vehicle) or 2.590 (LMX vs. vehicle) (closed arm latency), t (61) = 3.794 
(latency to freeze); for vehicle treatment group: means ± s.e.m. = 20.31 ± 4.530 (open arm latency), 
7.128 ± 2.202 (closed arm latency), 1.253 ± 0.4512 (latency to freeze), N = 18; for LM-4131 
treatment group: means ± s.e.m. = 1.028 ± 0.2234 (open arm latency), 23.94 ± 3.114 (closed arm 
latency), 8.856 ± 1.870 (latency to freeze), N = 24; for LMX treatment group: means ± s.e.m. = 
2.184 ± 0.6974 (open arm latency), 17.77 ± 2.729 (closed arm latency), N = 25).  Stressed adult 
male ICR mice showed significant differences in open arm latency (one-way ANOVA: F(2, 39) = 
8.922, p = 0.0006, ***p < 0.001), closed arm latency (one-way ANOVA: F(2, 36) = 8.354, p = 
0.0010, **p < 0.01), and latency to freeze (one-way ANOVA: F(2, 36) = 10.84, p = 0.0002, ***p < 
0.001) in the EPM.  The sample means are displayed in Figure Gd, which shows that the mice 
treated with an SSCI, LM-4131 (10 mg/kg) or LMX (1 mg/kg), scored lesser on open arm latency 
and greater on closed arm latency and latency to freeze than mice treated with vehicle (t (39) = 
3.032 (LM-4131 vs. vehicle) or 4.026 (LMX vs. vehicle) (open arm latency), t (36) = 3.367 (LM-
4131 vs. vehicle) or 3.860 (LMX vs. vehicle) (closed arm latency), t (36) = 4.484 (latency to 
freeze); for vehicle treatment group: means ± s.e.m. = 42.55 ± 10.50 (open arm latency), 0.3000 ± 
0.2191 (closed arm latency), 0.5333 ± 0.3163 (latency to freeze), N = 10; for LM-4131 treatment 
group: means ± s.e.m. = 12.37 ± 5.121 (open arm latency), 20.59 ± 3.428 (closed arm latency), N 
= 15; for LMX treatment group: means ± s.e.m. = 1.685 ± 0.5418 (open arm latency), 23.90 ± 
5.435 (closed arm latency), 9.164 ± 2.002 (latency to freeze), N = 14).  
We were able to replicate some of the effects of LM-4131 on stress-induced anxiety-like 
behavior in the mice that were cannulized for use in the in vivo electrophysiology experiments.  
The substrate-selective COX-2 inhibitor, LM-4131, compared to vehicle treatment decreased 
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anxiety-like behaviors in the EPM by increasing the number of open arm entries and time spent in 
the open arms while decreasing the latency to open arm entry after the mice were exposed to acute 
footshock stress (Fig. 18c).  An independent (unpaired) samples t test showed that the difference 
in open arm entries in juvenile male ICR mice 8h after acute stress exposure between the vehicle 
treatment group (means ± s.e.m. = 2.333 ± 0.8646, N = 12) and the LM-4131 treatment group 
(means ± s.e.m. = 8.333 ± 1.421, N = 12) were statistically significant (t (22) = 3.607, p = 0.0016, 
**p < 0.01, 95% CI [2.550, 9.450], d = 6.000 ± 1.664).  It also illustrated that the difference in 
open arm time in the mice 8h after acute stress exposure between the vehicle treatment group 
(means ± s.e.m. = 14.11 ± 5.910, N = 12) and the LM-4131 treatment group (means ± s.e.m. = 
68.13 ± 14.22, N = 12) were statistically significant (t (22) = 3.506, p = 0.0020, **p < 0.01, 95% 
CI [22.07, 85.96], d = 54.01 ± 15.40).  An independent (unpaired) samples t test also revealed a 
significant difference in open arm entry latency in the mice 8h after acute stress exposure between 
the vehicle treatment group and the LM-4131 treatment group (t (22) = 3.366, p = 0.0028, **p < 
0.01, 95% CI [-451.9, -107.3], d = -279.6 ± 83.07).  The sample means are displayed in Figure 
18c, which shows that the mice treated with LM-4131 (10 mg/kg) scored lower on open arm entry 
latency than the mice treated with vehicle (for LM-4131 treatment group, means ± s.e.m. = 32.15 
± 8.714, N = 12; for vehicle treatment group, means ± s.e.m. = 311.7 ± 82.61, N = 12).  There were 
no significant differences in closed arm entries (unpaired samples t test: t (22) = 1.498, p = 0.1483, 
ns), closed arm time (unpaired samples t test: t (22) = 1.817, p = 0.0828, ns), closed arm latency 
(unpaired samples t test: t (22) = 1.326, p = 0.1983, ns), closed arm exits or center entries (unpaired 
samples t test: t (22) = 0.1962, p = 0.8462, ns), and risk assessment (unpaired samples t test: t (22) 
= 1.399, p = 0.1757, ns).  The sample means are displayed in Figure 18c, which shows that the 
mice treated with LM-4131 (10 mg/kg) scored similar on closed arm entries, closed arm latency, 
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closed arm exits, and risk assessment compared to the mice treated with vehicle (for vehicle 
treatment group: means ± s.e.m. = 18.42 ± 1.663 (closed arm entries), 376.0 ± 28.61 (closed arm 
time), 21.29 ± 7.283 (closed arm latency), 362.2 ± 9.147 (closed arm exits), 25.35 ± 4.076 (risk 
assessment), N = 12; for LM-4131 treatment group: means ± s.e.m. = 21.58 ± 1.305 (closed arm 
entries), 310.4 ± 22.00 (closed arm time), 11.57 ± 0.7971 (closed arm latency), 364.6 ± 8.330 
(closed arm exits), 36.16 ± 6.564 (risk assessment), N = 12). 
Since excitatory neurotransmission can be enhanced by stress and induce anxiety-like 
behaviors in animals and humans240-242, we wanted to determine if our acute stress paradigm, 
which we have shown to induce anxiety-like behavior in the juvenile ICR mice (Fig. 2e), could 
induce changes in the levels of glutamate or GABA in the amygdala of these mice.  Using high 
performance liquid chromatography (HPLC), we measured glutamate and GABA levels in the 
amygdala from mice under non-stressed (control) or acute footshock stress conditions (see 
APPENDIX H).  We found that the acute footshock stress paradigm did not affect amygdala 
glutamate or GABA levels compared to non-stressed (control) conditions.  An independent 
(unpaired) samples t test showed that the difference in amygdala glutamate levels in juvenile male 
ICR mice between the non-stressed group (means ± s.e.m. = 101.7 ± 3.323, N = 10) and the stressed 
group (means ± s.e.m. = 93.15 ± 2.450, N = 10) was not statistically significant (t (18) = 2.069, p 
= 0.0533, ns, 95% CI [-17.21, 0.1338], d = -8.540 ± 4.129; see APPENDIX Ha).  It also illustrated 
that the difference in amygdala GABA levels in juvenile male ICR mice between the non-stressed 
group (means ± s.e.m. = 19.93 ± 1.025, N = 10) and the stressed group (means ± s.e.m. = 19.74 ± 
0.4566, N = 10) was not statistically significant (t (18) = 0.1685, p = 0.8681, ns, 95% CI [-2.546, 
2.168], d = -0.1890 ± 1.122; see APPENDIX Hb).  The unexpected findings may be due to the 
limitations of HPLC to accurately measure the effects of stress exposure on amygdala glutamate 
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or GABA levels, especially since site specificity of changes in neurotransmitter levels is lost in 
brain tissue sections that have subregions characterized by cell type differences.  The technique of 
microdialysis may be better suited to quantitatively measure neurotransmitters, such as glutamate 
or GABA, from tissue preparations, especially since it more precisely characterizes the quantity 
and distribution of an analyte, such as a neurotransmitter, and can measure the temporal pattern of 
the release of neurotransmitters in specific brain regions in an awake animal245. 
A schematic heat map of the elevated plus maze for vehicle-treated and LM-4131-treated 
mice after acute footshock stress exposure is depicted in Figure 18d, which shows that the juvenile 
male ICR mice exposed to acute footshock stress spent most of their time in the center or open 
arms after they exited a closed arm.  Since increased amygdala cell excitability has been suggested 
to be correlated to anxiogenic phenotypes in animals220,246-249, we wanted to determine if the SSCI, 
LM-4131, could reduce stress-induced anxiety-like behavior exhibited by the mice in the EPM by 
reducing cell excitability in the basolateral nucleus of the amygdala (BLA) of the mice.  Thus, we 
examined the average firing rate of excitatory neurons in the BLA in the mice exposed to acute 
footshock stress and administered either vehicle or the LM-4131 by i.p. (see APPENDIX Fig. Ia).  
To ensure that the baseline firing rate (spikes/s) of responsive excitatory cells before and after 
intraperitoneal (IP) injection were similar between vehicle-treated and LM-4131-treated mice 
exposed to acute footshock stress 8h prior to testing for anxiety-like behavior in the EPM and 
simultaneously recording firing rate of excitatory BLA cells, we performed two-way ANOVA 
factoring drug dose and time of i.p. injection, which revealed no significant effect of drug dose x 
time of i.p. injection interaction (F(1, 254) = 0.01199, p = 0.9129, ns) and drug dose (F(1, 254) = 3.063, 
p = 0.0813, ns), but a significant effect of time of i.p. injection (F(1, 254) = 4.241, p = 0.0405, *p < 
0.05; see APPENDIX Fig. Ib).  After performing the in vivo electrophysiology experiments, we 
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discovered that LM-4131 induced a reduction in the firing rate when the mice exited a closed arm 
to enter the center of the maze, which is a more aversive area of the EPM as opposed to the dimly 
lit closed arms (Fig. 18e and see APPENDIX Fig. Ic).  With respect to the effects of LM-4131 on 
the Z score of the average firing rate of excitatory cells in the BLA of mice exposed to acute 
footshock stress, two-way ANOVA factoring drug dose and time of exit from the closed arm 
(center entry) of the EPM revealed a significant effect of drug dose x time interaction (F(29, 1350) = 
1.648; p = 0.0168, *p < 0.05), time of exit from the closed arm (center entry) of the EPM (F(29, 
1350) = 3.236, ****p < 0.0001), and drug dose (F(1, 1350) = 7.749, **p < 0.01; Fig. 18e).  Post hoc 
Holm-Sidak’s multiple comparisons test revealed at the 10 mg/kg dose of LM-4131 compared to 
vehicle treatment a significant decrease in the average firing rate of excitatory cells in the BLA in 
the mice exposed to acute footshock stress when they exited a closed arm of the EPM (**p < 0.01, 
t = 3.835, df = 1350, at 0.7 s time bin; for LM-4131 treatment group, means ± s.e.m. = 0.07138 ± 
0.4274, N = 23 cells; for vehicle treatment group, means ± s.e.m. = 1.711 ± 0.4274, N = 24 cells).  
As depicted in the pie charts in Figure 18f, of all 62 BLA responsive cells recorded from in vehicle-
treated mice, 24% were excitatory, 9% were inhibitory, and 29% were neither excitatory nor 
inhibitory, and of all 66 BLA responsive cells recorded from in vehicle-treated mice, 35% were 
excitatory, 12% were inhibitory, and 53% were neither excitatory nor inhibitory.  From the cells 
that were recorded for firing rate, we found a positive correlation between open arm latency and 
maximum firing rate when the animals exited the closed arms in the EPM (Fig. 18g).  An 
independent (unpaired) samples t test showed that the difference in the Z score of maximum firing 
rate of all BLA responsive cells during closed arm exit from the EPM in juvenile male ICR mice 
8h after acute stress exposure between the vehicle treatment group (means ± s.e.m. = 2.174 ± 
0.2986, N = 62) and the LM-4131 treatment group (means ± s.e.m. = 1.616 ± 0.1671, N = 66) were 
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not statistically significant (t (126) = 1.657, p = 0.1001, ns, 95% CI [-1.224, 0.1086], d = -0.5580 
± 0.3368).  For the 128 BLA responsive cells from mice exposed to acute footshock stress, the Z 
scores of maximum firing rate of the cells during closed arm exit from the EPM (means ± s.e.m. 
= 1.886 ± 0.1695, N = 128 cells) and the latency to open arm entry of the EPM (means ± s.e.m. = 
166.5 ± 20.16, N = 12 animals) were strongly and significantly correlated, r = 0.3607, ****p < 
0.0001.  An independent (unpaired) samples t test showed that the difference in the Z score of 
maximum firing rate of excitatory BLA responsive cells during closed arm exit from the EPM in 
juvenile male ICR mice 8h after acute stress exposure between the vehicle treatment group (means 
± s.e.m. = 4.195 ± 0.5109, N = 24) and the LM-4131 treatment group (means ± s.e.m. = 2.990 ± 
0.2069, N = 23) was statistically significant (t (45) = 2.151, p = 0.0369, *p < 0.05, 95% CI [-2.333, 
-0.07678], d = -1.205 ± 0.5600).  For the 47 excitatory BLA responsive cells from mice exposed 
to acute footshock stress, the Z scores of maximum firing rate of the cells during closed arm exit 
from the EPM (means ± s.e.m. = 3.465 ± 0.2844, N = 47 cells) and the latency to open arm entry 
of the EPM (means ± s.e.m. = 244.9 ± 37.90, N = 12 animals) were significantly correlated, r = 
0.3016, p = 0.0333, *p < 0.05.  An independent (unpaired) samples t test showed that the difference 
in the Z score of maximum firing rate of inhibitory BLA responsive cells during closed arm exit 
from the EPM in juvenile male ICR mice 8h after acute stress exposure between the vehicle 
treatment group (means ± s.e.m. = 1.695 ± 0.3316, N = 9) and the LM-4131 treatment group 
(means ± s.e.m. = 1.363 ± 0.3759, N = 8) was not statistically significant (t (15) = 0.6642, p = 
0.5166, ns, 95% CI [-1.395, 0.7324], d = -0.3315 ± 0.4991).  For the 47 inhibitory BLA responsive 
cells from mice exposed to acute footshock stress, the Z scores of maximum firing rate of the cells 
during closed arm exit from the EPM (means ± s.e.m. = 1.539 ± 0.2448, N = 17 cells) and the 
latency to open arm entry of the EPM (means ± s.e.m. = 121.4 ± 55.72, N = 12 animals) were not 
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significantly correlated, r = 0.2273, p = 0.3804, ns.  An independent (unpaired) samples t test 
showed that the difference in the Z score of maximum firing rate of “none” BLA responsive cells 
(e.g., neither excitatory nor inhibitory) during closed arm exit from the EPM in juvenile male ICR 
mice 8h after acute stress exposure between the vehicle treatment group (means ± s.e.m. = 0.6500 
± 0.1477, N = 29) and the LM-4131 treatment group (means ± s.e.m. = 0.7706 ± 0.1334, N = 35) 
was statistically significant (t (62) = 0.6064, p = 0.5464, ns, 95% CI [-0.2770, 0.5183], d = 0.1206 
± 0.1989).  For the 47 “none” BLA responsive cells (e.g., neither excitatory nor inhibitory) from 
mice exposed to acute footshock stress, the Z scores of maximum firing rate of the cells during 
closed arm exit from the EPM (means ± s.e.m. = 0.7160 ± 0.09852, N = 64 cells) and the latency 
to open arm entry of the EPM (means ± s.e.m. = 114.5 ± 23.13, N = 12 animals) were not 
significantly correlated, r = 0.2134, p = 0.0904, ns.    
 
Conclusion  
 As illustrated in this chapter the anxiolytic potential of SSCI after an animal has been 
exposed to acute footshock stress is related to a decrease in the firing of excitatory cells in the 
amygdala.  Nevertheless, the mechanisms responsible or the sequence of events that leads up to 
this phenomenon is unknown and requires further investigation.  A recent study by Rau and others 
has suggested that activation of SK channels in the BLA can reduce BLA pyramidal cell 
excitability in an animal model of chronic early-life stress220.  This study supports our observation 
that stress-induced anxiety-like behavior in mice is mediated by the SK channel.  It also reinforces 
the notion that the SSCI, LM-4131, may be a target of the SK channels located possibly in the 
amygdala, specifically the BLA.  From our findings, we can construct a hypothetical model of  
cellular and molecular occurrences as a result of SSCI action under acute stress conditions in male 
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mice of juvenile age (5-7 weeks of age) (Fig. 19).  Through this hypothetical reconstruction, we 
have assumed that an increase of dopamine release in the amygdala from axon terminals 
originating in the ventral tegmental area of the brain is induced by the acute stress exposure and, 
subsequently, is restored by elevations of AEA via SSCI.  This increase in dopamine release may 
induce an increase in the firing of excitatory neurons along with other molecular changes at the 
synaptic level.  LM-4131 through AEA signaling reduces such increases and/or synaptic molecular 
changes by targeting calcium-activated potassium channels, resulting in a reduction in anxiogenic, 
anhedonic, and/or fearful behavioral responses in the mice.  Future studies will examine how 
applicable this model is to the cellular and molecular events occurring in the amygdala and other 
associated brain regions involved in modulating fear and stress responses in mice in relation to 
stress-induced anxiogenic, anheonic, and fear-related behaviors in animals. 
Figure 19.  Hypothetical working model of synaptic and behavioral effects of substrate-selective COX-2 
inhibition in the amygdala.  Acute stress exposure induces an increase in action potential firing in excitatory 
pyramidal neurons located in the basolateral nucleus of the amygdala and release of dopamine from the ventral 
tegmental area (VTA) onto neurons in the BLA.  Consequently, the endocannabinoid, anandamide, is reduced in 
content possibly by degradation of the enzyme cyclooxygenase-2 (COX-2) or other surrounding enzymes and the 
calcium activated potassium (SK) channel is decreased in content at the plasma membrane surface in either the 
amygdala or other brain regions involved in modulating anxiety, anhedonia, and/or fear in animals.  Due to these 
synaptic changes, animals exhibit an increase in anxiety, anhedonia, and/or contextual fear.  LM-4131, a substrate-
selective COX-2 inhibitor, counteracts these synaptic and behavioral effects. 
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APPENDIX
 
  
Figure A.   Time-dependent anxiolytic and anhedonic effects of COX-2 inhibitors in juvenile male mice.  (a-
c) Cumulative frequency of mice feeding and latency to feed in novelty-induced feeding suppression (NIFS) test 
at four, 24, and 72 hours after acute stress exposure.  (d-f) Cumulative frequency of mice consuming palatable 
shake and amount of shake consumed in novelty-induced feeding suppression (NIFS) test at four, 24, and 72 hours 
after acute stress exposure.  Data are shown as the mean ± s.e.m.  NS = no stress, S = stress (e.g., stress exposure 
in the form of an electric footshock administered 4/24/72h prior to testing), *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001 (COX-2 inhibitor compared to vehicle).  Statistical significance was calculated by two-tailed 
unpaired Student's t-test or Kolmogorov-Smirnov test (only for frequency plots) or one-way ANOVA with post 
hoc Holm-Sidak’s multiple comparisons test. 
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Figure B.  Anxiolytic effects of COX-2 inhibitors in the NIFS assay on juvenile female mice.  (a) Mean latency 
to feed and amount of shake consumed in the novelty-induced feeding suppression (NIFS) test under basal (no 
stress) conditions in juvenile ICR (CD-1) female mice, and (b) Mean latency to feed and amount of shake 
consumed in the novelty-induced feeding suppression (NIFS) test at 8 hours after acute stress exposure in juvenile 
ICR (CD-1) mice. Data are shown as the mean ± s.e.m. NS = no stress, S = stress (e.g., stress exposure in the form 
of an electric footshock administered 8h prior to testing), *P < 0.05, **P < 0.01 (COX-2 inhibitor compared to 
vehicle).  Statistical significance was calculated by unpaired, two-tailed t test.   
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Figure C.  Anxiolytic effects of COX-2 inhibitors in the elevated plus maze on adult female mice.  (a) Total 
distance traveled, (b) open arm entries, (c) open arm time, (d) closed arm entries, (e) closed arm time, (f) open 
arm latency, (g) closed arm latency, and (h) latency to freeze in adult female mice under non-stressful conditions 
and after acute stress exposure in the elevated plus maze. Data are shown as the mean ± s.e.m. NS = no stress, S = 
stress (e.g., stress exposure in the form of an electric footshock administered 8h prior to testing), *P < 0.05, **P < 
0.01, ***P<0.001, ****P<0.0001 (COX-2 inhibitor compared to vehicle).  Statistical significance was calculated 
by two-way ANOVA with post hoc Holm-Sidak’s multiple comparisons test.   
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Figure D.  Effects of SSCI on amygdala, PFC, and HPC monoamine levels. Effects of LM-4131 under control 
(non-stressed) conditions and 8 hours after acute (1 day) and chronic (5 days) foot-shock stress on dopamine (a), 
noradrenaline (b) and serotonin (5-HT) (c) levels in the amygdala. Effects of LM-4131 under control (non-
stressed) conditions and 8 hours after acute  and chronic foot-shock stress on dopamine (d), Noradrenaline (e) and 
Serotonin (5-HT) (f) levels in the PFC. Effects of LM-4131 under control (non-stressed) conditions and 8 hours 
after acute and chronic foot-shock stress on dopamine (g), Noradrenaline (h) and Serotonin (5-HT) (i) levels in 
the HPC. Significant F and P values for Two-way ANOVA shown above figures. ns, not significant, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 by Holm-Sidak multiple comparisons test after two-way ANOVA.  
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Figure E.  Effects of SSCI on amygdala serotonin and dopamine metabolite levels. Effects of LM-4131 under 
control (non-stressed) conditions and 8 hours after acute (1 day) and chronic (5 days) foot-shock stress on the 
dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) (a), the serotonin metabolite, 5-
hydroxyindoleacetic acid (5-HIAA), (b) and the DOPAC metabolite, homovanillic acid (HVA) (c) levels in the 
amygdala. Data are shown as the mean ± s.e.m.  NS = no stress, S = stress (e.g., stress exposure in the form of an 
electric footshock administered 8h prior to HPLC experiment), *P<0.05 (COX-2 inhibitor compared to vehicle or 
no stress compared to acute and/or chronic stress exposure paradigm).  Statistical significance was calculated by 
unpaired, two-tailed t test.  
.   
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Figure F.  Effects of SSCI on CORT levels. Effects of LM-4131 under control (non-stressed) conditions (a) and 
8 hours after acute (1 day) (b) and chronic (5 days) foot-shock stress (c) on plasma corticosterone (CORT) levels 
in juvenile male ICR mice.  Data are shown as the mean ± s.e.m.  NS = no stress, S = stress (e.g., stress exposure 
in the form of an electric footshock administered 8h prior to ELISA experiment). Statistical significance was 
calculated by unpaired two-tailed t test. 
.   
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Figure G.  Anxiolytic effects of COX-2 inhibitors in the elevated plus maze.  (a-d) Open arm time, entries, and 
latency, closed arm latency, latency to freeze, and/or total distance traveled by juvenile (a) and adult (c) male mice 
under non-stressful conditions and juvenile (b) and adult (d) male mice after acute stress exposure in the elevated 
plus maze. Data are shown as the mean ± s.e.m. NS = no stress, S = stress (e.g., stress exposure in the form of an 
electric footshock administered 8h prior to testing), *P < 0.05, **P < 0.01, ***P<0.001, ****P<0.0001 (COX-2 
inhibitor compared to vehicle).  Statistical significance was calculated by one-way ANOVA with post hoc Holm-
Sidak’s multiple comparisons test.   
 145 
 
Figure H.  Effects of acute footshock stress on amygdala amino acid levels. Effects of no stress (n = 10) and 
acute (1 day) stress (n = 10) on the amino acids, glutamate (a) and gamma-aminobutyric acid (GABA) (b). Data 
are shown as the mean ± s.e.m.  NS = no stress, S = stress (e.g., stress exposure in the form of an electric footshock 
administered 8h prior to HPLC experiment), Statistical significance was calculated by unpaired, two-tailed t test.  
.   
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Figure I.  Representative plots of cellular recordings using in vivo electrophysiology. (a) Histological 
reconstruction of the recording sites in the basolateral nucleus of the amygdala (BLA) with corresponding 
coordinates relative to bregma.  (b) Baseline firing rate (spikes/s) of responsive excitatory cells before and after 
intraperitoneal (IP) injection.  (c) Spike rasters (top) and peristimulus time histograms (PSTHs) (bottom) for 
representative responsive excitatory cell that is from a vehicle-treated animal versus an LM-4131-treated animal. 
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